Article Date	Headline / Summary	Publication	Edition	Page No.	Journalist
Mainlines					
15 Aug 2026	Stocks that made headlines this week	The Free Press Journal	Mumbai	17	Bureau
Online					
14 Aug 2026	Sentynl and Mereo partner on alvelestat for AATD lung disease	Pharma India Magazine	Online Web	NA	Bureau
12 Aug 2026	Stocks to Watch for August 12: Auto stocks, Manappuram Finance, NBCC, Larsen & Toubro and more	7 Globe News	Online Web	NA	Bureau
12 Aug 2026	Zydus' US Sentynl Therapeutics expands rare disease portfolio in partnership with Mereo BioPharma	Bio Spectrum India	Online Web	NA	Bureau
12 Aug 2026	Top stocks in news: L&T, Ardee, Tenneco, BEML, Manappuram, KFin Tech, Bata, Zydus Life	Business Today	Online Web	NA	Bureau
12 Aug 2026	Zydus Lifesciences' arm enters into option and license agreement with Mereo	Citrus Interactive	Online Web	NA	Bureau
12 Aug 2026	Pre-Market Update: Nifty 50 May Open Flat as Crude Oil, U.S.-Iran Tensions Weigh	Daily Hunt (Mobile)	Online Web	NA	Bureau
12 Aug 2026	Pre-Market Update: Nifty 50 May Open Flat as Crude Oil, U.S.-Iran Tensions Weigh	Dalal Street Investment Journal India	Online Web	NA	Bureau
12 Aug 2026	Stocks in Focus: Zydus Lifesciences, BEML, and Others	Equity Pandit	Online Web	NA	Ali Waghbakriwala
12 Aug 2026	Zydus’ Sentynl enters option and licence deal for alvelestat	Express Pharma	Online Web	NA	Bureau

12 Aug 2026	Dr Agarwals, Tenneco Clean Air India drop on block deals	Flipit Money	Online Web	NA	Bureau
12 Aug 2026	Stocks in Focus : Wednesday, 12 August	Gift Nifty	Online Web	NA	Bureau
12 Aug 2026	Stocks to Watch Today: Tenneco Clean Air, BEML, HG Infra Engg, Diamond Power, Larsen and Toubro, Ardee Industries, RHI Magnesita, Manappuram in focus on 12 August	Grow Mudra	Online Web	NA	Bureau
12 Aug 2026	Zydus' US Sentynl Therapeutics expands rare disease portfolio in partnership with Mereo BioPharma	HT Syndication	Online Web	NA	Bureau
12 Aug 2026	Zydus' Sentynl, Mereo BioPharma enter option deal for Alvelestat in rare lung disease	Indian Pharma Post	Online Web	NA	Bureau
12 Aug 2026	Zydus Lifesciences rises as its arm enters into option and license agreement with Mereo	Investment Guru India	Online Web	NA	Bureau
12 Aug 2026	Zydus Lifesciences' arm enters into option and license agreement with Mereo	Money Works 4 Me	Online Web	NA	Bureau
12 Aug 2026	Business news live: J&K Bank to raise Rs 1,000 crore; Tenneco, Dr Agarwal's Health Care, Thyrocare in focus	MSN India	Online Web	NA	Bureau
12 Aug 2026	Dr Agarwals Health Care, Tenneco Clean Air India slip on block deals; RHI Magnesita falls nearly 5%	MSN India	Online Web	NA	Bureau

12 Aug 2026	Stock market today: All you need to know going into trade on August 12	MSN India	Online Web	NA	Bureau
12 Aug 2026	Stocks to watch today: HAL, Apollo Hospitals, Petronet LNG, Tata Motors and IRCTC	MSN India	Online Web	NA	Bureau
12 Aug 2026	Stocks to watch: HAL, L&T, BEML among shares in focus today; check list here	MSN India	Online Web	NA	Bureau
12 Aug 2026	Top stocks in news: L&T, Ardee, Tenneco, BEML, Manappuram, KFin Tech, Bata, Zydus Life	MSN India	Online Web	NA	Bureau
12 Aug 2026	Sentynl Therapeutics and Mereo BioPharma Sign Licence Agreement for Alvelestat in Rare Lung Disease	Pharma Focus Asia	Online Web	NA	Bureau
12 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Sign Option and Licence Agreement for Alvelestat	Pharma Focus Europe	Online Web	NA	Bureau
12 Aug 2026	Sentynl Secures U.S. Option for Mereo's Alvelestat Ahead of Phase 3 in AATD Lung Disease	Pharmacally	Online Web	NA	Bureau
12 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Ink ~$475M Pact for Alvelestat	pharmashots	Online Web	NA	Ridhi Rastogi
12 Aug 2026	Market Wrap: Mixed Sentiment as Nifty Slips 0.15% While Auto and Consumer Durables Lead Gains	Scanx	Online Web	NA	Bureau
12 Aug 2026	L&T Share Price Momentum After Vyoma.AI Deal And August 12 Announcements	Swastika	Online Web	NA	Nidhi Thakur

12 Aug 2026	Stocks to Watch Today: GE Vernova T&D, MCX & Divi's Laboratories (12 August 2026)	Swastika	Online Web	NA	Santosh Meena
12 Aug 2026	Zydus' subsidiary inks optional licensing agreement with Mereo BioPharma for rare respiratory drug	The Economic Times	Online Web	NA	Bureau
12 Aug 2026	Stocks to Watch Today (August 12): Apollo Hospitals, Grasim, PI Industries, Manappuram Finance, GCPL and more	Zee Business	Online Web	NA	Abhay Shukla
11 Aug 2026	Zydus arm gets option on US rights to potential first oral drug for rare lung disease	7 Globe News	Online Web	NA	Bureau
11 Aug 2026	Sentynl, Mereo Sign Alvelestat Deal Worth Up to $40M Before NDA Filing	americanpharmaceuticalreview	Online Web	NA	Bureau
11 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	Bio Space	Online Web	NA	Bureau
11 Aug 2026	Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	Bio Space	Online Web	NA	Bureau
11 Aug 2026	Zydus arm gets option on US rights to potential first oral drug for rare lung disease	CNBC TV18	Online Web	NA	Srabastee Biswas

11 Aug 2026	Zydus' Sentynl pens $475M deal for Mereo's phase 3-ready rare genetic lung disease drug	Fierce Biotech	Online Web	NA	Bureau
11 Aug 2026	Zydus Lifesciences: Sentynl Licenses Alvelestat for US Market from Mereo	INV	Online Web	NA	Bureau
11 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease	Investingnews	Online Web	NA	Bureau
11 Aug 2026	Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease	Investingnews	Online Web	NA	Bureau
11 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	Manila Times	Online Web	NA	Bureau
11 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	Market Business Sider	Online Web	NA	Bureau

11 Aug 2026	Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	Morning Star	Online Web	NA	Bureau
11 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	My Carroll County News	Online Web	NA	Bureau
11 Aug 2026	Stocks To Watch Today: HAL, Apollo Hospitals, Petronet LNG, Tata Motors And IRCTC	NDTV Profit	Online Web	NA	Bureau
11 Aug 2026	Zydus Arm Secures US Rights Option for Pioneering Oral Drug for Rare Lung Disease	News 18	Online Web	NA	Bureau
11 Aug 2026	Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	PR Newswire	Online Web	NA	Bureau
11 Aug 2026	Zydus subsidiary Sentynl signs option and license deal for alvelestat	Scanx	Online Web	NA	Bureau
11 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	WBOC	Online Web	NA	Bureau

11 Aug 2026	Zydus Lifesciences Shares Rise 6% On US Drug Deal	Whalesbook	Online Web	NA	Ananya Iyer
11 Aug 2026	Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	Yahoo Finance	Online Web	NA	Bureau
11 Aug 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)	Yahoo Finance UK	Online Web	NA	Bureau

Mainlines

Published Date	15 Aug 2026	Publication	The Free Press Journal
Edition	Mumbai	Page No	17
Circulation	50,111		

Stocks

that made headlines this week

Maruti Suzuki

- Maruti Suzuki India plans to introduce seven SUVs over the next five to six years, deepening its presence in the segment and positioning the country's largest carmaker for further domestic passenger vehicle expansion.

Prestige Estates

- Canada Pension Plan Investment Board proposes investing up to ₹3,000 crore in Prestige Hospitality Ventures, acquiring an aggregate stake of up to 28% and giving the hospitality platform significant institutional backing.

JSW Energy

- JSW Energy has added 1,166 MW of renewable capacity since April 2026, taking installed capacity to 14,920 MW following the Maruti Clean Coal and Power acquisition, with renewables now representing 60%.

Jio Financial Services

- Jio Financial Services and Bank of America signed a definitive agreement allowing BofA to acquire up to 49.9% of Jio Credit through preferentially allotted equity shares and warrants as joint-venture partner.

Zydus Lifesciences

- Zydus Lifesciences arm Sentynl agreed with Mereo BioPharma to secure commercial and manufacturing rights for Alvelestat, with Mereo eligible to receive up to $40 million under terms of the agreement.

Bharti Airtel

- Bharti Airtel discontinued its ₹299 entry-level 28-day daily-data plan alongside ₹319, ₹579, ₹619 and ₹649 offerings across India, effectively raising the starting price of its unlimited-data proposition to ₹349.

Grasim

- Grasim's Q1 FY27 standalone EBITDA jumped 2.5 times year-on-year to ₹9.5 billion, around 20% above estimates, as operating margin widened 390 basis points to 8.1%, with PAT significantly exceeding expectations.

Lenskart

- Lenskart's Q1 FY27 revenue increased 34% year-on-year, underpinned by 26% volume growth, 6.5% ASP expansion and 18.3% India SSSG, while international revenue climbed 38%, demonstrating broad-based business momentum across geographies.

Online

Website:	Pharma India Magazine	Word count	560
Published Date	14 Aug 2026	Journalist:	Bureau

Sentynl and Mereo partner on alvelestat for AATD lung disease

https://www.pharmaindiamagazine.com/sentynl-and-mereo-partner-on-alvelestat-for-aatd-lung-disease/

Sentynl expands its rare disease portfolio with a potential first-in-class oral treatment for AATD-associated lung disease, while Mereo retains global development and rest-of-world commercial rights.

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (Zydus) and Mereo BioPharma Group plc (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that they have entered into an option and licence agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD . Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States [1, 2, 3, 4, 5, 6].

The option and licence agreement grants Sentynl has the exclusive right to acquire a licence to commercialise alvelestat for AATD-LD in the United States , with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD, and on option exercise, it provides funding for the alvelestat Phase 3 development programme, which could be initiated in early 2027

This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people, said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. For patients with AATD-LD, the current standard of care is demanding, often relying on generalised therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATDLD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies . We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat, and we look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design, said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

Mereo will receive a non-refundable option fee from Sentynl, and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing . Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat

Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed . However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design

Back To Index

Website:	7 Globe News	Word count	656
Published Date	12 Aug 2026	Journalist:	Bureau

Stocks to Watch for August 12: Auto stocks, Manappuram Finance, NBCC, Larsen & Toubro and more

https://www.7globe.in/stocks-to-watch-for-august-12-auto-stocks-manappuram-finance-nbcc-larsen-toubro-and-more/

JSW Dulux Ltd | The firm reported a 12.42% year-on-year decline in net profit to 79.7 crore for the first quarter of FY27, compared with 91 crore in the year-ago period.

Revenue declined 2.8% to 965 crore from 993.1 crore in Q1 FY26.

Manappuram Finance Ltd | Kerala-based gold loan financier reported net profit of 584.5 crore for the first quarter, compared with 138.3 crore in the corresponding quarter last year. Net interest income (NII) rose 28.1% year-on-year to 1,723.8 crore, from 1,345.3 crore in the year-ago period.

PI Industries | Gurugram-headquartered firm reported a 39% year-on-year decline in consolidated profit for the period to 244.2 crore for the quarter ended June 30, 2026, from 400 crore in the year-ago period.

Tenneco Clean Air India Ltd | Auto component manufacturer Tenneco Clean Air India Ltd's promoter entity, Tenneco Mauritius, is likely to sell an 8% stake in the company through a block deal, with an upsize option of another 2%, according to the deal terms.

Dr Agarwals Eye Hospital | Chennai-based Dr Agarwal's Health Care Ltd is set for a block deal in which Hyperion Investments Pte. Ltd, a TPG Private Equity vehicle, and Claymore Investments (Mauritius) Pte. Ltd, a Temasek Holdings Private Equity vehicle, will sell an 11% stake in the company.

Linde India | The industrial gases company reported a 2.4% year-on-year decline in consolidated net profit to 104.6 crore for the quarter ended June 30, 2026, compared with 107.2 crore in the year-ago period.

Bata India | The firm reported a 23.1% year-on-year rise in consolidated net profit to 64 crore for the quarter ended June 2026, compared with 52 crore in the corresponding quarter last year. Revenue from operations increased 3.9% YoY to 979 crore from 942 crore in Q1 FY26. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose 2.6% to 204 crore, compared with 199 crore in the year-ago period.

Zydus Lifesciences | The firm's wholly owned subsidiary Sentynl Therapeutics has entered into an option and licence agreement with Mereo BioPharma for alvelestat, an experimental treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, or AATD-LD, a rare genetic respiratory disease.

RHI Magnesita India | The firm reported an 83.2% year-on-year rise in consolidated net profit to 64.6 crore for the June quarter, as the refractory products maker improved margins despite higher input costs and pricing pressure. Revenue from operations rose 5.6% to 1,014 crore from 960.3 crore a year earlier.

NBCC (India) | State-owned firm reported a 17.2% year-on-year rise in net profit to 154.8 crore for the June quarter, even as revenue declined. Revenue from operations fell 6% from a year earlier to 2,259.5 crore.

BEML | State-owned Bharat Earth Movers Ltd on Tuesday (August 11) said it has secured an order worth 184.25 crore from Hindustan Aeronautics Ltd (HAL) for the manufacture and supply of Light Combat Helicopter (LCH) fuselage aerostructures.

(Photo Credit : Larsen and Toubro X

Larsen & Toubro Limited | Infrastructure major L&T on Tuesday (August 11) said it has entered into agreements with its wholly owned subsidiary Vyoma.AI Limited to transfer its Data Center and Cloud Services Business for 1,400 crore and divest its entire stake in L&T Network Services Private Ltd (LTNSPL) for 30 crore.

(Photo Credit : Canva

Auto Stocks | TVS Motor, Bajaj Auto, Hero MotoCorp, Ola Electric and Ather Energy could remain in focus after the government approved an additional 1,000 crore for electric two-wheelers under its incentive framework, with benefits for the segment extended until March 2028.

HG Infra Engineering Ltd | Infrastructure development company said it has received a Letter of Award (LOA) from the Department of Skill, Employment & Entrepreneurship, Government of Rajasthan, for the operation and management of the Industrial Training

Institute (ITI) Bhiwadi Cluster under Component-I of the Pradhan Mantri Skilling and Employability Transformation through Upgraded ITIs (PM-SETU).

Q1 Earnings | AMD Industries, Apollo Hospitals Enterprise, Astral, Eureka Forbes, Gujarat Fluorochemicals and Grasim Industries are among the companies scheduled to announce their quarterly results tomorrow.

Continue Reading

Source link

Leave a Reply

Back To Index

Website:	Bio Spectrum India	Word count	261
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus' US Sentynl Therapeutics expands rare disease portfolio in partnership with Mereo BioPharma

https://www.biospectrumindia.com/news/95/28294/zydus-us-sentynl-therapeutics-expands-rare-disease-portfolio-in-partnership-with-mereo-biopharma.html

Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed

image credit- freepik

Sentynl Therapeutics, Inc., a US-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences, and Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases, have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD).

Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialise alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development programme, which could be initiated in early 2027.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on US net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

Back To Index

Website:	Business Today	Word count	1157
Published Date	12 Aug 2026	Journalist:	Bureau

Top stocks in news: L&T, Ardee, Tenneco, BEML, Manappuram, KFin Tech, Bata, Zydus Life

https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-lt-ardee-tenneco-beml-manappuram-kfin-tech-bata-zydus-life-548633-2026-08-12

Stocks like L&T, Ardee Industries, Tenneco Clean Air, BEML, Manappuram Finance, KFin Tech, Bata, Zydus Life, Balrampur Chini will be in the spotlight on Wednesday, August 12.

Indian equity benchmark indices settled lower on Tuesday after the attention shifted to the rise in crude oil prices, highlighting the inflation risk, led by Strait of Hormuz blockade. The BSE Sensex shed 388.19 points, or 0.49 per cent, to close at 78,154.25, while NSE's Nifty50 tanked 112.10 points, or 0.46 per cent, to end at 24,471.70 for the day. Here are the stocks that may remain under spotlight before the opening bell on Wednesday, August 12, 2026:

Quarterly results today: Tata Motors, Grasim Industries, Apollo Hospitals, Lenskart Solutions, Hindustan Aeronautics, Arvind, Astral, Aditya Infotech, EID Parry, EMS, GMR Airports, Indiqube Spaces, IRCTC, Jyothy Labs, National Fertilizers, Petronet LNG, SKF India, Sun TV, Titagarh Rail Systems, VIP Industries, VA Tech Wabag and Yatra Online will announce their results for the June 2026 quarter today.

Corporate actions today: Shares of Computer Age Management Services, KPIT Technologies, NHPC, ASM Technologies, Dhunseri Tea, Gabriel India, Gujarat Containers, HG Infra Engineering, Industrial & Prudential Investment, KCP, Neelamalai Agro, Sandur Manganese, Narmada Gelatines, Uniparts India, Vaibhav Global, Voith Paper Fabrics India and more shall trade ex-dividend today.

Ardee Industries: The recycling and recovery solutions player will make its stock market debut on Wednesday, August 12 after the company raised a total of Rs 426 crore via IPO between August 05-07. The company sold its shares for Rs 53 apeice with a lot size of 281 shares. The issue was overall subscribed 133.66 times getting nearly 41.2 lakh applications.

Tenneco Clean Air India: Promoter entity Tenneco Mauritius is likely to sell an 8 per cent stake in Tenneco Clean Air India, with an upsize option of 2 pe rcent, through block deals. The floor price is expected to be Rs 515 per share, with a base offer size of Rs 1,663 crore, suggest some media report, citing sources.

Larsen and Toubro: The capital goods major has executed a Business Transfer Agreement with its subsidiary Vyoma.AI for the transfer of its data centre and cloud services business, on a going-concern basis through a slump sale, to Vyoma for Rs 1,400 crore.

Manappuram Finance: The gold loan player reported a 4-fold jump in the net profit at Rs 584.6 crore, while net-interest income (NIIs) soared 28.1 per cent YoY to Rs 1,723.7 crore for the June 2026 quarter. Its impairment on financial instruments sank 60.6 per cent YoY to Rs 225.5 crore. Its AUM jumped 57.2 per cent YoY to Rs 69,635 crore for the quarter.

Zydus Lifesciences: The pharma player's subsidiary, Sentynl Therapeutics, and Mereo BioPharma Group plc have entered into an option and licence agreement for the US commercialisation and global manufacturing rights to Alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being prepared for Phase 3 trials and would be the first oral treatment for this rare, progressive genetic lung disease.

Bata India: The footwear player reported a 23.04 per cent YoY jump in the net profit at Rs 63.98 crore, while revenue increased 3.9 per cent YoY to Rs 978.9 crore for the June 2026 quarter. Its Ebitda was up 2.6 per cent YoY to Rs 204 crore, while margins declined to 20.8 per cent for the quarter. The company board declared an interim dividend of Rs 25 per share for the investors.

BEML: The state-run defence player has secured an order worth Rs 184.25 crore from Hindustan Aeronautics (HAL) for the manufacture and supply of Light Combat Helicopter (LCH) fuselage aerostructures.

KFin Technologies: The financial services player announced the rollout of Klarity, an Agentic AI solution built to address two operational vulnerabilities in financial institutions operations skilled forgeries being incorrectly accepted as valid matches and legitimate behavioural signature variations resulting in wrongful rejections.

Balrampur Chini Mills: The sugar maker reported a 14.5 per cent YoY decline in net profit to Rs 44.1 crore, while revenue increased 6 per cent YoY to Rs 1,636.8 crore for the April-June 2026 period. Its EBITDA declined 15 per cent YoY to Rs 114 crore, while the EBITDA margin dropped to 6.96 per cent during the quarter.

PI Industries: The agrochemicals player reported a 39 per cent YoY decline in net profit to Rs 244.2 crore, while revenue fell 10.4 per cent YoY to Rs 1,702.3 crore for the Q1FY26. Its EBITDA declined 29.2 per cent YoY to Rs 367.4 crore, while the EBITDA margin dropped to 21.6 per cent during the quarter.

HG Infra Engineering: The infra & EPC company has received a letter of award (LoA) from the Department of Skill, Employment & Entrepreneurship, Government of Rajasthan, for the operation and management of the ITI Bhiwadi Cluster under Component-I of PM-SETU. Its share is 17.10 percent of the estimated cost of Rs 241 crore.

Linde India: The industrial gases maker reported a 2.4 per cent YoY decline in net profit to Rs 104.6 crore, even as revenue grew 21.6 per cent YoY to Rs 694.4 crore in the June 2026 quarter. Its EBITDA increased 17.9 per cent YoY to Rs 72 crore, while the EBITDA margin declined to 5.52 per cent for the quarter.

Landmark Cars: The automotive dealership player reported a 110.5 per cent YoY surge in net profit to Rs 14.5 crore, while revenue jumped 22.7 per cent YoY to Rs 1,302.4 crore during the first quarter of FY26. Its EBITDA grew 17.9 per cent YoY to Rs 72 crore, while the EBITDA margin declined to 5.52 per cent for the quarter.

JSW Dulux: The paints player reported a 12.4 per cent YoY decline in net profit to Rs 79.7 crore, while revenue fell 2.8 per cent YoY to Rs 965 crore for the April-June 2026. Its EBITDA declined 14.4 per cent YoY to Rs 115.1 crore, while the EBITDA margin dropped to 11.93 per cent during the quarter.

Diamond Power Infrastructure: The power transmission firm has received two orders worth Rs 195.48 crore from Rajesh Power Services for the supply of 11 kV Medium Voltage (MV) underground power cables for projects of Paschim Gujarat Vij Company under the State Disaster Mitigation Fund scheme and the System Improvement (Urban Underground) programme in Gujarat.

RHI Magnesita India: The refractory products maker reported an 83.2 per cent YoY surge in net profit to Rs 64.6 crore, while revenue increased 5.6 per cent YoY to Rs 1,014 crore for the quarter ended on June 30, 2026. Its EBITDA grew 34.7 per cent YoY to Rs 137.6 crore, while the EBITDA margin improved to 13.58 per cent for the quarter.

Tribhovandas Bhimji Zaveri: The jewellery retailer reported a 50.8 per cent YoY jump in net profit to Rs 33.92 crore, while revenue surged 34.8 per cent YoY to Rs 840.97 crore during the June 2026 quarter. Its EBITDA increased 36 per cent YoY to Rs 72.3 crore, while the EBITDA margin improved to 8.6 per cent for the quarter.

Back To Index

Website:	Citrus Interactive	Word count	248
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus Lifesciences' arm enters into option and license agreement with Mereo

http://www.citrusinteractive.in/News/OpenNewsContent.aspx?SecId=7&SubSecID=15&NewsID=1259641

Zydus Lifesciences' wholly-owned subsidiary -- Sentynl Therapeutics, Inc. (Sentynl) and Mereo BioPharma Group plc (Mereo), a clinical-stage

biopharmaceutical company focused on rare diseases, have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency Associated Lung Disease (AATD-LD). Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Back To Index

Website:	Daily Hunt (Mobile)	Word count	1310
Published Date	12 Aug 2026	Journalist:	Bureau

Pre-Market Update: Nifty 50 May Open Flat as Crude Oil, U.S.-Iran Tensions Weigh

http://m.dailyhunt.in/news/india/english/dalal+street+investment+journal-epaper-dlalstjl/premarket+update+nifty+50+may+open+flat+as+crude+oil+usiran+tensions+weigh-newsid-n722967623

T he Indian benchmark indices, Sensex and Nifty 50, are likely to open on a flat note on Wednesday, August 12, as mixed global cues and weakness in
U.S. equities are offset by concerns over rising crude oil prices and geopolitical tensions in the Middle East.

As of 7:27 AM, GIFT Nifty was trading around 24,550, indicating a discount of 34 points against the previous close of Nifty futures and signalling a muted start for the domestic market. Asian markets opened mixed, while U.S. stock futures declined for a second consecutive session.

Crude oil prices remained elevated amid uncertainty over a potential U.S.-Iran peace agreement and fresh attacks involving commercial vessels. Concerns over disruptions to crude supplies from the Middle East increased after separate attacks were reported near the Strait of Hormuz and the Bab el-Mandeb Strait. Brent crude futures rose 0.81 per cent to USD 89.63 a barrel, while West Texas Intermediate crude gained 0.85 per cent to USD 83.91 a barrel. Both benchmarks had gained more than USD 1 in the previous session and reached their highest closing levels since July 31. Oil prices had also climbed nearly 5 per cent on Monday as optimism surrounding a possible U.S.-Iran agreement weakened.

Geopolitical developments remain a key risk for global markets. The United States and Iran-aligned Houthi forces in Yemen reported separate attacks on commercial vessels on Tuesday, increasing concerns over the safety of important oil shipping routes. Iran's top security official Mohsen Rezaei said the Strait of Hormuz would remain closed until Washington accepts Tehran's conditions for ending the conflict. The demands reportedly include the unfreezing of Iranian assets and an end to other regional conflicts.

The ongoing Q1 FY27 earnings season will also remain in focus, with more than 470 companies scheduled to announce their April-June quarter results on Wednesday. Hindustan Aeronautics, Grasim Industries, Tata Motors, Lenskart Solutions, GMR Airports, IRCTC and Ircon International are among the prominent companies scheduled to report their quarterly numbers.

Gold prices remained largely steady as investors assessed developments surrounding the possible reopening of the Strait of Hormuz and awaited the July U.S. inflation data. Spot gold was down 0.1 per cent at USD 4,367.56 an ounce, while silver gained 0.1 per cent to USD 64.72 an ounce. Gold had retreated 0.5 per cent on Tuesday after touching a two-month high.

In the derivatives market, the Put-Call Ratio for the August 18 expiry stood at 0.85. On the put side, notable open interest addition was seen at the 24,500 strike, while significant open interest concentration was at 24,000. On the call side, substantial open interest addition was recorded at 24,500, with major open interest concentration at the 25,000 strike.

The Nifty 50 ended Tuesday at 24,471.70 after forming a sizeable bearish candle, reflecting selling pressure during a range-bound session. Immediate support is placed at 24,436, followed by 24,401 and 24,345. A decisive break below 24,345 could increase selling pressure, with the index potentially moving towards 24,350 and 24,200. On the upside, resistance is seen at 24,549, 24,584 and 24,640, while the broader resistance zone remains around 24,600-24,700. Although the index continues to trade above key moving averages, weakening momentum indicators point towards continued consolidation. A sustained move above 24,600 could improve sentiment, while a break below Tuesday's range may strengthen the bearish bias.

Stock-specific activity is expected to remain high. Bata India reported a 23.04 per cent YoY increase in consolidated profit to Rs 63.98 crore, while revenue rose 3.9 per cent to Rs 978.9 crore. The company also declared an interim Dividend of Rs 25 per share for FY27. Manappuram Finance reported more than a four-fold YoY increase in Q1 profit to Rs 584.6 crore, while net interest income rose 28.1 per cent to Rs 1,723.7 crore. Impairment on financial instruments declined 60.6 per cent to Rs 225.5 crore.

RHI Magnesita India reported an 83.2 per cent YoY increase in profit to Rs 64.6 crore, with revenue rising 5.6 per cent to Rs 1,014 crore. Tribhovandas Bhimji Zaveri posted a 50.8 per cent increase in profit to Rs 33.92 crore, while revenue jumped 34.8 per cent to Rs 840.97 crore. Landmark Cars more than doubled its profit, which rose 110.5 per cent YoY to Rs 14.5 crore, while revenue increased 22.7 per cent to Rs 1,302.4 crore.

PI Industries reported a 39 per cent YoY decline in profit to Rs 244.2 crore, while revenue fell 10.4 per cent to Rs 1,702.3 crore, making the stock notable following the weak quarterly performance. Linde India reported a 2.4 per cent decline in profit to Rs 104.6 crore despite a 21.6 per cent increase in revenue to Rs 694.4 crore. The company also appointed Vikash Dokania as CFO, effective September 15, 2026. JSW Dulux reported a 12.4 per cent decline in profit to Rs 79.7 crore, while revenue fell 2.8 per cent to Rs 965 crore.

Tenneco Clean Air India is also likely to remain in focus as promoter entity Tenneco Mauritius is reportedly looking to sell an 8 per cent stake through block deals, with an option to increase the transaction by another 2 per cent. The reported floor price is Rs 515 per share, with the base deal size estimated at around Rs 1,663 crore.

Zydus Lifesciences said its subsidiary Sentynl Therapeutics entered into an option and licence agreement with Mereo BioPharma covering U.S. commercialisation and global manufacturing rights for Alvelestat for AATD-LD. BEML secured an order worth Rs 184.25 crore from Hindustan Aeronautics for manufacturing and supplying Light Combat Helicopter fuselage aerostructures.

HG Infra Engineering received a letter of award from the Rajasthan government for the operation and management of the ITI Bhiwadi Cluster under PM-SETU. The company's share of the estimated Rs 241 crore project cost is 17.10 per cent. Larsen & Toubro executed a Business Transfer Agreement with its subsidiary Vyoma.AI to transfer its data centre and cloud services business for Rs 1,400 crore through a slump sale.

Godrej Consumer Products appointed Aasif Malbari as Managing Director and Chief Executive Officer with immediate effect, succeeding Sudhir Sitapati. KFin Technologies launched Klarity, an Agentic AI solution aimed at detecting skilled forgery and reducing wrongful rejection of legitimate behavioural signatures in financial institutions. Diamond Power Infrastructure secured two orders worth Rs 195.48 crore from Rajesh Power Services for supplying 11 kV medium-voltage underground power cables for PGVCL projects in Gujarat.

For the day, SAIL and Bandhan Bank are under the F&O ban.

Institutional activity was relatively subdued in the previous session. On August 10, Foreign Institutional Investors were net buyers of Indian equities worth Rs 258.55 crore, while Domestic Institutional Investors purchased shares worth Rs 24.77 crore.

The domestic market ended sharply lower on Tuesday as investors booked profits amid higher crude oil prices and continued uncertainty surrounding the reopening of the Strait of Hormuz and the possibility of a U.S.-Iran agreement. The Sensex declined 388 points, or 0.49 per cent, to close at 78,154.25, while the Nifty 50 fell 112 points, or 0.46 per cent, to settle at 24,471.70.

U.S. markets extended their losses for a second consecutive session on Tuesday as weakness in technology stocks weighed on sentiment and higher crude oil prices added to concerns. The Dow Jones Industrial Average fell 180 points after giving up more than 430 points from its Intraday high. The S&P 500 and Nasdaq Composite declined 0.3 per cent and 0.6 per cent, respectively.

Investors will now focus on the release of the U.S. Consumer Price Index data for July. The inflation reading will be closely watched for indications about the Federal Reserve's future interest-rate path. For Indian markets, movements in crude oil, developments around the Strait of Hormuz and U.S.-Iran tensions, global equity cues and the ongoing Q1 FY27 earnings season are likely to determine the near-term trend.

Disclaimer: The article is for informational purposes only and not investment advice.

Back To Index

Website:	Dalal Street Investment Journal India	Word count	1310
Published Date	12 Aug 2026	Journalist:	Bureau

Pre-Market Update: Nifty 50 May Open Flat as Crude Oil, U.S.-Iran Tensions Weigh

https://insights.dsij.in/dsijarticledetail/pre-market-update-nifty-50-may-open-flat-as-crude-oil-us-iran-tensions-weigh-58936

Key Takeaways The Indian benchmark indices, Sensex and Nifty 50, are likely to open on a flat note on Wednesday, August 12, as mixed global

cues and weakness in U.S. equities are offset by concerns over rising crude oil prices and geopolitical tensions in the Middle East.

As of 7:27 AM, GIFT Nifty was trading around 24,550, indicating a discount of 34 points against the previous close of Nifty futures and signalling a muted start for the domestic market. Asian markets opened mixed, while U.S. stock futures declined for a second consecutive session.

Crude oil prices remained elevated amid uncertainty over a potential U.S.-Iran peace agreement and fresh attacks involving commercial vessels. Concerns over disruptions to crude supplies from the Middle East increased after separate attacks were reported near the Strait of Hormuz and the Bab el-Mandeb Strait. Brent crude futures rose 0.81 per cent to USD 89.63 a barrel, while West Texas Intermediate crude gained 0.85 per cent to USD 83.91 a barrel. Both benchmarks had gained more than USD 1 in the previous session and reached their highest closing levels since July 31. Oil prices had also climbed nearly 5 per cent on Monday as optimism surrounding a possible U.S.-Iran agreement weakened.

Geopolitical developments remain a key risk for global markets. The United States and Iran-aligned Houthi forces in Yemen reported separate attacks on commercial vessels on Tuesday, increasing concerns over the safety of important oil shipping routes. Iran's top security official Mohsen Rezaei said the Strait of Hormuz would remain closed until Washington accepts Tehran's conditions for ending the conflict. The demands reportedly include the unfreezing of Iranian assets and an end to other regional conflicts.

The ongoing Q1 FY27 earnings season will also remain in focus, with more than 470 companies scheduled to announce their April-June quarter results on Wednesday. Hindustan Aeronautics, Grasim Industries, Motors, Lenskart Solutions, GMR Airports, IRCTC and Ircon International are among the prominent companies scheduled to report their quarterly numbers.

Gold prices remained largely steady as investors assessed developments surrounding the possible reopening of the Strait of Hormuz and awaited the July U.S. inflation data. Spot gold was down 0.1 per cent at USD 4,367.56 an ounce, while silver gained 0.1 per cent to USD 64.72 an ounce. Gold had retreated 0.5 per cent on Tuesday after touching a two-month high.

In the derivatives market, the Put-Call Ratio for the August 18 expiry stood at 0.85. On the put side, notable open interest addition was seen at the 24,500 strike, while significant open interest concentration was at 24,000. On the call side, substantial open interest addition was recorded at 24,500, with major open interest concentration at the 25,000 strike.

The Nifty 50 ended Tuesday at 24,471.70 after forming a sizeable bearish candle, reflecting selling pressure during a range-bound session. Immediate support is placed at 24,436, followed by 24,401 and 24,345. A decisive break below 24,345 could increase selling pressure, with the index potentially moving towards 24,350 and 24,200. On the upside, resistance is seen at 24,549, 24,584 and 24,640, while the broader resistance zone remains around 24,600-24,700. Although the index continues to trade above key moving averages, weakening momentum indicators point towards continued consolidation. A sustained move above 24,600 could improve sentiment, while a break below Tuesday's range may strengthen the bearish bias.

Stock-specific activity is expected to remain high. Bata India reported a 23.04 per cent YoY increase in consolidated profit to Rs 63.98 crore, while revenue rose 3.9 per cent to Rs 978.9 crore. The company also declared an interim of Rs 25 per share for FY27. Manappuram Finance reported more than a four-fold YoY increase in Q1 profit to Rs 584.6 crore, while net interest income rose 28.1 per cent to Rs 1,723.7 crore. Impairment on financial instruments declined 60.6 per cent to Rs 225.5 crore.

RHI Magnesita India reported an 83.2 per cent YoY increase in profit to Rs 64.6 crore, with revenue rising 5.6 per cent to Rs 1,014 crore. Tribhovandas Bhimji Zaveri posted a 50.8 per cent increase in profit to Rs 33.92 crore, while revenue jumped 34.8 per cent to Rs 840.97 crore. Landmark Cars more than doubled its profit, which rose 110.5 per cent YoY to Rs 14.5 crore, while revenue increased 22.7 per cent to Rs 1,302.4 crore.

PI Industries reported a 39 per cent YoY decline in profit to Rs 244.2 crore, while revenue fell 10.4 per cent to Rs 1,702.3 crore, making the stock notable following the weak quarterly performance. Linde India reported a 2.4 per cent decline in profit to Rs 104.6 crore despite a 21.6 per cent increase in revenue to Rs 694.4 crore. The company also appointed Vikash Dokania as CFO, effective September 15, 2026. JSW Dulux reported a 12.4 per cent decline in profit to Rs 79.7 crore, while revenue fell 2.8 per cent to Rs 965 crore.

Tenneco Clean Air India is also likely to remain in focus as promoter entity Tenneco Mauritius is reportedly looking to sell an 8 per cent stake through block deals, with an option to increase the transaction by another 2 per cent. The reported floor price is Rs 515 per share, with the base deal size estimated at around Rs 1,663 crore.

Zydus Lifesciences said its subsidiary Sentynl Therapeutics entered into an option and licence agreement with Mereo BioPharma covering U.S. commercialisation and global manufacturing rights for Alvelestat for AATD-LD. BEML secured an order worth Rs 184.25 crore from Hindustan Aeronautics for manufacturing and supplying Light Combat Helicopter fuselage aerostructures.

HG Infra Engineering received a letter of award from the Rajasthan government for the operation and management of the ITI Bhiwadi Cluster under PM-SETU. The company's share of the estimated Rs 241 crore project cost is 17.10 per cent. Larsen & Toubro executed a Business Transfer Agreement with its subsidiary Vyoma.AI to transfer its data centre and cloud services business for Rs 1,400 crore through a slump sale.

Godrej Consumer Products appointed Aasif Malbari as Managing Director and Chief Executive Officer with immediate effect, succeeding Sudhir Sitapati. KFin Technologies launched Klarity, an Agentic AI solution aimed at detecting skilled forgery and reducing wrongful rejection of legitimate behavioural signatures in financial institutions. Diamond Power Infrastructure secured two orders worth Rs 195.48 crore from Rajesh Power Services for supplying 11 kV medium-voltage underground power cables for PGVCL projects in Gujarat.

For the day, SAIL and Bandhan are under the F&O ban.

Institutional activity was relatively subdued in the previous session. On August 10, Foreign Institutional Investors were net buyers of Indian equities worth Rs 258.55 crore, while Domestic Institutional Investors purchased shares worth Rs 24.77 crore.

The domestic market ended sharply lower on Tuesday as investors booked profits amid higher crude oil prices and continued uncertainty surrounding the reopening of the Strait of Hormuz and the possibility of a U.S.-Iran agreement. The Sensex declined 388 points, or 0.49 per cent, to close at 78,154.25, while the Nifty 50 fell 112 points, or 0.46 per cent, to settle at 24,471.70.

U.S. markets extended their losses for a second consecutive session on Tuesday as weakness in technology stocks weighed on sentiment and higher crude oil prices added to concerns. The Dow Jones Industrial Average fell 180 points after giving up more than 430 points from its high. The S&P 500 and Nasdaq Composite declined 0.3 per cent and 0.6 per cent, respectively.

Investors will now focus on the release of the U.S. Consumer Price Index data for July. The inflation reading will be closely watched for indications about the Federal Reserve's future interest-rate path. For Indian markets, movements in crude oil, developments around the Strait of Hormuz and U.S.-Iran tensions, global equity cues and the ongoing Q1 FY27 earnings season are likely to determine the near-term trend.

Disclaimer: The article is for informational purposes only and not investment advice.

Share this article

Back To Index

Website:	Equity Pandit	Word count	376
Published Date	12 Aug 2026	Journalist:	Ali Waghbakriwala

Stocks in Focus: Zydus Lifesciences, BEML, and Others

https://www.equitypandit.com/stocks-in-focus-zydus-lifesciences-beml-and-others/

The GIFT Nifty futures, which is an early indicator of the Nifty50 index stocks, was trading higher by 6 points at 24,546, indicating that the domestic benchmark indices are likely to make a muted start on Wednesday.

Earlier on Tuesday, 11 August, the domestic benchmark indices S&P BSE Sensex slumped by 388 points or 0.49%, and settled at 78,154 while the Nifty50 traded 0.46% lower or 112 points, closing at 24,471.

Here are some stocks that are likely to remain in focus on 12 August.

Zydus Lifesciences: Zydus Lifesciences' subsidiary, Sentynl Therapeutics, has entered into an option and licence agreement with Mereo BioPharma Group for the US commercialisation and global manufacturing rights to Alvelestat for AATD-LD.

BEML: The company has secured an order worth Rs 184.25 crore from Hindustan Aeronautics (HAL) for the manufacture and supply of fuselage aerostructures for Light Combat Helicopters (LCH). HG Infra Engineering: HG Infra Engineering has received a Letter of Award (LOA) from the Department of Skill, Employment & Entrepreneurship, Government of Rajasthan, to operate and manage the ITI Bhiwadi Cluster under Component-I of the PM-SETU programme. The company's share represents 17.10% of the estimated project cost of Rs 241 crore.

Larsen and Toubro: Larsen & Toubro (L&T) has signed a Business Transfer Agreement with its subsidiary Vyoma.AI to transfer its data centre and cloud services business through a slump sale on a going-concern basis. The transaction has a value of Rs 1,400 crore.

KFin Technologies: KFin Technologies has launched Klarity, an Agentic AI solution designed to address two key operational challenges faced by financial institutions: the incorrect acceptance of sophisticated forgeries and the wrongful rejection of genuine customers due to legitimate variations in behavioural signatures.

Diamond Power Infrastructure: The company has secured two orders worth Rs 195.48 crore from Rajesh Power Services to supply 11 kV Medium Voltage (MV) underground power cables for PGVCL projects in Gujarat. The orders cover projects under the State Disaster Mitigation Fund (SDMF) scheme and the System Improvement (Urban Underground) programme, particularly in coastal areas, and will be completed over the next 12 months.

Back To Index

Website:	Express Pharma	Word count	527
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus' Sentynl enters option and licence deal for alvelestat

https://www.expresspharma.in/zydus-sentynl-enters-option-and-licence-deal-for-alvelestat/

The agreement covers US commercial and global manufacturing rights to Mereo BioPharmas alvelestat for AATD-LD

Sentynl Therapeutics, a US-based biopharmaceutical company and wholly owned subsidiary of Zydus Lifesciences, and Mereo BioPharma Group, a clinical-stage biopharmaceutical company focused on rare diseases, have entered into an option and licence agreement for the US commercial and global manufacturing rights to alvelestat for AATD-LD.

Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.

The option and licence agreement grants Sentynl the exclusive right to acquire a licence to commercialise alvelestat for AATD-LD in the United States, while Mereo will retain commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and, on exercise of the option, provides funding for the alvelestat Phase 3 development programme, which could be initiated in early 2027.

This partnership marks a pivotal moment for Sentynls rare disease strategy. Mereos alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. AATD-LD has a profound impact on patients lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people, said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynls commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design, said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under the terms, Mereo would also be eligible to receive double-digit tiered royalties on US net sales of alvelestat.

Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. During the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

Back To Index

Website:	Flipit Money	Word count	400
Published Date	12 Aug 2026	Journalist:	Bureau

Dr Agarwals, Tenneco Clean Air India drop on block deals

https://flipit.money/flips/dr-agarwals-tenneco-clean-air-india-drop-on-block-deals

Zydus Lifesciences saw its shares drop 2 percent after its subsidiary Sentynl Therapeutics, in partnership with Mereo BioPharma Group plc, announced an option and licence agreement.

The deal grants Sentynl US commercialisation and global manufacturing rights for Alvelestat, a treatment candidate for Alpha-1 Antitrypsin Deficiency Lung Disease (AATD-LD). Despite the potential of the agreement, investors appeared cautious on the stock.

Tenneco Clean Air India also lost 2 percent as a significant block deal took place. Roughly 3.2 crore shares, equivalent to 7.9 percent of the company's equity and worth Rs 1,699 crore, changed hands at a price of Rs 529 per share. The sizable transaction drew attention but weighed on the share price.

Among other notable movers, RHI Magnesita India slipped nearly 5 percent despite reporting robust results. The company posted an 83.2 percent jump in net profit for the first quarter to Rs 64.6 crore, compared to Rs 35.3 crore in the same period last year. Revenue rose 5.6 percent to Rs 1,014 crore from Rs 960.3 crore a year ago. The decline in share price suggests that expectations may have run ahead of the reported numbers or that investors booked profits following the results.

Dr Agarwals Health Care shares fell 6 percent following another large block deal, as 4.07 crore shares, or 12.9 percent of equity, worth Rs 2,065 crore, were exchanged at Rs 506.5 apiece. The heavy trading volume sent shares south despite the absence of an earnings-related catalyst.

Sectoral trends reflected a mixed picture. The Nifty PSU Bank index outperformed with a gain of 1.81 percent. Nifty Metal followed with a 0.51 percent rise, while Nifty Bank added 0.28 percent. In contrast, Nifty Realty dropped 1.07 percent, Nifty Consumer Durables declined 0.92 percent, Nifty IT lost 0.74 percent, Nifty FMCG was down by 0.77 percent, Nifty Infra dipped 0.58 percent, and Nifty Pharma slipped 0.48 percent.

Broader market indicators also pointed to a cautious tone. Both the Nifty midcap and smallcap indices traded down 0.3 percent each. On the Bombay Stock Exchange, market breadth was slightly negative, with 1,598 stocks advancing versus 1,758 declining, indicating a degree of caution despite ongoing action in specific counters.

Overall, while market indices showed a downward bias, much of the activity on Dalal Street was driven by stock-specific developments tied to earnings and major corporate transactions, underscoring the importance of company results and strategic moves in shaping investor sentiment.

Back To Index

Website:	Gift Nifty	Word count	563
Published Date	12 Aug 2026	Journalist:	Bureau

Stocks in Focus : Wednesday, 12 August

https://giftnifty.org/2026/08/stocks-in-focus-wednesday-12-august/

GIFT Nifty Opening Update GIFT Nifty opened today at 24,527.50. It is up 44.00 points (0.18%) from yesterday's close of 24,515.50 so the trend is positive.

The Indian stock market concluded significantly lower on Tuesday, August 11, as investors engaged in profit-booking in response to escalating oil prices and ongoing uncertainty regarding the reopening of the Strait of Hormuz and the potential for a US-Iran agreement. The Sensex experienced a decline of 388 points, equivalent to 0.49%, concluding at 78,154.25. Meanwhile, the Nifty 50 saw a reduction of 112 points, or 0.46%, finishing at 24,471.70.

Indian equity markets are expected to trade with a cautious undertone as persistent uncertainty surrounding the U.S.-Iran negotiations continues to weigh on investor sentiment. Overnight cues from Wall Street were subdued, with the S&P 500 and Dow Jones Industrial Average each declining about 0.3%, while the Nasdaq Composite slipped 0.6%, as investors turned cautious ahead of Wednesday's U.S. consumer price inflation data and amid the continuing stalemate between Washington and Tehran over the reopening of the Strait of Hormuz. Reflecting the mixed global backdrop, GIFT Nifty futures are trading just above the 24,500 mark, compared with the Nifty's previous close of 24,471, indicating a flat-to-mildly positive start for domestic equities, said Ponmudi R.

As the market indicates a flat opening, certain stocks are expected to attract attention on Wednesday owing to their individual positive or negative catalysts. Equities to Monitor:

Hindustan Aeronautics, Grasim Industries, Tata Motors, Lenskart Solutions, GMR Airports, and IRCTC are set to capture attention as these firms announce their Q1 results for 2026 today.

L&T

has consented to divest its complete stake in L&T Network Services to Vyoma for Rs 30 crore, contingent upon adjustments at closing, via a share-swap transaction. Upon completion of the deal, LTNSPL will become a direct wholly owned subsidiary of Vyoma and an indirect wholly owned subsidiary of L&T.

Manappuram Finance

reported a net profit of Rs 584.5 crore in the first quarter, reflecting a significant rise from Rs 138.3 crore noted in the corresponding period of the previous year. Net interest income (NII) experienced a significant increase of 28.1% year-on-year, reaching Rs 1,723.8 crore, in contrast to Rs 1,345.3 crore during the same quarter of the prior year.

Zydus Lifesciences

Sentynl Therapeutics, a wholly owned subsidiary of the company, has entered into an option and licence agreement with Mereo BioPharma for alvelestat, an investigational therapy being developed for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, a rare genetic respiratory condition.

NBCC (India)

reported a 17.2% year-on-year increase in net profit to Rs 154.8 crore in the June quarter, even as revenue experienced a decline. Revenue from operations decreased by 6% year-on-year, amounting to Rs 2,259.5 crore.

BEML

announced on Tuesday, August 11, that it has secured an order valued at Rs 184.25 crore from Hindustan Aeronautics Ltd (HAL) for the production and delivery of fuselage aerostructures for Light Combat Helicopters.

Bata India

reported a 23.1% year-on-year growth in consolidated net profit to Rs 64 crore for the quarter ended June 2026, compared with Rs 52 crore recorded in the same period a year earlier.

Man Industries

reported its highest-ever consolidated quarterly EBITDA at Rs 155 crore, registering a 92.6% year-on-year and 5.0% quarter-on-quarter growth. The robust performance was bolstered by an optimised product and geographical mix, in addition to the ongoing expansion of its global order pipeline.

Back To Index

Website:	Grow Mudra	Word count	1133
Published Date	12 Aug 2026	Journalist:	Bureau

Stocks to Watch Today: Tenneco Clean Air, BEML, HG Infra Engg, Diamond Power, Larsen and Toubro, Ardee Industries, RHI Magnesita, Manappuram in focus on 12 August

https://growmudra.com/news/details/ae45b0d5e8c171dbfdd200ddaf45a34d/stocks-to-watch-today-tenneco-clean-air-beml-hg-infra-engg-diamond-power-larsen-and-toubro-ardee-industries-rhi-magnesita-manappuram-in-focus-on-12-august

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, appointments, and order wins, here's a quick look at which stocks will be in focus in today's trade:

Results Today

Tata Motors, Grasim Industries, Apollo Hospitals Enterprise, Lenskart Solutions, Hindustan Aeronautics, Arvind, Astral, Aditya Infotech, EID Parry India, EMS, GMR Airports, Indiqube Spaces, Indian Railway Catering and Tourism Corporation, Jyothy Labs, National Fertilizers, Petronet LNG, SKF India, Sun TV Network, Titagarh Rail Systems, VIP Industries, VA Tech Wabag, and Yatra Online will announce their quarterly earnings today.

Quarterly Earnings

Bata India Q1 (Consolidated YoY)

Profit grows 23.04% to Rs 63.98 crore Vs Rs 52 crore

Revenue increases 3.9% to Rs 978.9 crore Vs Rs 941.9 crore

Board declared interim dividend of Rs 25 per share for FY27

Manappuram Finance Q1 (Consolidated YoY)

Profit jumps over 4-fold to Rs 584.6 crore Vs Rs 138.4 crore

Net interest income soars 28.1% to Rs 1,723.7 crore Vs Rs 1,345.3 crore

Impairment on financial instruments sink 60.6% to Rs 225.5 crore Vs Rs 572.4 crore

RHI Magnesita India Q1 (Consolidated YoY)

Profit zooms 83.2% to Rs 64.6 crore Vs Rs 35.3 crore

Revenue rises 5.6% to Rs 1,014 crore Vs Rs 960.3 crore

Tribhovandas Bhimji Zaveri Q1 (Consolidated YoY)

Profit surges 50.8% to Rs 33.92 crore Vs Rs 22.5 crore

Revenue soars 34.8% to Rs 840.97 crore Vs Rs 624 crore

PI Industries Q1 (Consolidated YoY)

Profit falls 39% to Rs 244.2 crore Vs Rs 400 crore

Revenue declines 10.4% to Rs 1,702.3 crore Vs Rs 1,900.5 crore

Linde India Q1 (Consolidated YoY)

Profit slips 2.4% to Rs 104.6 crore Vs Rs 107.2 crore

Revenue grows 21.6% to Rs 694.4 crore Vs Rs 571.1 crore

Board appoints Vikash Dokania as Chief Financial Officer of the company effective September 15, 2026

Landmark Cars Q1 (Consolidated YoY)

Profit zooms 110.5% to Rs 14.5 crore Vs Rs 6.9 crore

Revenue jumps 22.7% to Rs 1,302.4 crore Vs Rs 1,061.7 crore

JSW Dulux Q1 (Consolidated YoY)

Profit falls 12.4% to Rs 79.7 crore Vs Rs 91 crore

Revenue drops 2.8% to Rs 965 crore Vs Rs 993.1 cr...

Revenue drops 2.8% to Rs 965 crore Vs Rs 993.1 crore

Stocks To Watch

Tenneco Clean Air India

Promoter entity Tenneco Mauritius is likely to sell an 8 percent stake in Tenneco Clean Air India, with an upsize option of 2 percent, through block deals. The floor price is expected to be Rs 515 per share, with a base offer size of Rs 1,663 crore, CNBC-TV18 reported, citing sources.

Zydus Lifesciences

The company's subsidiary, Sentynl Therapeutics, and Mereo BioPharma Group plc have entered into an option and licence agreement for the US commercialisation and global manufacturing rights to Alvelestat for AATD-LD.

Alvelestat is a neutrophil elastase inhibitor being prepared for Phase 3 trials and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease. The option and licence agreement grants Sentynl the exclusive right to acquire a licence to commercialise Alvelestat for AATD-LD in the United States, while Mereo will retain commercial rights in the rest of the world.

BEML

BEML has secured an order worth Rs 184.25 crore from Hindustan Aeronautics (HAL) for the manufacture and supply of Light Combat Helicopter (LCH) fuselage aerostructures.

HG Infra Engineering

The company has received a Letter of Award (LOA) from the Department of Skill, Employment & Entrepreneurship, Government of Rajasthan, for the operation and management of the ITI Bhiwadi Cluster under Component-I of PM-SETU (Pradhan Mantri Skilling and Employability Transformation through Upgraded ITIs). Its share is 17.10 percent of the estimated cost of Rs 241 crore.

Larsen and Toubro

L&T has executed a Business Transfer Agreement with its subsidiary Vyoma.AI for the transfer of its data centre and cloud services business, on a going-concern basis through a slump sale, to Vyoma for Rs 1,400 crore.

Godrej Consumer Products

The Board announced the appointment of Aasif Malbari, currently Global Chief Financial Officer and President, Godrej Africa, as Managing Director and Chief Executive Officer of Godrej Consumer Products, effective immediately. He will succeed Sudhir Sitapati, who will step down as MD and CEO.

KFin Technologies

KFin Technologies announced the rollout of Klarity, an Agentic AI solution built to address two operational vulnerabilities in financial institutions' operations skilled forgeries being incorrectly accepted as valid matches and legitimate behavioural signature variations resulting in wrongful rejections.

Diamond Power Infrastructure

The company has received two orders worth Rs 195.48 crore from Rajesh Power Services for the supply of 11 kV Medium Voltage (MV) underground power cables for projects of Paschim Gujarat Vij Company Limited (PGVCL) under the State Disaster Mitigation Fund (SDMF) scheme and the System Improvement (Urban Underground) programme in Gujarat, with a focus on coastal areas. The orders are to be executed over the next 12 months.

Bulk & Block Deals

Metropolis Healthcare

Promoter entities Duru Shah Family Trust and Metz Advisory LLP each sold 10.5 lakh shares of Metropolis Healthcare for Rs 59.22 crore, taking the total transaction value to Rs 118.44 crore. The shares changed hands at Rs 564 apiece, with the combined sale representing a 1.01 percent stake.

Aditya Birla Sun Life Mutual Fund acquired 10.49 lakh shares for Rs 59.16 crore, while ICICI Prudential Mutual Fund and Morgan Stanley Asia Singapore Pte each bought 5.25 lakh shares for Rs 29.63 crore. As of June 2026, Aditya Birla Sun Life Flexi Cap Fund already held a 1.95 percent stake in Metropolis Healthcare.

Univastu India

Taurus Mutual Fund acquired 3.77 lakh shares, or 0.99 percent of the paid-up equity, in Univastu India for Rs 4.9 crore. The shares were bought at Rs 130 apiece.

Rolex Rings

German investment firm Bayerninvest KVG MBH, on behalf of ERI Bayerninvest Fonds Aktien Asien, acquired 8.98 lakh shares, or a 0.33 percent stake, in auto parts maker Rolex Rings for Rs 15.33 crore at Rs 170.59 per share.

RPP Infra Projects

Chennai-based construction and infrastructure company Diva Projects acquired 8.48 lakh shares, or a 1.71 percent stake, in RPP Infra Projects for Rs 4.99 crore at Rs 58.90 per share.

On the selling side, promoter Arul Sundaram Nithya sold 5.13 lakh shares for Rs 3.01 crore at Rs 58.74 per share, while P Arul Sundaram sold 3.59 lakh shares for Rs 2.13 crore at Rs 59.21 per share. The combined promoter sale represented a 1.76 percent stake.

Mainboard Listing

Ardee Industries

SME Listing

GV Electricals

Stocks Trade Ex-Dividend

Computer Age Management Services

KPIT Technologies

NHPC

ASM Technologies

Dhunseri Tea & Industries

Gabriel India

Gujarat Containers

HG Infra Engineering

Industrial & Prudential Investment Company

KCP

Neelamalai Agro Industries

Sandur Manganese & Iron Ores

Narmada Gelatines

Uniparts India

Vaibhav Global

Voith Paper Fabrics India

Stock Trades Ex-Date for Income Distribution

National Highways Infra Trust

Stocks in F&O Ban

SAIL, Bandhan Bank

Back To Index

Website:	HT Syndication	Word count	104
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus' US Sentynl Therapeutics expands rare disease portfolio in partnership with Mereo BioPharma

https://htsyndication.com/biospectrum-india/article/zydus--us-sentynl-therapeutics-expands-rare-disease-portfolio-in-partnership-with-mereo-biopharma/103125158

India, Aug. 12 -- image credit- freepik Sentynl Therapeutics, Inc., a US-based biopharmaceutical company and wholly-owned subsidiary of

Zydus Lifesciences, and Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases, have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD).

Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.

The option and license agreement grants Sentynl the exclus...

Back To Index

Website:	Indian Pharma Post	Word count	423
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus' Sentynl, Mereo BioPharma enter option deal for Alvelestat in rare lung disease

https://www.indianpharmapost.com/news/zydus-sentynl-mereo-biopharma-enter-option-deal-for-alvelestat-in-rare-lung-disease-21349

Zydus Lifesciences subsidiary Sentynl Therapeutics will have an exclusive option to acquire a licence to commercialise the drug in the United States, while Mereo BioPharma will retain commercial rights in the rest of the world

By IPP Bureau | August 12, 2026

Sentynl Therapeutics, the U.S.-based biopharmaceutical subsidiary of Zydus Lifesciences, and clinical-stage biopharmaceutical company Mereo BioPharma Group have entered into an option and license agreement covering the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Under the agreement, Sentynl will have the exclusive option to acquire a licence to commercialise alvelestat for AATD-LD in the United States, while Mereo will retain commercial rights in the rest of the world. Sentynl will also receive global manufacturing rights for the therapy.

Alvelestat is a neutrophil elastase inhibitor being prepared for Phase 3 development and, if approved, could become the first oral treatment for AATD-LD, a rare and progressive genetic lung disease estimated to affect 50,00080,000 people in the U.S.

If Sentynl exercises the option, the agreement will provide funding for the Phase 3 development programme, which could begin in early 2027. Mereo will lead the global Phase 3 study and regulatory interactions until completion, while the two companies will collaborate during the option period on manufacturing and refining the Phase 3 study design.

This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

Matt Heck, Chief Executive Officer, Sentynl Therapeutics, said the partnership would expand the company's focus within the rare disease segment. For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat.

He added, Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

Denise Scots-Knight, Chief Executive Officer, Mereo BioPharma, said, We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies.

Back To Index

Website:	Investment Guru India	Word count	337
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus Lifesciences rises as its arm enters into option and license agreement with Mereo

https://investmentguruindia.com/newsdetail/zydus-lifesciences-rises-as-its-arm-enters-into-option-and-license-agreement-with-mereo875002

Zydus Lifesciences is currently trading at Rs. 1194.00, up by 14.00 points or 1.19% from its previous closing of Rs. 1180.00 on the BSE.

The scrip opened at Rs. 1198.60 and has touched a high and low of Rs. 1198.60 and Rs. 1151.40 respectively. So far 1.01 lakh shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1205.00 on 11-Aug-2026 and a 52 week low of Rs. 835.85 on 02-Apr-2026.

Last one week high and low of the scrip stood at Rs. 1205.00 and Rs. 1093.30 respectively. The current market cap of the company is Rs. 1,19,101.96 crore.

The promoters holding in the company stood at 75.01%, while Institutions and Non-Institutions held 18.15% and 6.83% respectively.

Zydus Lifesciences' wholly-owned subsidiary -- Sentynl Therapeutics, Inc. (Sentynl) and Mereo BioPharma Group plc (Mereo), a clinical-stage biopharmaceutical company focused on rare diseases, have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency Associated Lung Disease (AATD-LD). Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat.

Back To Index

Website:	Money Works 4 Me	Word count	260
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus Lifesciences' arm enters into option and license agreement with Mereo

https://www.moneyworks4me.com/company/news/index/id/832135

Zydus Lifesciences' wholly-owned subsidiary -- Sentynl Therapeutics, Inc. (Sentynl) and Mereo BioPharma Group plc (Mereo), a clinical-stage
biopharmaceutical company focused on rare diseases, have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency Associated Lung Disease (AATD-LD). Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

*Color code for outperformance consistency

*Number is average 3 year rolling returns

Back To Index

Website:	MSN India	Word count	259
Published Date	12 Aug 2026	Journalist:	Bureau

Business news live: J&K Bank to raise Rs 1,000 crore; Tenneco, Dr Agarwal's Health Care, Thyrocare in focus

https://www.msn.com/en-in/money/top-stocks/business-news-live-j-k-bank-to-raise-rs-1-000-crore-tenneco-dr-agarwal-s-health-care-thyrocare-in-focus/ar-AA29SMMt

Moneycontrol News Welcome to Moneycontrol's market blog. Here's a quick roundup of the key corporate developments and stock-specific updates to watch.

First up, Glenmark Pharmaceuticals: Glenmark's US subsidiary has settled a lawsuit filed by Humana for $15.28 million. Dr Agarwal's Health Care: TPG and Temasek-linked investment vehicles are set to sell a stake in the company through a block deal. The floor price has been set at Rs 500 per share, a 7.7% discount to the previous close. The base offer represents 11% of the company's equity and is valued at around Rs 1,750 crore, with an upsizing option of another 2% worth Rs 250 crore. Thyrocare: A block deal has been launched in Thyrocare and is likely to take place during the block window. Around 1.5 crore shares are on offer, with the transaction valued at approximately Rs 1,000 crore at the floor price. The indicative floor price is in the range of Rs 630-631 per share, implying a discount of up to 3% to the previous close. The seller is likely to be the company's parent. DIACABS: The company has secured two orders worth Rs 195.5 crore from Rajesh Power Services for a project of Paschim Gujarat Vij Company Limited (PGVCL) in Gujarat. KFin Technologies: The company has launched Klarity, an enterprise-grade agentic AI solution aimed at eliminating signature fraud in the banking, financial services and insurance (BFSI) sector. Zydus Lifesciences: Sentynl Therapeutics and Mereo BioPharma have announced an option and licence agreement for Alvelestat, a treatment being developed for lung disease associated with alpha-1 antitrypsin deficiency.

Back To Index

Website:	MSN India	Word count	261
Published Date	12 Aug 2026	Journalist:	Bureau

Dr Agarwals Health Care, Tenneco Clean Air India slip on block deals; RHI Magnesita falls nearly 5%

https://www.msn.com/en-in/money/top-stocks/price-action-dr-agarwals-health-care-tenneco-clean-air-india-slip-on-block-deals-rhi-magnesita-falls-nearly-5/ar-AA29Ub82

Moneycontrol News Stock-specific action dominated Dalal Street on August 12 as investors reacted to another batch of June-quarter earnings
and key corporate developments, while benchmark indices traded with a negative bias. Earnings and company-specific triggers continued to drive sharp moves across mid- and small-cap stocks.

Zydus Lifesciences shares shed 2% after its subsidiary, Sentynl Therapeutics, and Mereo BioPharma Group plc have entered into an option and licence agreement for the US commercialisation and global manufacturing rights to Alvelestat for AATD-LD.

Tenneco Clean Air India share price fell 2% after 3.2 crore shares (7.9% equity) worth Rs 1,699 crore change hands at Rs 529/share bia block deal.

RHI Magnesita India shares slipped nearly 5% despite Q1 profit zooms 83.2% to Rs 64.6 crore Vs Rs 35.3 crore and revenue rises 5.6% to Rs 1,014 crore Vs Rs 960.3 crore.

Share price of Dr Agarwals Health Care declined 6% after 4.07 crore shares (12.9% equity) worth Rs 2065 crore change hands at RS 506.5/share via block deals.

On the sectoral front, the Nifty PSU Bank index rose 1.81%, while Nifty Metal gained 0.51% and Nifty Bank advanced 0.28%.

On the downside, Nifty Realty fell 1.07%, Nifty Consumer Durables declined 0.92%, Nifty IT dropped 0.74%, Nifty FMCG shed 0.77%, Nifty Infra declined 0.58%, and Nifty Pharma fell 0.48%.

The broader market also trading lower, with Nifty midcap and smallcap indices down 0.3% each.

Market breadth remained slightly negative, with 1598 stocks advancing against 1758 declining on the BSE, indicating a cautious undertone in the broader market despite continued activity in individual stocks.

Back To Index

Website:	MSN India	Word count	3356
Published Date	12 Aug 2026	Journalist:	Bureau

Stock market today: All you need to know going into trade on August 12

https://www.msn.com/en-in/money/top-stocks/stock-market-today-all-you-need-to-know-going-into-trade-on-august-12/ar-AA29Tq7I

Author: NDTV Profit Research GIFT Nifty Check GIFT Nifty traded at 24,544.50, up 4 points, indicating a flat-to-muted start for the Nifty and Sensex.

Asian Market Check

Asian stock markets were mixed on Wednesday as investors assessed the latest signals from efforts to ease tensions around the Strait of Hormuz. South Korean shares advanced sharply, while Japanese and Australian equities were little changed to lower.

South Korea's Kospi rose 2.02%, while Japan's Nikkei 225 slipped 0.01%. Australia's ASX 200 declined 0.40%.

Commodity Check

Oil prices held near multi-month highs on Wednesday as traders weighed signs that the US and Iran could be moving closer to an arrangement over the Strait of Hormuz, even as physical traffic through the critical waterway remains severely disrupted.

Brent crude traded near $89 a barrel after gaining 12% over the previous five sessions, while West Texas Intermediate was above $83. Pakistan's Defence Minister Khawaja Asif said Washington and Tehran were close to some sort of arrangement over Hormuz, adding that things are shaping up in favor of peace. Pakistan has been mediating efforts to end the conflict.

US Market Recap

Walll Street indices ended in the red on Wednesday amid a boiling crude and growing uncertainties regarding re-opening of the Hormuz strait and a between Washington and Tehran.

S&P 500 ended 0.32% lower at 7,728.20, Dow Jones Industrial Average closed 0.34% lower at 53,791.85, and the tech-heavy Nasdaq Composite closed 0.60% lower at 26,445.45 after big tech names like Google-parent Alphabet Inc. and Amazon weighed on the index.

India Market Recap

Indian equity benchmarks continued to decline after a brief oause on Monday amid NSE's weekly F&O expiry day. The Nifty 50 ended 112.10 points, or 0.46%, lower at 24,471.70. The Sensex dropped 388.19 points, or 0.49%, to close at 78,154.25.

Earnings In Focus

63 Moons Technologies, Abbott India, AIA Engineering, Apollo Hospitals, Arvind, Astral, Bliss GVS Pharma, Caplin Point Laboratories, DCX Systems, Dev Accelerator, EID Parry India, EMS, Eureka Forbes, Fiem Industries, Gujarat Fluorochemicals, General Insurance Corporation of India, Globe Civil Projects, GMR Airports, Gujarat Pipavav Port, Grasim Industries, Gujarat State Fertilizers & Chemicals, Hindustan Aeronautics, H.G. Infra Engineering, Hindustan Oil Exploration Company, Hindware Home Innovation, Hi-Tech Pipes, Indo Count Industries, India Glycols, Indian Hume Pipe Company, Indiqube Spaces, IRCON International, IRCTC, Jagran Prakashan, Jyothy Labs, Kirloskar Industries, La Opala RG, Man Infraconstruction, Marksans Pharma, MIDHANI, Motisons Jewellers, MTNL, National Fertilizers, Petronet LNG, Religare Enterprises, Sansera Engineering, Scoda Tubes, Shalby, Shringar House of Mangalsutra, Shriram Properties, SKF India, Somany Ceramics, Sudarshan Chemical Industries, Sun TV Network, Tasty Bite Eatables, Titagarh Rail Systems, Tata Motors, Vadilal Industries, Vesuvius India, VIP Industries, VA Tech Wabag, West Coast Paper Mills, Yatra Online.

Earnings post Market

IFCI (Q1 FY27, Consolidated YoY)

Total income down 19.6% to Rs. 358 crore versus Rs. 445 crore.

Net profit down 16% to Rs. 33.5 crore versus Rs. 39.9 crore.

RHI Magnesita India (Q1 FY27, Consolidated YoY)

Revenue up 5.6% to Rs. 1,014 crore versus Rs. 960 crore.

EBITDA up 34.9% to Rs. 137.5 crore versus Rs. 101.9 crore.
EBITDA margin at 13.6% versus 10.6%.
Net profit up 83% to Rs. 64.6 crore versus Rs. 35.3 crore.
S.P. Apparels (Q1 FY27, Consolidated YoY)
Revenue down 0.6% to Rs. 401.1 crore versus Rs. 403.4 crore.
EBITDA up 16.1% to Rs. 61.4 crore versus Rs. 52.9 crore.
EBITDA margin at 15.3% versus 13.1%.
Net profit up 20.3% to Rs. 24.9 crore versus Rs. 20.7 crore.
Final dividend of Rs. 3 per share approved for FY26.
Approves stock split of 1 share into 5 shares.
Sunflag Iron & Steel (Q1 FY27, Consolidated YoY)
Revenue up 6.5% to Rs. 1,079 crore versus Rs. 1,013 crore.
EBITDA up 8.6% to Rs. 119 crore versus Rs. 110 crore.
EBITDA margin at 11% versus 10.8%.
Net profit up 5.6% to Rs. 66.1 crore versus Rs. 62.6 crore.
EPL (Q1 FY27, Consolidated YoY)
Revenue up 25.3% to Rs. 1,388 crore versus Rs. 1,108 crore.
EBITDA up 15.2% to Rs. 261 crore versus Rs. 227 crore.
EBITDA margin at 18.8% versus 20.5%.
Net profit down 1.4% to Rs. 98.6 crore versus Rs. 100 crore.
Piccadily Agro Industries (Q1 FY27, Consolidated YoY)
Revenue up 18.1% to Rs. 270.5 crore versus Rs. 229 crore.
EBITDA up 16.2% to Rs. 43.8 crore versus Rs. 37.7 crore.
EBITDA margin at 16.2% versus 16.5%.
Net profit up 15.1% to Rs. 21.3 crore versus Rs. 18.5 crore.
JSW Dulux (Q1 FY27, Consolidated YoY)
Revenue down 2.8% to Rs. 965 crore versus Rs. 993 crore.
EBITDA down 14.4% to Rs. 115 crore versus Rs. 134 crore.
EBITDA margin at 11.9% versus 13.5%.
Net profit down 12.4% to Rs. 79.7 crore versus Rs. 91 crore.
Approves stock split of 1 share into 10 shares.
TD Power Systems (Q1 FY27, Consolidated YoY)
Revenue up 72% to Rs. 640 crore versus Rs. 372 crore.
EBITDA up 74.9% to Rs. 121.4 crore versus Rs. 69.4 crore.
EBITDA margin at 19% versus 18.7%.
Net profit up 72% to Rs. 86 crore versus Rs. 50 crore.
Borana Weaves (Q1 FY27, YoY)
Revenue up 24.7% to Rs. 101 crore versus Rs. 81 crore.
EBITDA up 51.4% to Rs. 26 crore versus Rs. 17.2 crore.
EBITDA margin at 25.8% versus 21.2%.
Net profit up 35.2% to Rs. 16.5 crore versus Rs. 12.2 crore.
Manappuram Finance (Q1 FY27, Consolidated YoY)
NII up 28.2% to Rs. 1,725 crore versus Rs. 1,346 crore.
AUM up 57% to Rs. 69,635 crore versus Rs. 44,304 crore.
Net profit at Rs. 585 crore versus Rs. 138 crore.
Gujarat Energy (Q1 FY27, Consolidated QoQ)
Revenue up 64.8% to Rs. 9,545 crore versus Rs. 5,792 crore.
EBITDA at Rs. 1,381 crore versus Rs. 609 crore.

EBITDA margin at 14.5% versus 10.5%.
Net profit at Rs. 999 crore versus Rs. 351 crore.
Precision Camshafts (Q1 FY27, Consolidated YoY)
Revenue down 3.6% to Rs. 188 crore versus Rs. 195 crore.
EBITDA down 49% to Rs. 7.5 crore versus Rs. 14.7 crore.
EBITDA margin at 4% versus 7.5%.
Net profit down 55.3% to Rs. 8.4 crore versus Rs. 18.8 crore.
Harsha Engineers (Q1 FY27, Consolidated YoY)
Revenue up 25.2% to Rs. 457 crore versus Rs. 365 crore.
EBITDA up 22% to Rs. 67.6 crore versus Rs. 55.4 crore.
EBITDA margin at 14.8% versus 15.2%.
Net profit down 1.3% to Rs. 37.4 crore versus Rs. 37.9 crore.
Repco Home Finance (Q1 FY27, Consolidated YoY)
Total income up 6.2% to Rs. 468 crore versus Rs. 441 crore.
Net profit up 5.7% to Rs. 114.2 crore versus Rs. 108 crore.
TARC (Q1 FY27, Consolidated YoY)
Revenue at Rs. 217.1 crore versus Rs. 75.9 crore.
EBITDA at Rs. 40.2 crore versus loss of Rs. 120.3 crore.
Net profit down 58.1% to Rs. 22.7 crore versus Rs. 54.2 crore.
Other income at Rs. 1.6 crore versus Rs. 219 crore.
Flair Writing Industries (Q1 FY27, Consolidated YoY)
Revenue up 10.7% to Rs. 319 crore versus Rs. 289 crore.
EBITDA up 7.9% to Rs. 53.4 crore versus Rs. 49.5 crore.
EBITDA margin at 16.7% versus 17.1%.
Net profit down 0.3% to Rs. 28.6 crore versus Rs. 28.6 crore.
Landmark Cars (Q1 FY27, Consolidated YoY)
Revenue up 22.7% to Rs. 1,302 crore versus Rs. 1,062 crore.
EBITDA up 18.2% to Rs. 72.1 crore versus Rs. 61 crore.
EBITDA margin at 5.5% versus 5.7%.
Net profit at Rs. 14.5 crore versus Rs. 6.9 crore.
Linde India (Q1 FY27, Consolidated YoY)
Revenue up 21.6% to Rs. 694 crore versus Rs. 571 crore.
EBITDA up 1.8% to Rs. 201 crore versus Rs. 197 crore.
EBITDA margin at 28.9% versus 34.5%.
Net profit down 2.4% to Rs. 104.6 crore versus Rs. 107.2 crore.
Appoints Vikash Dokania as CFO from September 15.
Innova Captab (Q1 FY27, Consolidated YoY)
Revenue up 34% to Rs. 471 crore versus Rs. 351.5 crore.
EBITDA up 40.3% to Rs. 73.1 crore versus Rs. 52.1 crore.
EBITDA margin at 15.5% versus 14.8%.
Net profit up 42.3% to Rs. 44.1 crore versus Rs. 31 crore.
Ashiana Housing (Q1 FY27, Consolidated YoY)
Revenue down 63.3% to Rs. 108 crore versus Rs. 293 crore.
EBITDA down 36.3% to Rs. 7.6 crore versus Rs. 11.9 crore.
EBITDA margin at 7% versus 4%.
Net profit up 3.1% to Rs. 13.1 crore versus Rs. 12.7 crore.
Nephrocare Health Services (Q1 FY27, Consolidated YoY)
Revenue up 23.7% to Rs. 282 crore versus Rs. 228 crore.

EBITDA up 34.2% to Rs. 63.9 crore versus Rs. 47.6 crore.
EBITDA margin at 22.7% versus 20.9%.
Net profit up 35% to Rs. 32 crore versus Rs. 23.7 crore.
Som Distilleries & Breweries (Q1 FY27, Consolidated YoY)
Revenue down 49.2% to Rs. 269 crore versus Rs. 528 crore.
EBITDA down 78.8% to Rs. 14.9 crore versus Rs. 70.2 crore.
EBITDA margin at 5.5% versus 13.3%.
Net profit down 96.2% to Rs. 1.6 crore versus Rs. 42.1 crore.
DAM Capital Advisors (Q1 FY27, Consolidated QoQ)
Total income up 2.4% to Rs. 30 crore versus Rs. 29.3 crore.
Net profit down 40% to Rs. 15 lakh versus Rs. 25 lakh.
PI Industries (Q1 FY27, Consolidated YoY)
Revenue down 10.4% to Rs. 1,702 crore versus Rs. 1,901 crore.
EBITDA down 29.2% to Rs. 367.4 crore versus Rs. 519.1 crore.
EBITDA margin at 21.6% versus 27.3%.
Net profit down 39% to Rs. 244 crore versus Rs. 400 crore.
Bata India (Q1 FY27, Consolidated YoY)
Revenue up 3.9% to Rs. 979 crore versus Rs. 942 crore.
EBITDA up 2.6% to Rs. 204 crore versus Rs. 199 crore.
EBITDA margin at 20.8% versus 21.1%.
Net profit up 23.1% to Rs. 64 crore versus Rs. 52 crore.
Declares interim dividend of Rs. 25 per share.
Polyplex Corporation (Q1 FY27, Consolidated YoY)
Revenue up 29.6% to Rs. 2,254 crore versus Rs. 1,739 crore.
EBITDA at Rs. 297 crore versus loss of Rs. 0.6 crore.
Net profit at Rs. 91 crore versus loss of Rs. 19.3 crore.
MMTC (Q1 FY27, Consolidated YoY)
Revenue down 50% to Rs. 0.7 crore versus Rs. 1.4 crore.
EBITDA loss at Rs. 20.2 crore versus loss of Rs. 23.1 crore.
Net profit at Rs. 104 crore versus Rs. 44 crore.
Other income at Rs. 145 crore versus Rs. 70 crore.
Techno Electric & Engineering (Q1 FY27, Consolidated YoY)
Revenue up 19.8% to Rs. 630.3 crore versus Rs. 526 crore.
EBITDA up 7.7% to Rs. 99.5 crore versus Rs. 92.4 crore.
EBITDA margin at 15.8% versus 17.6%.
Net profit down 31.5% to Rs. 93.3 crore versus Rs. 136 crore.
Man Industries (Q1 FY27, Consolidated YoY)
Revenue up 41.9% to Rs. 1,053 crore versus Rs. 742 crore.
EBITDA up 89.2% to Rs. 143 crore versus Rs. 75.8 crore.
EBITDA margin at 13.6% versus 10.2%.
Net profit at Rs. 61.4 crore versus Rs. 27.6 crore.
Senco Gold (Q1 FY27, Consolidated YoY)
Revenue up 67.4% to Rs. 3,056 crore versus Rs. 1,826 crore.
EBITDA up 16.2% to Rs. 213 crore versus Rs. 184 crore.
EBITDA margin at 7% versus 10%.
Net profit down 3.4% to Rs. 101 crore versus Rs. 105 crore.
Delta Corp (Q1 FY27, Consolidated YoY)
Revenue down 8.2% to Rs. 169 crore versus Rs. 184 crore.

EBITDA down 19.5% to Rs. 31.5 crore versus Rs. 39.2 crore.
EBITDA margin at 18.7% versus 21.3%.
Net loss at Rs. 212 crore versus profit of Rs. 29.5 crore.
Saw one-time loss of Rs. 307 crore in Q1.
Caliber Mining & Logistics (Q1 FY27, Consolidated YoY)
Revenue up 67.2% to Rs. 657 crore versus Rs. 393 crore.
EBITDA up 15.8% to Rs. 110.2 crore versus Rs. 95.2 crore.
EBITDA margin at 16.8% versus 24.2%.
Net profit down 21.1% to Rs. 30 crore versus Rs. 38 crore.
JNK India (Q1 FY27, Consolidated YoY)
Revenue up 81.8% to Rs. 180 crore versus Rs. 99 crore.
EBITDA at Rs. 16.3 crore versus Rs. 3.2 crore.
EBITDA margin at 9.1% versus 3.2%.
Net profit at Rs. 11.5 crore versus Rs. 1.1 crore.
SKF India (Q1 FY27, YoY)
Revenue up 18.3% to Rs. 971 crore versus Rs. 821 crore.
EBITDA down 5.5% to Rs. 89 crore versus Rs. 94 crore.
EBITDA margin at 9.2% versus 11.5%.
Net profit down 13.9% to Rs. 62 crore versus Rs. 72 crore.
Ashoka Buildcon (Q1 FY27, Consolidated YoY)
Revenue down 20.5% to Rs. 1,500 crore versus Rs. 1,887 crore.
EBITDA down 56.9% to Rs. 258 crore versus Rs. 599 crore.
EBITDA margin at 17.2% versus 31.7%.
Net profit down 41.0% to Rs. 127.8 crore versus Rs. 217.4 crore.
ESAB India (Q1 FY27, YoY)
Revenue up 19.6% to Rs. 421 crore versus Rs. 352 crore.
EBITDA up 33.8% to Rs. 79.2 crore versus Rs. 59.2 crore.
EBITDA margin at 18.8% versus 16.8%.
Net profit up 37.0% to Rs. 56.1 crore versus Rs. 40.9 crore.
Gokaldas Exports (Q1 FY27, Consolidated YoY)
Revenue up 20.7% to Rs. 1,154 crore versus Rs. 956 crore.
EBITDA up 15.6% to Rs. 112.5 crore versus Rs. 97.3 crore.
EBITDA margin at 9.8% versus 10.2%.
Net profit up 6.8% to Rs. 44.3 crore versus Rs. 41.5 crore.
Stocks In News
Clean Max Enviro Energy Solutions: The company will issue a corporate guarantee of Rs. 92 crore for its subsidiary.
Landmark Cars: The company signs an MoU with Tecso Charge Zone to offer wallet credits and other customer benefits.
Godrej Consumer Products: The company appoints Aasif Malbari as MD & CEO from August 12; Sudhir Sitapati resigns as MD & CEO, while Vishal Kedia takes over as Interim CFO.
L&T: The company signs a business transfer agreement with arm Vyoma.AI to transfer its data centre and cloud services business for Rs. 1,400 crore.
Grasim Industries: The company commences commercial production at its 50,000 MTPA CPVC resin plant in Gujarat.
Firstsource Solutions: The company enters into a partnership with Cresta to deliver AI technology solutions.
GMR Power & Urban Infra : The board will consider raising up to Rs. 3,000 crore via QIP, bonds and other instruments on August 14.
Avenue Supermarts: The company allots commercial paper worth Rs. 300 crore.
Natco Pharma: The board will consider fundraising via equity issuance on August 14.
Prestige Estates: CPPIB to invest up to Rs. 3,000 crore in Prestige Hospitality and acquire up to 28% stake.

Zydus Lifesciences: Arm Sentynl enters pact with Mereo BioPharma for commercial and manufacturing rights of Alvelestat; Mereo eligible for up to USD 40 million under the agreement.

Shareholders approve re-appointment of Sharvil Patel as Managing Director for five years.

Canara Bank: The bank hikes 1-month MCLR by 5 bps to 8.05%, 1-year MCLR by 5 bps to 8.80% and 3-year MCLR by 5 bps to 9.10%.

BEML : The company receives a Rs. 184 crore order from HAL to supply Light Combat Helicopter fuselage aerostructures.

3M India: The company fully resumes production and operations at its Ahmedabad plant after completing restoration activities.

KFin Technologies: The company launches agentic AI solution Klarity' to eliminate signature fraud in the BFSI segment

Jash Engineering: The company re-appoints Pratik Patel as Managing Director for five years.

Adani Ports: Arm Ocean Sparkle incorporates subsidiary Ocean Sparkle Offshore.

SKF India: The company appoints Sujeeth Pai as MD from September 1; Mukund Vasudevan resigns as MD from August 31. The company also declares an interim dividend of Rs. 20 per share.

Allcargo Terminals: Appointments Mr. Pranav as Managing Director of the company w.e.f. September 01, 2026

V-Mart Retail: The company launches its 600th store.

Muthoot Microfin: Shareholders approve fundraising through private placement.

Manappuram Finance : Appoints Ashish Singh as MD & CEO for five years effective January 1 and approves fundraising of up to Rs. 1 lakh crore via NCDs and other instruments.

SBI: The bank concludes issuance of USD 500 million senior unsecured notes.

Saatvik Green Energy: The company secures a Rs. 400 crore order from an EPC player for supply of solar PV modules.

CAMS : The company acquires the first tranche of Think founders' stake, raising its holding in Think to 77.7% for Rs. 18 crore.

Puravankara : The company extends closure of the Rs. 145 crore Purva Ruby deal by 30 days.

HG Infra Engineering : The company receives a Letter of Award worth Rs. 241 crore from the Rajasthan government.

Escorts Kubota: The company preponees groundbreaking ceremony for its new greenfield manufacturing facility to August 19 from August 20.

Diamond Power Infrastructure: The company secures a Rs. 195 crore order from Rajesh Power Services for underground power cables.

Ashoka Buildcon: The company appoints Sanjay Prabhakar Londhe and Ashish Ashok Kataria as Joint Managing Directors.

ITI : The company clarifies that it has signed a pact with Airtel Business to accelerate digital transformation, though the financial impact of the partnership is not yet quantifiable.

Omaxe : The company's arm receives a RERA certificate for a project in Uttar Pradesh.

IPO UPDATE

Technocraft Ventures IPO

Overall subscription stands at 38.69x on Day 3

NIIs lead at 65.06x

QIBs at 42.26x

Retail at 25.35x.

Leap India IPO

Overall subscription stands at 8.38x on Day 3

QIBs subscribed 16.84x

NIIs 12.64x

Retail 1.71x

Dhoot Transmission IPO

Overall subscription stands at 3.94x on Day 2

NIIs subscribed 10.62x

Retail 2.97x

QIBs 0.50x.

Molbio Diagnostics IPO

Overall subscription stands at 3.11x on Day 2

NIIs subscribed 5.21x

Retail 3.18x

QIBs 1.39x.

Milky Mist IPO

Overall subscription stands at 0.79x on Day 1

Retail subscribed 0.96x

NIIs 0.92x

QIBs 0.39x.

IPO LISTINGS

Ardee Industries

Recycles used lead-acid batteries and non-ferrous metal scrap to produce high-purity refined lead and customized lead alloys

The issue is subscribed times. The company's shares will debut on the stock exchange on Wednesday. The public issue was subscribed times on day 3. The bids were led by non-institutional investors, QIBs at and retail at

IPO To Open

Shiprocket

About the company

E-commerce enablement company. It provides tech-driven solutions that help micro, small and medium enterprises (MSMEs), direct-to-consumer (D2C) brands, and large retailers manage and grow their online and offline businesses.

IPO Details

Total issue size of Rs. 1,617.48 Cr

Issue mix has fresh issue of Rs.885.50 crores and offer for sale of Rs.731.98 crores

IPO opening on the 12th of August and closing on the 14th of August

Key Financials

Particulars (INR Cr)

FY24

FY25

FY26

Revenue

Growth (% YoY)

EBITDA

EBITDA Margin

PAT

Behari Lal Engineering

About the company

Integrated iron and steel manufacturing company specialising in customised engineering solutions

IPO Details

Total issue of Rs. 302 Cr

Mix of fresh issue of Rs.93 crores and offer for sale of Rs.208.62 crores

IPO opening on the 12th of August and closing on the 14th of August

Key Financials

Particulars

31 Mar 2026

31 Mar 2025

31 Mar 2024

Total Income

EBITDA

EBITDA Margin

Profit After Tax

BOARD MEETINGS

STOCK SPLITS

Bansal Wire Industries

FUNDRAISING

Balu Forge Industries

Dishman Carbogen Amcis

GMR AIRPORTS

Shalimar Paints

AGM

United Breweries Ltd, Sika Interplant, ADF Foods, Galaxy Surf, BASF, Automotive Axle, Disa India, Va Tech Wabag, EID Parry, Goodyear, Indiqube Spaces, Sammaan Capital, Nephrocare Heal, TD Power System, Niva Bupa Health, Bata India, Man Infra, Insecticides, HCL Tech, Manappuram Fin, Somany Ceramics, Mukand, Kabra Extrusion, Berger Paints, Sangam India

Bulk & Block Deals

Metropolis Healthcare: Aditya Birla Sun Life Mutual Fund bought 10.49 lakh shares at Rs. 564 per share, while Duru Shah Family Trust sold 10.50 lakh shares at the same price. ICICI Prudential Mutual Fund bought 5.25 lakh shares at Rs. 564 per share, while Metz Advisory LLP sold 10.50 lakh shares at the same price. Morgan Stanley Asia Singapore Pte bought 5.25 lakh shares at Rs. 564 per share.

Rolex Rings: BayernInvest KVG bought 8.99 lakh shares at Rs. 170.59 per share

LOCK IN

Kusumgar : 1 Month Lock in, 2 Million Shares, 2% of Total Outstanding

Insider trade

Prataap Snacks: Promoter Authum Investment & Infrastructure acquires 2.74 lakh shares in the company.

GNA Axles: Promoter group entity Maninder Singh Seehra disposes of 4.18 lakh shares in the company.

Additional Surveillance Measure (ASM)

List of securities shortlisted in Long - Term: Aimtron Electronics

List of securities shortlisted in Short - Term ASM: Vedant Fashions, Shivalik Bimetal Controls, Shilpa Medicare

Price Band

Price Band change from 10% to 5%: SUDEEP PHARMA

Price Band change from 20% to 10%: V MARC INDIA

F&O Cues

Nifty Aug futures is down 0.55% to 24,525.10 at a premium of 53 points.

Nifty Options 18th Aug Expiry: Maximum Call open interest at 25,000 and Maximum Put open interest at 24,000.

Securities in ban period: BANDHANBNK, SAIL

Back To Index

Website:	MSN India	Word count	2120
Published Date	12 Aug 2026	Journalist:	Bureau

Stocks to watch today: HAL, Apollo Hospitals, Petronet LNG, Tata Motors and IRCTC

https://www.msn.com/en-in/money/top-stocks/stocks-to-watch-today-hal-apollo-hospitals-petronet-lng-tata-motors-and-irctc/ar-AA29S2Kt

Author: NDTV Profit Research Shares of Tata Motors Ltd., Petronet LNG Ltd., Hindustan Aeronautics Ltd., Apollo Hospitals Ltd., and Indian Railway Catering And Tourism Corp.
Ltd. will be in focus on Wednesday.
Here are the notable corporate announcements that came after Tuesday's market hours:

Earnings Today
63 Moons Technologies, Abbott India, AIA Engineering, Apollo Hospitals, Arvind, Astral, Bliss GVS Pharma, Caplin Point Laboratories, DCX Systems, Dev Accelerator, EID Parry India, EMS, Eureka Forbes, Fiem Industries, Gujarat Fluorochemicals, General Insurance Corporation of India, Globe Civil Projects, GMR Airports, Gujarat Pipavav Port, Grasim Industries, Gujarat State Fertilizers & Chemicals, Hindustan Aeronautics, H.G. Infra Engineering, Hindustan Oil Exploration Company, Hindware Home Innovation, Hi-Tech Pipes, Indo Count Industries, India Glycols, Indian Hume Pipe Company, Indiqube Spaces, IRCON International, IRCTC, Jagran Prakashan, Jyothy Labs, Kirloskar Industries, La Opala RG, Man Infraconstruction, Marksans Pharma, MIDHANI, Motisons Jewellers, MTNL, National Fertilizers, Petronet LNG, Religare Enterprises, Sansera Engineering, Scoda Tubes, Shalby, Shringar House of Mangalsutra, Shriram Properties, SKF India, Somany Ceramics, Sudarshan Chemical Industries, Sun TV Network, Tasty Bite Eatables, Titagarh Rail Systems, Tata Motors, Vadilal Industries, Vesuvius India, VIP Industries, VA Tech Wabag, West Coast Paper Mills, Yatra Online.
Earnings Post Market Hours
IFCI (Q1 FY27, Consolidated YoY)
Total income down 19.6% to Rs. 358 crore versus Rs. 445 crore.
Net profit down 16% to Rs. 33.5 crore versus Rs. 39.9 crore.
RHI Magnesita India (Q1 FY27, Consolidated YoY)
Revenue up 5.6% to Rs. 1,014 crore versus Rs. 960 crore.
EBITDA up 34.9% to Rs. 137.5 crore versus Rs. 101.9 crore.
EBITDA margin at 13.6% versus 10.6%.
Net profit up 83% to Rs. 64.6 crore versus Rs. 35.3 crore.
S.P. Apparels (Q1 FY27, Consolidated YoY)
Revenue down 0.6% to Rs. 401.1 crore versus Rs. 403.4 crore.
EBITDA up 16.1% to Rs. 61.4 crore versus Rs. 52.9 crore.
EBITDA margin at 15.3% versus 13.1%.
Net profit up 20.3% to Rs. 24.9 crore versus Rs. 20.7 crore.
Final dividend of Rs. 3 per share approved for FY26.
Approves stock split of 1 share into 5 shares.
Sunflag Iron & Steel (Q1 FY27, Consolidated YoY)
Revenue up 6.5% to Rs. 1,079 crore versus Rs. 1,013 crore.
EBITDA up 8.6% to Rs. 119 crore versus Rs. 110 crore.
EBITDA margin at 11% versus 10.8%.
Net profit up 5.6% to Rs. 66.1 crore versus Rs. 62.6 crore.
EPL (Q1 FY27, Consolidated YoY)
Revenue up 25.3% to Rs. 1,388 crore versus Rs. 1,108 crore.

EBITDA up 15.2% to Rs. 261 crore versus Rs. 227 crore.
EBITDA margin at 18.8% versus 20.5%.
Net profit down 1.4% to Rs. 98.6 crore versus Rs. 100 crore.
Piccadily Agro Industries (Q1 FY27, Consolidated YoY)
Revenue up 18.1% to Rs. 270.5 crore versus Rs. 229 crore.
EBITDA up 16.2% to Rs. 43.8 crore versus Rs. 37.7 crore.
EBITDA margin at 16.2% versus 16.5%.
Net profit up 15.1% to Rs. 21.3 crore versus Rs. 18.5 crore.
JSW Dulux (Q1 FY27, Consolidated YoY)
Revenue down 2.8% to Rs. 965 crore versus Rs. 993 crore.
EBITDA down 14.4% to Rs. 115 crore versus Rs. 134 crore.
EBITDA margin at 11.9% versus 13.5%.
Net profit down 12.4% to Rs. 79.7 crore versus Rs. 91 crore.
Approves stock split of 1 share into 10 shares.
TD Power Systems (Q1 FY27, Consolidated YoY)
Revenue up 72% to Rs. 640 crore versus Rs. 372 crore.
EBITDA up 74.9% to Rs. 121.4 crore versus Rs. 69.4 crore.
EBITDA margin at 19% versus 18.7%.
Net profit up 72% to Rs. 86 crore versus Rs. 50 crore.
Borana Weaves (Q1 FY27, YoY)
Revenue up 24.7% to Rs. 101 crore versus Rs. 81 crore.
EBITDA up 51.4% to Rs. 26 crore versus Rs. 17.2 crore.
EBITDA margin at 25.8% versus 21.2%.
Net profit up 35.2% to Rs. 16.5 crore versus Rs. 12.2 crore.
Manappuram Finance (Q1 FY27, Consolidated YoY)
NII up 28.2% to Rs. 1,725 crore versus Rs. 1,346 crore.
AUM up 57% to Rs. 69,635 crore versus Rs. 44,304 crore.
Net profit at Rs. 585 crore versus Rs. 138 crore.
Gujarat Energy (Q1 FY27, Consolidated QoQ)
Revenue up 64.8% to Rs. 9,545 crore versus Rs. 5,792 crore.
EBITDA at Rs. 1,381 crore versus Rs. 609 crore.
EBITDA margin at 14.5% versus 10.5%.
Net profit at Rs. 999 crore versus Rs. 351 crore.
Precision Camshafts (Q1 FY27, Consolidated YoY)
Revenue down 3.6% to Rs. 188 crore versus Rs. 195 crore.
EBITDA down 49% to Rs. 7.5 crore versus Rs. 14.7 crore.
EBITDA margin at 4% versus 7.5%.
Net profit down 55.3% to Rs. 8.4 crore versus Rs. 18.8 crore.
Harsha Engineers (Q1 FY27, Consolidated YoY)
Revenue up 25.2% to Rs. 457 crore versus Rs. 365 crore.
EBITDA up 22% to Rs. 67.6 crore versus Rs. 55.4 crore.
EBITDA margin at 14.8% versus 15.2%.
Net profit down 1.3% to Rs. 37.4 crore versus Rs. 37.9 crore.
Repco Home Finance (Q1 FY27, Consolidated YoY)
Total income up 6.2% to Rs. 468 crore versus Rs. 441 crore.
Net profit up 5.7% to Rs. 114.2 crore versus Rs. 108 crore.
TARC (Q1 FY27, Consolidated YoY)
Revenue at Rs. 217.1 crore versus Rs. 75.9 crore.

EBITDA at Rs. 40.2 crore versus loss of Rs. 120.3 crore.
Net profit down 58.1% to Rs. 22.7 crore versus Rs. 54.2 crore.
Other income at Rs. 1.6 crore versus Rs. 219 crore.
Flair Writing Industries (Q1 FY27, Consolidated YoY)
Revenue up 10.7% to Rs. 319 crore versus Rs. 289 crore.
EBITDA up 7.9% to Rs. 53.4 crore versus Rs. 49.5 crore.
EBITDA margin at 16.7% versus 17.1%.
Net profit down 0.3% to Rs. 28.6 crore versus Rs. 28.6 crore.
Landmark Cars (Q1 FY27, Consolidated YoY)
Revenue up 22.7% to Rs. 1,302 crore versus Rs. 1,062 crore.
EBITDA up 18.2% to Rs. 72.1 crore versus Rs. 61 crore.
EBITDA margin at 5.5% versus 5.7%.
Net profit at Rs. 14.5 crore versus Rs. 6.9 crore.
Linde India (Q1 FY27, Consolidated YoY)
Revenue up 21.6% to Rs. 694 crore versus Rs. 571 crore.
EBITDA up 1.8% to Rs. 201 crore versus Rs. 197 crore.
EBITDA margin at 28.9% versus 34.5%.
Net profit down 2.4% to Rs. 104.6 crore versus Rs. 107.2 crore.
Appoints Vikash Dokania as CFO from September 15.
Innova Captab (Q1 FY27, Consolidated YoY)
Revenue up 34% to Rs. 471 crore versus Rs. 351.5 crore.
EBITDA up 40.3% to Rs. 73.1 crore versus Rs. 52.1 crore.
EBITDA margin at 15.5% versus 14.8%.
Net profit up 42.3% to Rs. 44.1 crore versus Rs. 31 crore.
Ashiana Housing (Q1 FY27, Consolidated YoY)
Revenue down 63.3% to Rs. 108 crore versus Rs. 293 crore.
EBITDA down 36.3% to Rs. 7.6 crore versus Rs. 11.9 crore.
EBITDA margin at 7% versus 4%.
Net profit up 3.1% to Rs. 13.1 crore versus Rs. 12.7 crore.
Nephrocare Health Services (Q1 FY27, Consolidated YoY)
Revenue up 23.7% to Rs. 282 crore versus Rs. 228 crore.
EBITDA up 34.2% to Rs. 63.9 crore versus Rs. 47.6 crore.
EBITDA margin at 22.7% versus 20.9%.
Net profit up 35% to Rs. 32 crore versus Rs. 23.7 crore.
Som Distilleries & Breweries (Q1 FY27, Consolidated YoY)
Revenue down 49.2% to Rs. 269 crore versus Rs. 528 crore.
EBITDA down 78.8% to Rs. 14.9 crore versus Rs. 70.2 crore.
EBITDA margin at 5.5% versus 13.3%.
Net profit down 96.2% to Rs. 1.6 crore versus Rs. 42.1 crore.
DAM Capital Advisors (Q1 FY27, Consolidated QoQ)
Total income up 2.4% to Rs. 30 crore versus Rs. 29.3 crore.
Net profit down 40% to Rs. 15 lakh versus Rs. 25 lakh.
PI Industries (Q1 FY27, Consolidated YoY)
Revenue down 10.4% to Rs. 1,702 crore versus Rs. 1,901 crore.
EBITDA down 29.2% to Rs. 367.4 crore versus Rs. 519.1 crore.
EBITDA margin at 21.6% versus 27.3%.
Net profit down 39% to Rs. 244 crore versus Rs. 400 crore.
Bata India (Q1 FY27, Consolidated YoY)

Revenue up 3.9% to Rs. 979 crore versus Rs. 942 crore.
EBITDA up 2.6% to Rs. 204 crore versus Rs. 199 crore.
EBITDA margin at 20.8% versus 21.1%.
Net profit up 23.1% to Rs. 64 crore versus Rs. 52 crore.
Declares interim dividend of Rs. 25 per share.
Polyplex Corporation (Q1 FY27, Consolidated YoY)
Revenue up 29.6% to Rs. 2,254 crore versus Rs. 1,739 crore.
EBITDA at Rs. 297 crore versus loss of Rs. 0.6 crore.
Net profit at Rs. 91 crore versus loss of Rs. 19.3 crore.
MMTC (Q1 FY27, Consolidated YoY)
Revenue down 50% to Rs. 0.7 crore versus Rs. 1.4 crore.
EBITDA loss at Rs. 20.2 crore versus loss of Rs. 23.1 crore.
Net profit at Rs. 104 crore versus Rs. 44 crore.
Other income at Rs. 145 crore versus Rs. 70 crore.
Techno Electric & Engineering (Q1 FY27, Consolidated YoY)
Revenue up 19.8% to Rs. 630.3 crore versus Rs. 526 crore.
EBITDA up 7.7% to Rs. 99.5 crore versus Rs. 92.4 crore.
EBITDA margin at 15.8% versus 17.6%.
Net profit down 31.5% to Rs. 93.3 crore versus Rs. 136 crore.
Man Industries (Q1 FY27, Consolidated YoY)
Revenue up 41.9% to Rs. 1,053 crore versus Rs. 742 crore.
EBITDA up 89.2% to Rs. 143 crore versus Rs. 75.8 crore.
EBITDA margin at 13.6% versus 10.2%.
Net profit at Rs. 61.4 crore versus Rs. 27.6 crore.
Senco Gold (Q1 FY27, Consolidated YoY)
Revenue up 67.4% to Rs. 3,056 crore versus Rs. 1,826 crore.
EBITDA up 16.2% to Rs. 213 crore versus Rs. 184 crore.
EBITDA margin at 7% versus 10%.
Net profit down 3.4% to Rs. 101 crore versus Rs. 105 crore.
Delta Corp (Q1 FY27, Consolidated YoY)
Revenue down 8.2% to Rs. 169 crore versus Rs. 184 crore.
EBITDA down 19.5% to Rs. 31.5 crore versus Rs. 39.2 crore.
EBITDA margin at 18.7% versus 21.3%.
Net loss at Rs. 212 crore versus profit of Rs. 29.5 crore.
Saw one-time loss of Rs. 307 crore in Q1.
Caliber Mining & Logistics (Q1 FY27, Consolidated YoY)
Revenue up 67.2% to Rs. 657 crore versus Rs. 393 crore.
EBITDA up 15.8% to Rs. 110.2 crore versus Rs. 95.2 crore.
EBITDA margin at 16.8% versus 24.2%.
Net profit down 21.1% to Rs. 30 crore versus Rs. 38 crore.
JNK India (Q1 FY27, Consolidated YoY)
Revenue up 81.8% to Rs. 180 crore versus Rs. 99 crore.
EBITDA at Rs. 16.3 crore versus Rs. 3.2 crore.
EBITDA margin at 9.1% versus 3.2%.
Net profit at Rs. 11.5 crore versus Rs. 1.1 crore.
SKF India (Q1 FY27, YoY)
Revenue up 18.3% to Rs. 971 crore versus Rs. 821 crore.
EBITDA down 5.5% to Rs. 89 crore versus Rs. 94 crore.

EBITDA margin at 9.2% versus 11.5%.

Net profit down 13.9% to Rs. 62 crore versus Rs. 72 crore.

Ashoka Buildcon (Q1 FY27, Consolidated YoY)

Revenue down 20.5% to Rs. 1,500 crore versus Rs. 1,887 crore.

EBITDA down 56.9% to Rs. 258 crore versus Rs. 599 crore.

EBITDA margin at 17.2% versus 31.7%.

Net profit down 41.0% to Rs. 127.8 crore versus Rs. 217.4 crore.

ESAB India (Q1 FY27, YoY)

Revenue up 19.6% to Rs. 421 crore versus Rs. 352 crore.

EBITDA up 33.8% to Rs. 79.2 crore versus Rs. 59.2 crore.

EBITDA margin at 18.8% versus 16.8%.

Net profit up 37.0% to Rs. 56.1 crore versus Rs. 40.9 crore.

Gokaldas Exports (Q1 FY27, Consolidated YoY)

Revenue up 20.7% to Rs. 1,154 crore versus Rs. 956 crore.

EBITDA up 15.6% to Rs. 112.5 crore versus Rs. 97.3 crore.

EBITDA margin at 9.8% versus 10.2%.

Net profit up 6.8% to Rs. 44.3 crore versus Rs. 41.5 crore.

Stocks In News

Godrej Consumer Products: The company appoints Aasif Malbari as MD & CEO from August 12; Sudhir Sitapati resigns as MD & CEO, while Vishal Kedia takes over as Interim CFO.

L&T: The company signs a business transfer agreement with arm Vyoma.AI to transfer its data centre and cloud services business for Rs. 1,400 crore.

Grasim Industries: The company commences commercial production at its 50,000 MTPA CPVC resin plant in Gujarat.

Firstsource Solutions: The company enters into a partnership with Cresta to deliver AI technology solutions.

GMR Power & Urban Infra: The board will consider raising up to Rs. 3,000 crore via QIP, bonds and other instruments on August 14.

Prestige Estates: CPPIB to invest up to Rs. 3,000 crore in Prestige Hospitality and acquire up to 28% stake.

Zydus Lifesciences: Arm Sentynl enters pact with Mereo BioPharma for commercial and manufacturing rights of Alvelestat; Mereo eligible for up to USD 40 million under the agreement.

Shareholders approve re-appointment of Sharvil Patel as Managing Director for five years.

Canara Bank: The bank hikes 1-month MCLR by 5 bps to 8.05%, 1-year MCLR by 5 bps to 8.80% and 3-year MCLR by 5 bps to 9.10%.

SKF India: The company appoints Sujeeth Pai as MD from September 1; Mukund Vasudevan resigns as MD from August 31. The company also declares an interim dividend of Rs. 20 per share.

Muthoot Microfin: Shareholders approve fundraising through private placement.

Back To Index

Website:	MSN India	Word count	614
Published Date	12 Aug 2026	Journalist:	Bureau

Stocks to watch: HAL, L&T, BEML among shares in focus today; check list here

https://www.msn.com/en-in/money/top-stocks/stocks-to-watch-hal-l-t-beml-among-shares-in-focus-today-check-list-here/ar-AA29TofK

Vaamanaa Sethi Stock market today: The Indian stock market ended sharply lower on Tuesday, August 11, as investors resorted to profit-booking

amid rising oil prices and persistent uncertainty over the reopening of the Strait of Hormuz and the prospects of a US-Iran agreement. The Sensex fell 388 points, or 0.49%, to close at 78,154.25, while the Nifty 50 declined 112 points, or 0.46%, to settle at 24,471.70.

The market is likely to open flat as trends in the Gift Nifty index signalled a muted opening on Wednesday, 12 August. Gift Nifty was trading near the 24,546.50 mark, up over 6 points from the previous close of Nifty futures.

"Indian equity markets are expected to trade with a cautious undertone as persistent uncertainty surrounding the U.S.-Iran negotiations continues to weigh on investor sentiment. Overnight cues from Wall Street were subdued, with the S&P 500 and Dow Jones Industrial Average each declining about 0.3%, while the Nasdaq Composite slipped 0.6%, as investors turned cautious ahead of Wednesday's U.S. consumer price inflation data and amid the continuing stalemate between Washington and Tehran over the reopening of the Strait of Hormuz. Reflecting the mixed global backdrop, GIFT Nifty futures are trading just above the 24,500 mark, compared with the Nifty's previous close of 24,471, indicating a flat-to-mildly positive start for domestic equities," said Ponmudi R, CEO of Enrich Money.

As the market is pointing towards a flat start, some stocks are likely to remain in focus on Wednesday due to their own positive/negative triggers.

Stocks to Watch

Hindustan Aeronautics, Grasim Industries, Tata Motors, Lenskart Solutions, GMR Airports, IRCTC

Shares of Hindustan Aeronautics, Grasim Industries, Tata Motors, Lenskart Solutions, GMR Airports, IRCTC will remain in focus as the companies will declare their Q1 results 2026 today.

L&T

L&T has agreed to sell its entire holding in L&T Network Services (LTNSPL) to Vyoma for 30 crore, subject to adjustments at closing, through a share-swap transaction. Upon completion of the deal, LTNSPL will become a direct wholly owned subsidiary of Vyoma and an indirect wholly owned subsidiary of L&T.

Manappuram Finance

The Kerala-based gold loan financier posted a net profit of 584.5 crore in the first quarter, marking a sharp increase from 138.3 crore recorded in the same period a year earlier. Net interest income (NII) climbed 28.1% year-on-year to 1,723.8 crore, compared with 1,345.3 crore in the corresponding quarter of the previous year.

Zydus Lifesciences

Sentynl Therapeutics, a wholly owned subsidiary of the company, has entered into an option and licence agreement with Mereo BioPharma for alvelestat, an investigational therapy being developed for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD), a rare genetic respiratory condition.

NBCC (India)

The state-owned company posted a 17.2% year-on-year increase in net profit to 154.8 crore in the June quarter, despite a decline in revenue. Revenue from operations dropped 6% year-on-year to 2,259.5 crore.

BEML

State-owned Bharat Earth Movers Ltd on Tuesday, August 11, announced that it has received an order worth 184.25 crore from Hindustan Aeronautics Ltd (HAL) for the manufacture and supply of fuselage aerostructures for Light Combat Helicopters (LCH).

Bata India

The company reported a 23.1% year-on-year growth in consolidated net profit to 64 crore for the quarter ended June 2026, compared with 52 crore recorded in the same period a year earlier.

Man Industries

Man Industries reported its highest-ever consolidated quarterly EBITDA at 155 crore, registering a 92.6% year-on-year and 5.0% quarter-on-quarter growth. The strong performance was supported by an optimised product and geographical mix, along with the continued expansion of its global order pipeline.

Disclaimer : This story is for educational purposes only. Please consult with an investment advisor before making any investment decisions.

Back To Index

Website:	MSN India	Word count	1132
Published Date	12 Aug 2026	Journalist:	Bureau

Top stocks in news: L&T, Ardee, Tenneco, BEML, Manappuram, KFin Tech, Bata, Zydus Life

https://www.msn.com/en-in/money/top-stocks/top-stocks-in-news-l-t-ardee-tenneco-beml-manappuram-kfin-tech-bata-zydus-life/ar-AA29TorF

Pawan Kumar Nahar Indian equity benchmark indices settled lower on Tuesday after the attention shifted to the rise in crude oil prices, highlighting
the inflation risk, led by Strait of Hormuz blockade. The BSE Sensex shed 388.19 points, or 0.49 per cent, to close at 78,154.25, while NSE's Nifty50 tanked 112.10 points, or 0.46 per cent, to end at 24,471.70 for the day. Here are the stocks that may remain under spotlight before the opening bell on Wednesday, August 12, 2026:

Quarterly results today: Tata Motors, Grasim Industries, Apollo Hospitals, Lenskart Solutions, Hindustan Aeronautics, Arvind, Astral, Aditya Infotech, EID Parry, EMS, GMR Airports, Indiqube Spaces, IRCTC, Jyothy Labs, National Fertilizers, Petronet LNG, SKF India, Sun TV, Titagarh Rail Systems, VIP Industries, VA Tech Wabag and Yatra Online will announce their results for the June 2026 quarter today.

Corporate actions today: Shares of Computer Age Management Services, KPIT Technologies, NHPC, ASM Technologies, Dhunseri Tea, Gabriel India, Gujarat Containers, HG Infra Engineering, Industrial & Prudential Investment, KCP, Neelamalai Agro, Sandur Manganese, Narmada Gelatines, Uniparts India, Vaibhav Global, Voith Paper Fabrics India and more shall trade ex-dividend today.

Ardee Industries: The recycling and recovery solutions player will make its stock market debut on Wednesday, August 12 after the company raised a total of Rs 426 crore via IPO between August 05-07. The company sold its shares for Rs 53 apeice with a lot size of 281 shares. The issue was overall subscribed 133.66 times getting nearly 41.2 lakh applications.

Tenneco Clean Air India: Promoter entity Tenneco Mauritius is likely to sell an 8 per cent stake in Tenneco Clean Air India, with an upsize option of 2 pe rcent, through block deals. The floor price is expected to be Rs 515 per share, with a base offer size of Rs 1,663 crore, suggest some media report, citing sources.

Larsen and Toubro: The capital goods major has executed a Business Transfer Agreement with its subsidiary Vyoma.AI for the transfer of its data centre and cloud services business, on a going-concern basis through a slump sale, to Vyoma for Rs 1,400 crore.

Manappuram Finance: The gold loan player reported a 4-fold jump in the net profit at Rs 584.6 crore, while net-interest income (NIIs) soared 28.1 per cent YoY to Rs 1,723.7 crore for the June 2026 quarter. Its impairment on financial instruments sank 60.6 per cent YoY to Rs 225.5 crore. Its AUM jumped 57.2 per cent YoY to Rs 69,635 crore for the quarter.

Zydus Lifesciences: The pharma player's subsidiary, Sentynl Therapeutics, and Mereo BioPharma Group plc have entered into an option and licence agreement for the US commercialisation and global manufacturing rights to Alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being prepared for Phase 3 trials and would be the first oral treatment for this rare, progressive genetic lung disease.

Bata India: The footwear player reported a 23.04 per cent YoY jump in the net profit at Rs 63.98 crore, while revenue increased 3.9 per cent YoY to Rs 978.9 crore for the June 2026 quarter. Its Ebitda was up 2.6 per cent YoY to Rs 204 crore, while margins declined to 20.8 per cent for the quarter. The company board declared an interim dividend of Rs 25 per share for the investors.

BEML: The state-run defence player has secured an order worth Rs 184.25 crore from Hindustan Aeronautics (HAL) for the manufacture and supply of Light Combat Helicopter (LCH) fuselage aerostructures.

KFin Technologies: The financial services player announced the rollout of Klarity, an Agentic AI solution built to address two operational vulnerabilities in financial institutions operations skilled forgeries being incorrectly accepted as valid matches and legitimate behavioural signature variations resulting in wrongful rejections.

Balrampur Chini Mills: The sugar maker reported a 14.5 per cent YoY decline in net profit to Rs 44.1 crore, while revenue increased 6 per cent YoY to Rs 1,636.8 crore for the April-June 2026 period. Its EBITDA declined 15 per cent YoY to Rs 114 crore, while the EBITDA margin dropped to 6.96 per cent during the quarter.

PI Industries: The agrochemicals player reported a 39 per cent YoY decline in net profit to Rs 244.2 crore, while revenue fell 10.4 per cent YoY to Rs 1,702.3 crore for the Q1FY26. Its EBITDA declined 29.2 per cent YoY to Rs 367.4 crore, while the EBITDA margin dropped to 21.6 per cent during the quarter.

HG Infra Engineering: The infra & EPC company has received a letter of award (LoA) from the Department of Skill, Employment & Entrepreneurship, Government of Rajasthan, for the operation and management of the ITI Bhiwadi Cluster under Component-I of PM-SETU. Its share is 17.10 percent of the estimated cost of Rs 241 crore.

Linde India: The industrial gases maker reported a 2.4 per cent YoY decline in net profit to Rs 104.6 crore, even as revenue grew 21.6 per cent YoY to Rs 694.4 crore in the June 2026 quarter. Its EBITDA increased 17.9 per cent YoY to Rs 72 crore, while the EBITDA margin declined to 5.52 per cent for the quarter.

Landmark Cars: The automotive dealership player reported a 110.5 per cent YoY surge in net profit to Rs 14.5 crore, while revenue jumped 22.7 per cent YoY to Rs 1,302.4 crore during the first quarter of FY26. Its EBITDA grew 17.9 per cent YoY to Rs 72 crore, while the EBITDA margin declined to 5.52 per cent for the quarter.

JSW Dulux: The paints player reported a 12.4 per cent YoY decline in net profit to Rs 79.7 crore, while revenue fell 2.8 per cent YoY to Rs 965 crore for the April-June 2026. Its EBITDA declined 14.4 per cent YoY to Rs 115.1 crore, while the EBITDA margin dropped to 11.93 per cent during the quarter.

Diamond Power Infrastructure: The power transmission firm has received two orders worth Rs 195.48 crore from Rajesh Power Services for the supply of 11 kV Medium Voltage (MV) underground power cables for projects of Paschim Gujarat Vij Company under the State Disaster Mitigation Fund scheme and the System Improvement (Urban Underground) programme in Gujarat.

RHI Magnesita India: The refractory products maker reported an 83.2 per cent YoY surge in net profit to Rs 64.6 crore, while revenue increased 5.6 per cent YoY to Rs 1,014 crore for the quarter ended on June 30, 2026. Its EBITDA grew 34.7 per cent YoY to Rs 137.6 crore, while the EBITDA margin improved to 13.58 per cent for the quarter.

Tribhovandas Bhimji Zaveri: The jewellery retailer reported a 50.8 per cent YoY jump in net profit to Rs 33.92 crore, while revenue surged 34.8 per cent YoY to Rs 840.97 crore during the June 2026 quarter. Its EBITDA increased 36 per cent YoY to Rs 72.3 crore, while the EBITDA margin improved to 8.6 per cent for the quarter.

Back To Index

Website:	Pharma Focus Asia	Word count	307
Published Date	12 Aug 2026	Journalist:	Bureau

Sentynl Therapeutics and Mereo BioPharma Sign Licence Agreement for Alvelestat in Rare Lung Disease

https://www.pharmafocusasia.com/news/sentynl-therapeutics-and-mereo-biopharma

Sentynl Therapeutics, a US-based biopharmaceutical company and subsidiary of Zydus Lifesciences, and Mereo BioPharma Group have entered into an option and licence agreement covering the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Alvelestat is a neutrophil elastase inhibitor being prepared for Phase III development. If approved, it could become the first oral treatment for AATD-LD, a rare and progressive genetic lung disease estimated to affect 50,00080,000 people in the US.

Under the agreement, Sentynl has the exclusive option to obtain a licence to commercialise alvelestat in the US, while Mereo will retain commercial rights in other markets. Sentynl will also receive global manufacturing rights for the treatment.

If the option is exercised, the agreement will provide funding for the Phase III development programme, which could begin in early 2027. Mereo will lead the global Phase III trial and regulatory activities until the study is completed, while both companies will work together during the option period on manufacturing and the development of the Phase III study design.

The agreement follows positive efficacy results from two Phase II studies supporting the further development of alvelestat.

Mereo will receive a non-refundable option fee from Sentynl and could receive up to $40 million in upfront and research and development payments through to the filing of a New Drug Application (NDA). Mereo will also be eligible for double-digit tiered royalties on US net sales of alvelestat.

AATD is a rare genetic condition that causes low levels of alpha-1 antitrypsin, a protein that helps protect the lungs from damage. Severe deficiency can lead to pulmonary emphysema and other progressive lung conditions, resulting in symptoms such as breathlessness, chronic cough and recurrent exacerbations.

The agreement strengthens Sentynls rare disease portfolio and supports Mereos plans to advance alvelestat towards Phase III development.

Back To Index

Website:	Pharma Focus Europe	Word count	347
Published Date	12 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Sign Option and Licence Agreement for Alvelestat

https://www.pharmafocuseurope.com/news/mereo-biopharma-and-sentynl-therapeutics-sign

Mereo BioPharma Group and Sentynl Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, have entered into an option and licence agreement covering the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Alvelestat is a neutrophil elastase inhibitor being prepared for Phase III development. If approved, it could become the first oral treatment for AATD-LD, a rare and progressive genetic lung disease estimated to affect 50,00080,000 people in the US.

Under the agreement, Sentynl has the exclusive option to obtain a licence to commercialise alvelestat in the US, while Mereo will retain commercial rights in other global markets. Sentynl will also receive global manufacturing rights for the treatment.

If Sentynl exercises the option, the agreement provides funding for the Phase III development programme, which could begin in early 2027. Mereo will lead the global Phase III study and regulatory activities until the study is completed. The companies will work together during the option period to advance manufacturing plans and refine the Phase III study design.

The partnership follows positive efficacy results from two Phase II studies, which support the planned late-stage development of alvelestat.

Mereo will receive a non-refundable option fee from Sentynl. If the option is exercised, Mereo will receive $40 million in upfront and research and development payments. The company could also receive up to $435 million in regulatory and commercial milestone payments, along with tiered royalties in the double-digit range on US net sales of alvelestat.

AATD is a genetic disorder that causes low levels of alpha-1 antitrypsin, a protein that helps protect the lungs from damage caused by enzymes released during inflammation. Severe deficiency can lead to pulmonary emphysema, a progressive and potentially life-threatening condition associated with breathlessness, chronic cough, sputum production and recurrent exacerbations.

People with AATD may also develop conditions such as asthma and bronchiectasis. The estimated US prevalence of AATD-LD associated with the Pi*ZZ variant is around 50,00080,000 people.

The agreement expands Sentynl's focus on rare diseases while supporting Mereo's plans to advance alvelestat into Phase III development.

Source: globenewswire.com

Back To Index

Website:	Pharmacally	Word count	643
Published Date	12 Aug 2026	Journalist:	Bureau

Sentynl Secures U.S. Option for Mereo's Alvelestat Ahead of Phase 3 in AATD Lung Disease

https://pharmacally.com/sentynl-mereo-alvelestat-option-license-aatd-lung-disease/

Share on Social Media Sentynl Therapeutics secured a U.S. option for Mereo BioPharma's alvelestat, an oral neutrophil elastase inhibitor advancing toward Phase 3 in AATD-LD.

Written By: Samiksha Jadhav, BPharm

Reviewed By: Pharmacally Editorial Team

Sentynl Therapeutics, the U.S.-based biopharmaceutical subsidiary of Zydus Lifesciences , has entered an option and license agreement with Mereo BioPharma for alvelestat, an oral neutrophil elastase inhibitor in development for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). If Sentynl exercises the option, it will commercialize alvelestat in the United States, while Mereo will retain rights in the rest of the world and lead global development.

Partnership Advances Alvelestat Toward Phase 3

The agreement covers U.S. commercial rights and global manufacturing rights for alvelestat. Mereo will receive a non-refundable option fee and, if Sentynl exercises the option, up to $40 million in upfront and research and development payments through the filing of a New Drug Application (NDA). Mereo will also receive double-digit tiered royalties on U.S. net sales.

The companies will use the option period to refine the design of a global Phase 3 program and advance manufacturing activities. The Phase 3 study could begin in early 2027, with Mereo leading the trial and regulatory interactions until study completion.

Targeting a Key Driver of Lung Damage

AATD is a genetic disorder characterized by deficient levels of alpha-1 antitrypsin, a protein that protects lung tissue from enzymes released during inflammation. Severe deficiency can lead to pulmonary emphysema, causing progressive shortness of breath, chronic cough, sputum production and susceptibility to acute exacerbations.

Patients can also develop asthma and bronchiectasis. The companies estimate that approximately 50,000 to 80,000 people in the U.S. have the Pi*ZZ form of AATD associated with lung disease.

Current management can involve generalized respiratory therapies and, for some patients, frequent intravenous treatment. The development of an oral therapy could therefore address an important treatment burden if clinical efficacy and safety are confirmed.

Phase 2 Data Support Further Development

Alvelestat is an oral small molecule that inhibits neutrophil elastase (NE), an enzyme involved in inflammation and lung tissue destruction. According to the companies, its small-molecule properties allow it to reach both cell-bound and soluble elastase and penetrate lung tissue.

Mereo has reported positive efficacy findings from two Phase 2 studies and is preparing the candidate for Phase 3. However, the announcement does not disclose the numerical efficacy results, endpoint data or statistical analyses from those studies.

The safety and tolerability profile has been evaluated in more than 1,000 patients across respiratory disease programs, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplantation.

Executive Perspective

Dr. Sharvil P. Patel, Zydus Lifesciences highlighted alvelestat's potential to address a significant unmet need in AATD-LD by providing a new treatment option for patients.

Denise Scots-Knight, Mereo BioPharma emphasized that positive Phase 2 efficacy data have positioned alvelestat for global Phase 3 development, with the partners now refining the trial design.

Regulatory Designations and Next Steps

Alvelestat has received Orphan Drug Designation from both the FDA and European Commission for AATD-LD, as well as FDA Fast Track designation.

The partnership now shifts the program toward Phase 3 preparation. If Sentynl exercises its option, it will fund the Phase 3 development program and commercialize alvelestat in the U.S., while Mereo continues global development and retains commercial rights elsewhere.

For AATD-LD, the key development question is whether the Phase 3 program can translate the Phase 2 efficacy signal into clinically meaningful outcomes and establish alvelestat as an effective oral treatment option for this progressive genetic lung disease.

Reference

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1

Option and license agreement in AATD-LD | Mereo BioPharma

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Sentynl Therapeutics, Inc.

Share on Social Media

Back To Index

Website:	pharmashots	Word count	140
Published Date	12 Aug 2026	Journalist:	Ridhi Rastogi

Mereo BioPharma and Sentynl Therapeutics Ink ~$475M Pact for Alvelestat

https://pharmashots.com/35165/mereo-biopharma-and-sentynl-therapeutics-ink-475m-pact-for-alvelestat/

Shots: Sentynl, a subsidiary of Zydus, has entered into an option & license agreement with Mereo for the US commercial & global manufacturing

rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Sentynl will have an exclusive option to license alvelestat in the US, while Mereo retains ex-US commercial rights; Sentynl will also hold global manufacturing rights &, upon exercising the option, fund a P-III program potentially starting in early 2027

Mereo will receive a non-refundable option fee &, upon exercise, ~$40M in upfront & R&D payments, ~$435M in regulatory/commercial milestones & tiered double-digit royalties. Mereo will lead P-III & regulatory activities, while both companies collaborate on manufacturing & study design during the option period.

Ref: Globenewswire | Image: Sentynl & Mereo | Press Release

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com

Back To Index

Website:	Scanx	Word count	526
Published Date	12 Aug 2026	Journalist:	Bureau

Market Wrap: Mixed Sentiment as Nifty Slips 0.15% While Auto and Consumer Durables Lead Gains

https://scanx.trade/stock-market-news/markets/market-wrap-mixed-sentiment-as-nifty-slips-0-15-while-auto-and-consumer-durables-lead-gains/48074502

Indian markets closed marginally lower with Nifty 50 down 35.75 points at 24,471.70 (-0.15%) and Sensex falling 187.90 points to 78,154.25 (-0.24%). Market breadth remained weak with 2,608 stocks declining against 2,073 advancing out of 4,681 traded. Consumer Durables and Automobile sectors led gains at +2.83% each, while Diamond & Jewellery (-1.80%) and Aviation (-1.73%) underperformed. Key buzzing stocks included Symphony with management interaction, Godrej Consumer with mixed brokerage ratings, Zydus Lifesciences expecting strong branded portfolio growth, Deccan Gold Mines receiving production approval, and MCX India getting SEBI nod for commodity exchange investment.

Market Overview

Indian equity markets closed on a mixed note, with benchmark indices ending slightly lower despite selective buying in certain sectors. The Nifty 50 declined by 35.75 points to close at 24,471.70, marking a marginal drop of 0.15%. Similarly, the BSE Sensex fell 187.90 points to settle at 78,154.25, down 0.24% for the session.

Index

Closing Price

Change

Percentage Change

Nifty 50

BSE Sensex

Market Breadth

Market breadth painted a cautious picture with more stocks declining than advancing. Out of 4,681 scrips traded during the session, 2,608 stocks closed in negative territory while 2,073 ended with gains.

Market Breadth

Count

Total Scrips Traded

Positive Scrips

Negative Scrips

Sectoral Performance

Sectoral movements showed a clear divergence, with consumer-focused sectors leading the charge while commodity and aviation-related sectors faced selling pressure.

Top Performing Sectors

Sector

Average Percentage Change

Consumer Durables

Automobile & Auto Components

Cables

Trading

Underperforming Sectors

Sector

Average Percentage Change

Diamond, Gems and Jewellery

Aviation

Petroleum Products

Engineering Services

Buzzing Stocks

Several companies made headlines with significant corporate developments and strategic announcements:

Symphony Limited management is scheduled to interact with NDTV Profit to discuss the business overview, with telecast details expected to be available on the company website.

Godrej Consumer Products remained in focus as Citi and Jefferies maintain Buy ratings with targets of 1,350.00 and 1,400.00 respectively, while HSBC downgraded the stock to Hold at 1,120.00 following Sudhir Sitapati's resignation. The company also conducted a virtual conference call for institutional investors and analysts.

Zydus Lifesciences expects over two-thirds of revenue from its branded portfolio, with the U.S. business projected to grow 10%-15% by fiscal year end. The company's subsidiary Sentynl Therapeutics entered an option and license agreement with Mereo BioPharma for alvelestat in AATD-LD, with Mereo set to receive up to $40.00 million in payments.

Deccan Gold Mines received approval to increase gold production at its Jonnagiri mine to over 700 kg per year, targeting more than 1 tonne annually. The company also plans to apply for a mining license for its Bhalukona project.

Multi Commodity Exchange of India received SEBI approval to invest up to 100.00 crore in a proposed Mineral Spot Exchange Company, aiming to create a regulated platform for mined natural resources.

Conclusion

The trading session reflected cautious sentiment among investors, with benchmark indices closing marginally lower despite strong performance in consumer durables and automobile sectors. While market breadth favored declines, the relatively narrow losses in major indices suggest selective stock picking rather than broad-based selling. The divergent sectoral performance indicates investors are rotating towards domestic consumption themes while remaining cautious on commodity and aviation-related stocks. Read Next Article

Back To Index

Website:	Swastika	Word count	1208
Published Date	12 Aug 2026	Journalist:	Nidhi Thakur

L&T Share Price Momentum After Vyoma.AI Deal And August 12 Announcements

https://www.swastika.co.in/blog/lt-share-price-momentum-after-vyomaai-deal-and-august-12-announcements

Nidhi Thakur August 12, 2026 Key Takeaways L&T share price could move on Vyoma.AI's 1,400 crore data centre deal.
Canara Bank MCLR increase by 5 basis points across three tenors.
Prestige Estates gets private equity backing with CPPIB investment up to 3,000 crore.
Grasim CPVC plant start and Zydus Lifesciences Alvelestat deals add sector signals for investors.

Investors woke up to August 12's wave of corporate updates across Indian markets, with leadership shifts, strategic deals, and fundraising moves that could tilt stock narratives across sectors. The most watched signal for the L&T share price centers on Vyoma.AI's data centre and cloud services transfer, a deal valued at 1,400 crore. Market participants will parse how this reallocation of assets might influence earnings trajectory, capital allocation, and risk exposure for the conglomerate in the months ahead.

To navigate these catalysts, retail investors should consider both headline moves and underlying fundamentals. The day also featured leadership changes at Godrej Consumer Products that could alter execution risk and consumer trends, as well as significant fundraising and strategic investments across hospitality, infrastructure, and financial services. Taken together, the August 12 announcements set a high-velocity backdrop for stock-specific decisions, where L&T's price action could set the tone for related engineering, IT-enabled services, and infrastructure plays.

L&AmpT Share Price Momentum After Vyoma.AI Deal Valued At 1,400 Crore

The Vyoma.AI deal marks a strategic repositioning, with L&T transferring data centre and cloud services to accelerate specialization in high-growth technology domains. The 1,400 crore valuation is a signpost for the market to assess incremental free cash flow, potential synergies, and the risk profile of the technology portfolio as part of the wider L&T ecosystem. Investors will be closely watching subsequent board communications and quarterly commentary to determine whether the deal meaningfully improves return metrics or simply shifts assets within the group's balance sheet. In the near term, the L&T share price could respond to sentiment around asset rationalization, regulatory clarity, and the pace of integration with Vyoma.AI's operations.

For deeper stock-level catalysts and scenario analysis, check Swastika's Sarthi AI stock assistant

Godrej Consumer Products Leadership Change And Its Stock Implications

Godrej Consumer Products named Aasif Malbari as Managing Director and Chief Executive Officer effective August 12. Sudhir Sitapati has resigned, while Vishal Kedia will take charge as Interim Chief Financial Officer. This leadership transition introduces a new execution dynamic for a large consumer-products player, especially as markets weigh product launches, margin discipline, and capital allocation under new leadership. In the near term, investors will monitor guidance from the new management on innovation cycles, margin management, and potential strategic reviews that could influence the stock's risk-reward profile.

Prestige Estates And Canada Pension Plan Investment Board Up To 3,000 Crore Investment

Prestige Estates said the Canada Pension Plan Investment Board will invest up to 3,000 crore in Prestige Hospitality and acquire up to a 28% stake in the business. This marks a substantial private equity endorsement and improves the capital framework for Prestige Hospitality's expansion plans. The market will assess how this backing translates into faster project execution, asset turn, and earnings visibility, which could influence Prestige Estates' stock sentiment and valuation benchmarks in the hospitality and real estate space.

Canara Bank MCLR Increase: Details And Retail Impact

Canara Bank has raised its marginal cost of funds-based lending rates by 5 basis points across three tenures. The one-month MCLR now stands at 8.05%, the one-year MCLR at 8.80%, and the three-year MCLR at 9.10%. This adjustment signals tighter funding costs and could influence lending pricing for new loans while potentially affecting the broader credit cycle dynamics. Retail borrowersespecially homebuyers and personal loan customersmay see modest changes in EMI projections, while deposit competition might intensify as banks recalibrate to current rate environments.

Grasim Industries CPVC Resin Plant Start: Production And Market Signals

Grasim Industries has started commercial production at its CPVC resin plant in Gujarat, with an annual production capacity of 50,000 MTPA. This milestone expands Grasim's polymer portfolio and offers potential margin upside if feedstock costs and domestic demand align favorably. Investors will watch for how this new output integrates with Grasim's other business segments and how the plant's steady-state performance impacts the stock's valuation in the medium term.

Zydus Lifesciences Alvelestat Agreement With Mereo BioPharma: What It Means For Investors

Zydus Lifesciences said its subsidiary Sentynl Therapeutics has entered into an agreement with Mereo BioPharma for commercial and manufacturing rights to Alvelestat. Mereo is eligible to receive up to $40 million under the agreement, providing a potential upside for Zydus Lifesciences depending on milestone achievements and market access. The market will weigh this deal against the company's broader pipeline and regulatory milestones to gauge the probability of incremental revenue contribution and risk-adjusted upside.

SKF India Management Change And Interim Dividend

SKF India has appointed Sujeeth Pai as Managing Director with effect from September 1. Mukund Vasudevan will step down from the role on August 31. The company also declared an interim dividend of 20 per share, signaling continued shareholder value distribution amidst leadership transition. Investors will assess management's strategic plan, capital allocation philosophy, and the consistency of returning capital to shareholders as they evaluate the stock's long-term trajectory.

Other notable moves on August 12 include Muthoot Microfin's fundraising through private placement and Firstsource Solutions' collaboration with Cresta to deliver artificial intelligence technology solutions. These developments add to the sector-wide narrative of capital-raising, technology acceleration, and portfolio optimization across Indian markets. For a consolidated view of these catalysts and to track how they interplay with price dynamics, stay engaged with the Swastika platform and its research insights.

Related Reads

Frequently Asked Questions

What is the Vyoma.AI deal and how does it relate to L&T share price?

L&T's arm Vyoma.AI will transfer the data centre and cloud services business for 1,400 crore; markets will weigh this as a strategic realignment and watch for the stock's reaction.

What is the CPVC resin plant start by Grasim Industries?

Grasim Industries started commercial production at a CPVC resin plant in Gujarat with annual capacity of 50,000 MTPA.

Canara Bank MCLR increase details and what rates?

Canara Bank raised MCLR by 5 basis points across three tenures: 1-month MCLR 8.05%, 1-year MCLR 8.80%, and 3-year MCLR 9.10%.

What investment did Canada Pension Plan Investment Board announce in Prestige Hospitality?

Canada Pension Plan Investment Board will invest up to 3,000 crore and acquire up to 28% stake in Prestige Hospitality.

What is the Alvelestat deal between Zydus Lifesciences and Mereo BioPharma?

Sentynl Therapeutics, a Zydus Lifesciences subsidiary, entered into an agreement with Mereo BioPharma for commercial and manufacturing rights to Alvelestat; Mereo could receive up to $40 million.

Conclusion

In the near term, retail investors face a mixed risk-reward landscape as August 12's announcements filter into market sentiment. The L&T share price could display directional moves depending on how investors interpret Vyoma.AI's asset reallocation, along with ongoing boardroom changes and capital allocation signals. The broader suite of announcementsfrom Canara Bank's MCLR shift to Prestige Estates' private equity backing and Grasim's CPVC expansionoffers both catalysts and constraints for sector-specific stocks. A disciplined approach that tracks sector catalysts, monitors rate cycles, and weighs company-specific fundamentals will help you navigate the volatility with clarity.

Back To Index

Website:	Swastika	Word count	1163
Published Date	12 Aug 2026	Journalist:	Santosh Meena

Stocks to Watch Today: GE Vernova T&D, MCX & Divi's Laboratories (12 August 2026)

https://www.swastika.co.in/blog/stocks-to-watch-today-12-august-2026-ge-vernova-mcx-divis-laboratories

Santosh Meena August 12, 2026 Looking for stocks to watch today? Stock picking is getting a little tougher in the current market, with
only a handful of names really moving, but three stand out technically: GE Vernova T&D India, MCX, and Divi's Laboratories. On the index front, Nifty today is showing early signs of weakness near its 200-DMA, while Bank Nifty today is consolidating with a slightly negative bias.

This is today's edition of Trader's Breakfast, Swastika Investmart's daily stock market update today briefing, your share market news live and technical analysis today; watch and read before the opening bell.

Key Takeaways

Today's stocks to watch, GE Vernova T&D India, MCX, and Divi's Laboratories, are flagged as portfolio-worthy names, not just trading bets.

GE Vernova T&D shrugged off weak Q1 results and is building a solid base, in line with the broader bullish view on the data centre and AI theme.

MCX could see a gap-up open today on FPI/FII commodity trading access and a bullish JPMorgan report.

Nifty today is showing early weakness near its 200-DMA, with 24,42824,367 as immediate support.

Bank Nifty today remains in consolidation with a slightly negative bias.

Watch Today's Complete Market Outlook

Catch the full technical breakdown and stock-specific view in today's Trader's Breakfast with Santosh Meena, Head of Research, Swastika Investmart.

Stocks to Watch Today

GE Vernova T&D India

With a broader bullish view on India's data center and AI theme, GE Vernova T&D India's recent Q1 results came in weak, yet the stock didn't react negatively and is building a good base instead. A similar bullish call was made on ABB from the start of 2026, and GE Vernova T&D India could follow a similar outperformance path, given reports of a strongly bullish outlook from its global parent company on the data center theme.

Technical View (as discussed in today's Trader's Breakfast):

Risk-reward is favourable at current levels.

A good base has already formed on a positional basis around 4,000.

Immediate target: 4,700, and the stock could pause a bit around this level.

Once 4,700 is crossed, fresh highs could follow.

Flagged more as a positional pick, though the structure could support some intraday moves too.

MCX

Commodities have now been opened up to FPI participation, allowing FIIs to trade in the segment. With traders finding less excitement in Nifty options (due to rising STT and more trading systems), business activity is shifting toward commodities, where volatility and options participation are picking up, a direct positive for MCX . Fresh FPI entry into commodities adds to the tailwind.

Technical View:

Stock could see a gap-up opening today.

A bullish JPMorgan report on the stock came out today.

Flagged as a portfolio stock, expected to outperform from here.

Divi's Laboratories

Divi's Laboratories is in strong momentum, having shown a pullback before forming a fresh flag formation and gearing up for further upside.

Technical View:

Could show levels up to 8,800 today.

May see some consolidation/pause around the 8,800 level worth keeping an eye on.

Structure looks strong, with the stock already delivering a 34% return this year (CY2026 YTD).

Flagged as a portfolio stock for long-term wealth creation, not just a short-term trade.

Stocks in News Today

Here are today's key stocks in news , covering major corporate developments and order wins:

Saatvik Green : Secured a 400 crore order from an EPC player for the supply of solar PV modules.

Zydus Life : Its arm Sentynl entered a pact with Mereo BioPharma for commercial and manufacturing rights of Alvelestat; Mereo is eligible for up to USD 40 million under the agreement.

BEML : Received a 184 crore order from HAL to supply Light Combat Helicopter fuselage aerostructures.

Firstsource Solutions : Entered a partnership with Cresta to deliver AI technology solutions.

Market Setup Today (12 August 2026)

Here's today's market outlook at a glance, global cues, FII DII data today, and the India VIX today reading:

Global Markets

US markets ended lower (Dow Jones -184 points).

Dow Futures trading flat, down ~2 points.

Asian markets trading on a mixed note.

GIFT Nifty : +22 points.

FII/DII Data (Cash Market)

FII: +258 crore

DII: +25 crore

Net: +283 crore

Interpretation: FIIs created a short position in index futures, while options data isn't very useful today due to the weekly expiry in F&O.

Technical Outlook: Nifty & Bank Nifty Today

Today's technical analysis for the two key benchmarks:

Nifty (Spot)

Showing some signs of weakness near its 200-DMA.

24,42824,367 is an immediate support zone, with as the next support level.

23,50023,600 has now become an immediate supply zone.

Bank Nifty (Spot)

Still consolidating, with a slightly negative bias.

is immediate support, with 56,500 and 56,000 as the next support levels.

57,600, 58,000, and 58,300 are the immediate resistance levels.

Q1 Results Today: 12 August 2026

Frequently Asked Questions

Why is GE Vernova T&D India in focus today?

Despite weak Q1 results, the stock didn't react negatively and is building a good base, in line with a bullish view on India's data center and AI theme and the global parent company's bullish outlook. It has an immediate target of 4,700 off a 4,000 base, with fresh highs possible once 4,700 is crossed.

Why is Divi's Laboratories on the radar today?

The stock is in strong momentum, having formed a fresh flag pattern after a pullback, with potential to touch 8,800 today (possible pause there). It has already delivered a 34% return this year and is viewed as a long-term portfolio stock.

What are Nifty's key support and resistance levels today?

Nifty is showing some weakness near its 200-DMA, with 24,42824,367 as immediate support, 24,200 as the next support, and 23,50023,600 now acting as a supply zone.

What are Bank Nifty's key levels today?

Bank Nifty remains in consolidation with a slightly negative bias support at 57,000, then 56,500/56,000, with resistance at 57,600, 58,000, and 58,300.

What is today's FII/DII data?

FIIs were net buyers at +258 crore, and DIIs bought a net +25 crore, taking net cash market flows to +283 crore.

Which companies are announcing Q1 results today?

Key F&O names reporting today include Apollo Hospitals, Astral, Grasim, HAL, and Petronet LNG, alongside other companies like IRCTC, Lenskart, and Abbott India.

Over to You

Stock selection is getting trickier in the current market, but GE Vernova T&D India, MCX, and Divi's Laboratories stand out as names worth tracking, not just for trades, but as potential long-term portfolio holdings. On the index side, Nifty is flashing early signs of weakness near its 200-DMA, while Bank Nifty stays in a cautious consolidation phase.

As always, track price action around key support and resistance levels, follow the broader market outlook, and apply disciplined risk management before taking any trading or investment decision. For more stocks to watch today, stock market news today, and share market news live, keep following Swastika Investmart's Trader's Breakfast.

Back To Index

Website:	The Economic Times	Word count	33
Published Date	12 Aug 2026	Journalist:	Bureau

Zydus' subsidiary inks optional licensing agreement with Mereo BioPharma for rare respiratory drug

https://pharma.economictimes.indiatimes.com/news/pharma-industry/zydus-subsidiary-inks-optional-licensing-agreement-with-mereo-biopharma-for-rare-respiratory-drug/133184214

The agreement gives Zydus' subsidiary, Sentynl Therapeutics option to acquire exclusive commercial rights of, alvelestat' for the treatment of AATD-LD (a rare genetic respiratory disease) in the US along with global manufacturing rights.

Back To Index

Website:	Zee Business	Word count	2518
Published Date	12 Aug 2026	Journalist:	Abhay Shukla

Stocks to Watch Today (August 12): Apollo Hospitals, Grasim, PI Industries, Manappuram Finance, GCPL and more

https://www.zeebiz.com/market-news/news-stocks-to-watch-today-august-12-apollo-hospitals-grasim-pi-industries-manappuram-finance-gcpl-and-more-400314

PI Industries, Manappuram Finance and a large set of cash market names have already posted their results, while Apollo Hospitals and Grasim are among the key names set to report through the day. Here's a look at the key stocks and triggers for today's session.

Markets will track a busy set of June quarter earnings, block deals and stock-specific news on Wednesday. PI Industries, Manappuram Finance and a large set of cash market names have already posted their results, while Apollo Hospitals and Grasim are among the key names set to report through the day. Here's a look at the key stocks and triggers for today's session.

Both stocks have variable result timings today.

Among F&O stocks, Astral will report post-market, HAL between 1:30 pm and 3:30 pm, and Petronet LNG and GMR Airports post-market.

NSE will launch F&O contracts on the Nifty India FPI 150 index today.

Both stocks turn ex-dividend today. KPIT Technologies will pay a final dividend of Rs 5.25 per share, and Computer Age Management Services an interim dividend of Rs 2.5 per share.

The company's IPO opens today and will remain open until August 14, with a price band of Rs 271-285 and a lot size of 52 shares. The issue size is Rs 302 crore, comprising a fresh issue of Rs 93 crore and an offer for sale of Rs 209 crore. The company raised Rs 90.48 crore from anchor investors including Tata AIA Insurance, Bandhan Fund, Whiteoak and 360 One.

PI Industries' June quarter results came in below estimates, with operationally weak performance. Revenue fell 10.4 per cent to Rs 1,702 crore from Rs 1,900 crore, short of the Rs 1,792 crore estimate. EBITDA fell 29 per cent to Rs 367 crore from Rs 519 crore, well below the Rs 432 crore estimate, with margins contracting to 21.6 per cent from 27.3 per cent. Net profit fell 39 per cent to Rs 244 crore from Rs 400 crore, missing the Rs 311 crore estimate. Other income fell to Rs 64 crore from Rs 86 crore. Agrochemicals revenue fell 10 per cent to Rs 1,649 crore, while pharma revenue fell 25 per cent to Rs 54 crore. The earnings call is scheduled for August 12 at 12 noon.

Manappuram Finance posted strong June quarter numbers with a robust outlook. Net interest income rose 25 per cent to Rs 1,724 crore from Rs 1,380 crore, ahead of the Rs 1,630 crore estimate. Net profit jumped four-fold to Rs 584 crore from Rs 132 crore, well ahead of the Rs 465 crore estimate. Gross NPA improved to 1.6 per cent from 1.8 per cent sequentially, and net NPA to 1.1 per cent from 1.5 per cent. Return on assets rose to 3.5 per cent from 1.1 per cent, and return on equity to 14.3 per cent from 4.3 per cent, while cost of borrowing eased to 8.8 per cent from 9.2 per cent. Fee income more than doubled to Rs 11.5 crore, and other income rose four-fold to Rs 6 crore. Impairment on financial instruments fell 60 per cent to Rs 225 crore. Assets under management grew 57.20 per cent year-on-year, with gold loan AUM rising 97.9 per cent to Rs 57,006 crore. Non-gold businesses made up 18.14 per cent of total AUM, and subsidiary Asirvad Microfinance returned to profit with Rs 21 crore during the quarter. Management guided for 25-30 per cent AUM growth in the gold loan business for FY27, plans to open 500 new branches during the year, and is targeting ROA of 3.5-4 per cent and ROE of 18 per cent within three years. Gold loan yields are expected to stabilise around 18 per cent, while the vehicle finance business will stay in collection-focused mode with no new disbursements planned for FY27.

A large set of cash market companies have posted June quarter results:

Ashiana Housing Revenue fell 63.3 per cent to Rs 107 crore from Rs 293 crore, while EBITDA fell 37 per cent to Rs 8 crore from Rs 12 crore. Net profit rose 3 per cent to Rs 13.1 crore from Rs 12.7 crore.

Bata India Revenue rose 4 per cent to Rs 980 crore from Rs 942 crore, while EBITDA grew 3 per cent to Rs 205 crore from Rs 199 crore. Net profit rose 23 per cent to Rs 64 crore from Rs 52 crore, and the company declared an interim dividend of Rs 25 per share.

Linde India Revenue rose 21.6 per cent to Rs 694 crore from Rs 571 crore, while EBITDA grew 2 per cent to Rs 201 crore from Rs 197 crore. Net profit fell 2 per cent to Rs 105 crore from Rs 107 crore.

JSW Paints (JSW Dulux) Revenue fell 2.8 per cent to Rs 965 crore from Rs 993 crore, while EBITDA fell 14.4 per cent to Rs 115 crore from Rs 134 crore. Net profit fell 12 per cent to Rs 80 crore from Rs 91 crore. The board approved a 1:10 stock split.

IFCI Standalone revenue fell 30.9 per cent to Rs 125 crore from Rs 181 crore, while net profit rose 28.6 per cent to Rs 9 crore from Rs 7 crore.

ISGEC Heavy Engineering Revenue rose 46 per cent to Rs 1,980 crore from Rs 1,356 crore, while EBITDA was nearly flat at Rs 124 crore. Net profit rose 29 per cent to Rs 9 crore from Rs 7 crore.

Man Industries Revenue rose 42 per cent to Rs 1,053 crore from Rs 742 crore, while EBITDA jumped 89 per cent to Rs 143 crore from Rs 76 crore. Net profit more than doubled to Rs 61 crore from Rs 28 crore.

RHI Magnesita India Revenue rose 6 per cent to Rs 1,014 crore from Rs 960 crore, while EBITDA grew 35 per cent to Rs 138 crore from Rs 102 crore.

Som Distilleries & Breweries Revenue fell 49 per cent to Rs 269 crore from Rs 528 crore, while adjusted EBITDA fell 79 per cent to Rs 15 crore from Rs 70 crore. Net profit fell 96 per cent to Rs 1.6 crore from Rs 42 crore.

TD Power Systems Revenue rose 72 per cent to Rs 640 crore from Rs 372 crore, while EBITDA grew 77 per cent to Rs 122 crore from Rs 69 crore. Net profit rose 73 per cent to Rs 86 crore from Rs 50 crore. The board will consider fund raising via QIP, debt and rights issue at its August 14 meeting.

Walchandnagar Industries Revenue rose 84 per cent to Rs 91 crore from Rs 49 crore, and the company swung to an EBITDA profit of Rs 7 crore from a loss of Rs 2 crore, and to a net profit of Rs 1 crore from a loss of Rs 10 crore.

Nephrocare Health Services Revenue rose 24 per cent to Rs 282 crore from Rs 228 crore, while EBITDA grew 34 per cent to Rs 64 crore from Rs 48 crore. Net profit rose 35 per cent to Rs 32 crore from Rs 24 crore.

Ashoka Buildcon Revenue fell 20.6 per cent to Rs 1,499 crore from Rs 1,887 crore, while EBITDA fell 57 per cent to Rs 258 crore from Rs 599 crore. Net profit fell 41.5 per cent to Rs 127 crore from Rs 217 crore.

Concord Enviro Systems Revenue fell 16.6 per cent to Rs 85 crore from Rs 102 crore, and the company swung to a net loss of Rs 18 crore from a profit of Rs 4 crore.

Delta Corp Revenue fell 8.5 per cent to Rs 169 crore from Rs 184 crore, while EBITDA fell 21.5 per cent to Rs 31 crore from Rs 39 crore. The company posted a net loss of Rs 212 crore against a profit of Rs 29 crore, including an exceptional loss of Rs 306 crore during the quarter.

Camlin Fine Sciences Revenue rose 27.5 per cent to Rs 520 crore from Rs 408 crore, but EBITDA fell 54.3 per cent to Rs 9.2 crore from Rs 20 crore, with the net loss widening to Rs 32 crore from Rs 10 crore.

Precision Camshafts Revenue fell 3.6 per cent to Rs 188 crore from Rs 195 crore, while EBITDA fell 50.4 per cent to Rs 7.2 crore from Rs 15 crore. Net profit fell 55.1 per cent to Rs 8 crore from Rs 19 crore, aided by an exceptional gain of Rs 39.7 crore.

Senco Gold Revenue rose 67.4 per cent to Rs 3,056 crore from Rs 1,826 crore, while EBITDA grew 16.3 per cent to Rs 213.4 crore from Rs 184 crore. Net profit fell 3.3 per cent to Rs 101 crore from Rs 105 crore, as finance costs rose to Rs 68 crore from Rs 43 crore.

Repco Home Finance Net interest income rose 12.4 per cent to Rs 206 crore from Rs 183 crore, while net profit rose 6 per cent to Rs 114 crore from Rs 108 crore. Gross NPA rose to 3.33 per cent from 3.19 per cent sequentially.

SP Apparels Revenue was flat at Rs 401 crore versus Rs 403 crore, while EBITDA rose 17 per cent to Rs 61 crore from Rs 52 crore. Net profit rose 16.6 per cent to Rs 36 crore from Rs 31 crore. The board approved a 1:5 stock split.

Amrutanjan Health Care Revenue rose 10.6 per cent to Rs 150 crore from Rs 135 crore, while EBITDA grew 44 per cent to Rs 25.5 crore from Rs 17.7 crore. Net profit rose 6.7 per cent to Rs 16 crore from Rs 15 crore.

Enviro Infra Engineers Revenue rose 49 per cent to Rs 359 crore from Rs 241 crore, while EBITDA grew 17.6 per cent to Rs 75.5 crore from Rs 64.2 crore. Net profit rose 6.6 per cent to Rs 45 crore from Rs 42 crore.

Epack Durable Revenue rose 33.8 per cent to Rs 886 crore from Rs 662 crore, while EBITDA was nearly flat at Rs 55 crore. Net profit fell 48.2 per cent to Rs 12 crore from Rs 23 crore on higher operating expenses.

Polyplex Corporation Revenue rose 29.6 per cent to Rs 2,253 crore from Rs 1,738 crore, and the company swung to an EBITDA of Rs 296 crore from a loss of Rs 1 crore, and to a net profit of Rs 91 crore from a loss of Rs 19 crore.

Gokaldas Exports Revenue rose 20.7 per cent to Rs 1,154 crore from Rs 956 crore, while EBITDA grew 15 per cent to Rs 112.5 crore from Rs 97 crore. Net profit rose 6.8 per cent to Rs 44 crore from Rs 41 crore.

Techno Electric & Engineering Revenue rose 19.8 per cent to Rs 630 crore from Rs 526 crore, while EBITDA grew 7 per cent to Rs 99.2 crore from Rs 92.4 crore. Net profit fell 32 per cent to Rs 93 crore from Rs 136 crore, as other income fell to Rs 29 crore from Rs 48 crore.

Landmark Cars Revenue rose 22.6 per cent to Rs 1,302 crore from Rs 1,062 crore, while EBITDA grew 17 per cent to Rs 71.7 crore from Rs 61.4 crore. Net profit more than doubled to Rs 15 crore from Rs 7 crore, aided by other income.

Vidya Wires Revenue rose 33.5 per cent to Rs 550 crore from Rs 412 crore, while EBITDA grew 19 per cent to Rs 22.4 crore from Rs 18.8 crore. Net profit rose 42 per cent to Rs 17 crore from Rs 12 crore.

Vikran Engineering Revenue fell 10.7 per cent to Rs 142 crore from Rs 159 crore, while EBITDA fell 48 per cent to Rs 11.7 crore from Rs 22.5 crore. Net profit fell 29 per cent to Rs 4 crore from Rs 5.7 crore.

A block deal worth around Rs 2,080 crore is possible today, with promoter Tenneco Mauritius potentially selling a 10 per cent stake (8 per cent base plus 2 per cent upsize) at a floor price of Rs 515 per share, a 6.4 per cent discount to the last close. The promoter, which currently holds a 74.79 per cent stake, will face a 90-day lock-in on further stake sales.

A block deal worth around Rs 2,000 crore is possible today, with Temasek and TPG potentially selling a combined 13 per cent stake (11 per cent base plus 2 per cent upsize) at a floor price of Rs 500 per share, an 8 per cent discount.

A block deal worth around Rs 1,000 crore is possible today, involving the sale of 1.57 crore shares at a floor price of Rs 630 per share, a 3 per cent discount.

SEBI has issued a consultation paper seeking feedback on foreign portfolio investor (FPI) participation in non-agricultural commodities. The regulator has also amended the Municipal Debt Securities Regulations (MDSR).

Godrej Consumer's MD & CEO Sudhir Sitapati has resigned. Aasif Malbari has taken over as the company's MD & CEO with effect from today, while Vishal Kedia has been appointed CFO.

L&T will transfer its data centre and cloud business to subsidiary Vyoma.ai in a deal valued at around Rs 1,400 crore.

Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an agreement with Mereo BioPharma for Alvelestat, a treatment for a lung disease. Sentynl may receive US commercial rights, with Mereo potentially receiving up to Rs 381.5 crore ($40 million) under the deal. A Phase 3 trial is expected to begin in early 2027.

The High Court has ordered that Sun Pharma must seek court permission before launching its semaglutide tablet, in a case linked to a petition by Novo Nordisk. Novo Nordisk's oral semaglutide drug, Rybelsus, is protected by a separate formulation patent that it claims Sun Pharma has infringed.

Firstsource Solutions has partnered with Cresta to advance AI-driven customer experience solutions, targeting the US, UK, Australia and Middle East markets, backed by a dedicated AI centre.

Saatvik Green Energy has secured an order worth Rs 400 crore from an EPC player for the supply of PV solar modules, to be completed by March 2027.

BEML has received an order worth Rs 184 crore from HAL for the supply of Light Combat Helicopter fuselages.

The board has approved fund raising of Rs 1,000 crore through a QIP.

KFin Technologies has launched an AI solution called Klarity AI, aimed at helping BFSI companies detect fraudulent signatures.

HG Infra Engineering has secured a 10-year public-private partnership project to operate and manage the Bhiwadi ITI Cluster. The project is estimated to cost Rs 241 crore, with HG Infra holding a 17.10 per cent stake worth around Rs 41 crore.

SJVN has commissioned a 75 MW solar project in Jamui, Bihar, at a cost of Rs 1,342 crore.

SKF India has appointed Sujeeth Pai as its new Managing Director, following the resignation of Mukund Vasudevan from the post.

The board will meet on August 14 to consider raising up to Rs 3,000 crore through a QIP.

Innovision has secured an order from NHAI for the Aashpur Toll Plaza, worth Rs 83.29 crore, for a one-year contract period.

Back To Index

Website:	7 Globe News	Word count	225
Published Date	11 Aug 2026	Journalist:	Bureau

Zydus arm gets option on US rights to potential first oral drug for rare lung disease

https://www.7globe.in/zydus-arm-gets-option-on-us-rights-to-potential-first-oral-drug-for-rare-lung-disease/

Under the agreement, Sentynl will have the exclusive option to acquire a licence to commercialise alvelestat for AATD-LD in the US, while Mereo will retain commercial rights in the rest of the world.

Sentynl will also receive global manufacturing rights for the drug.

Alvelestat is an oral neutrophil elastase inhibitor being prepared for Phase 3 development. If approved, it could become the first oral treatment for AATD-LD, which is estimated to affect between 50,000 and 80,000 people in the US.

The companies expect the Phase 3 development programme could begin in early 2027.

Mereo will receive a non-refundable option fee from Sentynl. If Sentynl exercises the option, Mereo will be eligible to receive up to $40 million in upfront and research-and-development payments through the filing of a New Drug Application, as well as double-digit tiered royalties on US net sales of alvelestat.

Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed.

During the option period, the companies will work together to refine the Phase 3 study design and advance manufacturing activities.Alvelestat has received Orphan Drug Designation for AATD-LD from both the US Food and Drug Administration and the European Commission. It has also received Fast Track designation from the FDA.

Zydus Lifesciences shares closed 6.43% higher at 1,191 on the NSE on Tuesday.

Source link

Leave a Reply

Back To Index

Website:	americanpharmaceuticalreview	Word count	331
Published Date	11 Aug 2026	Journalist:	Bureau

Sentynl, Mereo Sign Alvelestat Deal Worth Up to $40M Before NDA Filing

https://www.americanpharmaceuticalreview.com/1315-News/627345-Sentynl-Mereo-Sign-Alvelestat-Deal-Worth-Up-to-40M-Before-NDA-Filing/

Sentynl Therapeutics and Mereo BioPharma have entered an option and license agreement covering U.S. commercial rights and global manufacturing rights for alvelestat, an investigational oral treatment for alpha-1 antitrypsin deficiency-associated lung disease.

Under the agreement, Sentynl has the exclusive right to acquire a license to commercialize alvelestat in the United States. Mereo will retain commercial rights outside the U.S. and lead global development, including the planned Phase 3 study and regulatory interactions through completion of that trial.

Mereo will receive a non-refundable option fee. If Sentynl exercises its option, Mereo would be eligible for up to $40 million in upfront and research-and-development payments through filing of a New Drug Application, along with double-digit tiered royalties on U.S. net sales.

Sentynl, a U.S.-based biopharmaceutical company and wholly owned subsidiary of Zydus Lifesciences, would also receive global manufacturing rights for alvelestat in the AATD-LD indication. Exercise of the option would provide funding for the Phase 3 development program, which could begin in early 2027.

Alvelestat is a neutrophil elastase inhibitor being prepared for Phase 3 testing. If approved, the companies said it could become the first oral treatment for AATD-LD, a rare, progressive genetic respiratory disease estimated to affect 50,000 to 80,000 people in the United States.

The companies will work together during a short option period to advance manufacturing activities and refine the planned global Phase 3 study design. Mereo said the program is supported by positive efficacy data from two Phase 2 studies.

Sentynl Chief Executive Officer Matt Heck said current AATD-LD care can be demanding, often involving generalized therapies or frequent intravenous treatment. He said the company sees an opportunity for alvelestat to improve on existing approaches if the drug is successful in later-stage development.

Mereo Chief Executive Officer Denise Scots-Knight said Sentynls rare-disease focus and commercial infrastructure make it a suitable partner to advance the program. Zydus Managing Director Sharvil P. Patel said the agreement expands Sentynls rare-disease portfolio and addresses an area of significant unmet need.

Back To Index

Website:	Bio Space	Word count	1958
Published Date	11 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://www.biospace.com/press-releases/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease

On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights

Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales

Companies will collaborate to refine the Phase 3 design during short option period

LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (Zydus), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynls commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design, said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

This partnership marks a pivotal moment for Sentynls rare disease strategy. Mereos alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people,

said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive $40 million in upfront and R&D payments. Under these terms, Mereo would also be eligible to receive up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. (Sentynl) is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Companys reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Companys dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Companys dependence on its key executives; the Companys dependence on its strategic partners; and the Companys ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Companys business, including those described in the Risk Factors section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Companys subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words believe, expect, anticipate, plan, intend, foresee, should, would, could, may, estimate, outlook, will, continue and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Companys current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to

publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.

[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.

[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.

[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts

[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Investor Contacts

Mereo BioPharma

Denise Scots-Knight, Chief Executive Officer

Christine Fox, Chief Financial Officer

+44 (0)333 023 7300

investors@mereobiopharma.com

Sentynl Therapeutics, Inc.

Media: Maureen Roberts, maureen.roberts@omc.com

Sentynl: Michael Hercz, ir@sentynl.com

Zydus Lifesciences Limited

Media: Sujatha Rajesh; sujatha.rajesh@zyduslife.com; +91-9974051180

Investor Relations: Arvind Bothra, arvind.bothra@zyduslife.com, +91-7045656895

Website:	Bio Space	Word count	1898
Published Date	11 Aug 2026	Journalist:	Bureau

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://www.biospace.com/press-releases/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease

On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights

Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, and double-digit tiered royalties on U.S. sales

Companies will collaborate to refine the Phase 3 design during short option period

SOLANA BEACH, Calif. and AHMEDABAD, India and LONDON, Aug. 11, 2026 /PRNewswire/ -- Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus") and Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need," said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life."

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people," said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development."

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl's

commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs' airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl") is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; the Company's dependence on its strategic partners; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.

[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.

[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.

[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts

[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

View original content to download multimedia:https://www.prnewswire.com/news-releases/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld-302847861.html

SOURCE Sentynl Therapeutics

Back To Index

Website:	CNBC TV18	Word count	289
Published Date	11 Aug 2026	Journalist:	Srabastee Biswas

Zydus arm gets option on US rights to potential first oral drug for rare lung disease

https://www.cnbctv18.com/business/companies/zydus-arm-gets-option-on-us-rights-to-potential-first-oral-drug-for-rare-lung-disease-19967018.htm

Sentynl Therapeutics has secured an option for US commercial rights to alvelestat, a potential first oral treatment for a rare genetic lung disease affecting up to 80,000 Americans.

2 Min Read

Zydus Lifesciences ' wholly owned subsidiary Sentynl Therapeutics has entered into an option and licence agreement with Mereo BioPharma for alvelestat, an experimental treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, or AATD-LD, a rare genetic respiratory disease.

Under the agreement, Sentynl will have the exclusive option to acquire a licence to commercialise alvelestat for AATD-LD in the US, while Mereo will retain commercial rights in the rest of the world. Sentynl will also receive global manufacturing rights for the drug.

Alvelestat is an oral neutrophil elastase inhibitor being prepared for Phase 3 development. If approved, it could become the first oral treatment for AATD-LD, which is estimated to affect between 50,000 and 80,000 people in the US.

The companies expect the Phase 3 development programme could begin in early 2027.

Mereo will receive a non-refundable option fee from Sentynl. If Sentynl exercises the option, Mereo will be eligible to receive up to $40 million in upfront and research-and-development payments through the filing of a New Drug Application, as well as double-digit tiered royalties on US net sales of alvelestat.

Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed.

During the option period, the companies will work together to refine the Phase 3 study design and advance manufacturing activities.

Alvelestat has received Orphan Drug Designation for AATD-LD from both the US Food and Drug Administration and the European Commission. It has also received Fast Track designation from the FDA.

Zydus Lifesciences shares closed 6.43% higher at 1,191 on the NSE on Tuesday.

Back To Index

Website:	Fierce Biotech	Word count	418
Published Date	11 Aug 2026	Journalist:	Bureau

Zydus' Sentynl pens $475M deal for Mereo's phase 3-ready rare genetic lung disease drug

https://www.fiercebiotech.com/biotech/mereo-springs-475m-biobucks-sentynl-phase-3-ready-rare-genetic-lung-disease-drug

Sentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.

In return for an undisclosed upfront payment, Sentynla subsidiary of Zydus Lifesciencesha s secured the option to commercialize alvelestat in the U.S. The plan is for Mereo to lead a planned global phase 3 study of the neutrophil elastase inhibitor in patients with alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), although the two companies will collaborate to advance manufacturing and streamline the trial design, according to an August 11 release.

Should Sentynl take up its option to secure the U.S. license, the company will pay out $40 million in upfront and R&D payments, with potentially up to $435 million in regulatory and commercial milestone payments to follow, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the development of the drug in the rest of the world.

London-based Mereo, founded in 2015, focuses on developing therapeutics for rare diseases. One of their key interests is AATD-LD, a rare genetic respiratory disease that often starts in early adulthood and can lead to irreversible loss of lung function, early-onset emphysema or chronic obstructive pulmonary disease.

AATD-LD is caused by a deficiency of the alpha-1 antitrypsin protein, which is in charge of protecting the lungs against damaging enzymes released during inflammation. Mereo acquired alvelestat from AstraZeneca for $5 million upfront back in 2017. By inhibiting neutrophil elastase, the drug is designed to block an enzyme produced by white blood cells involved in the inflammation and destruction of the lung seen in AATD-LD.

We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD, Mereo co-founder and CEO Denise Scots-Knight, Ph.D., said in the release. We have been preparing alvelestat for a global phase 3 study, backed by positive efficacy data from two phase 2 studies.

California-based Sentynl, which was bought by Zydus in 2017, has three FDA-approved therapies aimed at rare diseases, including Nulibry for molybdenum cofactor deficiency type A and Zokinvy for Hutchinson-Gilford progeria syndrome.

For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments, said Sentynl CEO Matt Heck.

The only FDA-approved treatment in the space is pooled plasma alpha-1 antitrypsin protein intravenously administered weekly. Alvelestat has the potential to offer targeting of neutrophil elastase, the direct enzyme that causes tissue damage, in an oral form.

Back To Index

Website:	INV	Word count	366
Published Date	11 Aug 2026	Journalist:	Bureau

Zydus Lifesciences: Sentynl Licenses Alvelestat for US Market from Mereo

https://www.investywise.com/zydus-lifesciences-collaboration-for-novel-lung-disease-treatment/

Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has entered into an option and license agreement with Mereo BioPharma for alvelestat.

Sentynl gains exclusive US commercial rights for the oral treatment of Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). The deal includes an option fee, potential milestone payments up to $40 million , and double-digit tiered royalties on US sales, significantly expanding Sentynl's rare disease portfolio.

Zydus Subsidiary Secures US Rights for Rare Disease Drug

Sentynl Therapeutics, Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited, has entered into an option and license agreement with Mereo BioPharma Group plc for alvelestat. This agreement grants Sentynl the exclusive right to acquire the license to commercialize alvelestat, a first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD), in the United States. Mereo will retain commercial rights for the rest of the world.

Deal Structure and Financials

The agreement includes a non-refundable option fee. Upon exercise of the option, Sentynl will provide Mereo with up to $40 million in upfront and R&D payments until the New Drug Application (NDA) filing. Furthermore, Mereo will be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat. Sentynl will also receive global rights to manufacture alvelestat for AATD-LD and will provide funding for the alvelestat Phase 3 development program, which could commence in early 2027.

Strategic Importance for Sentynl

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, highlighted that this partnership is a pivotal moment for Sentynl's rare disease strategy. Alvelestat is considered a highly promising candidate that meaningfully expands Sentynl's portfolio and addresses a significant unmet need. AATD-LD is a rare, progressive genetic lung disease estimated to affect 50,000-80,000 individuals in the United States. If approved, alvelestat could offer a crucial new oral treatment option for patients.

About Alvelestat and the Disease

Alvelestat is a novel, oral small molecule designed to inhibit neutrophil elastase (NE), a key enzyme implicated in inflammation and lung tissue destruction. It has received Orphan Drug Designation and Fast Track designation from the European Commission and the FDA for AATD-LD. The agreement also stipulates collaboration between the companies to refine the Phase 3 study design during the option period.

Source: BSE

Back To Index

Website:	Investingnews	Word count	1933
Published Date	11 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

https://investingnews.com/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease/

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease
On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights
Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales
Companies will collaborate to refine the Phase 3 design during short option period

Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus"), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

"This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need," said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life."

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people," said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development."

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive $40 million in upfront and R&D payments. Under these terms, Mereo would also be eligible to receive up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs' airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is

driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl") is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; the Company's dependence on its strategic partners; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.
[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.
[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.
[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts
[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Investor Contacts

Mereo BioPharma

Denise Scots-Knight, Chief Executive Officer
Christine Fox, Chief Financial Officer
+44 (0)333 023 7300
investors@mereobiopharma.com

Sentynl Therapeutics, Inc.

Media: Maureen Roberts, maureen.roberts@omc.com
Sentynl: Michael Hercz, ir@sentynl.com

Zydus Lifesciences Limited

Media: Sujatha Rajesh; sujatha.rajesh@zyduslife.com; +91-9974051180
Investor Relations: Arvind Bothra, arvind.bothra@zyduslife.com, +91-7045656895

Back To Index

Website:	Investingnews	Word count	1730
Published Date	11 Aug 2026	Journalist:	Bureau

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

https://investingnews.com/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease/

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease
On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights
Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, and double-digit tiered royalties on U.S. sales
Companies will collaborate to refine the Phase 3 design during short option period
Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus") and Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

Sentynl Therapeutics, Inc.

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need," said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life."

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people," said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development."

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs' airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl") is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; the Company's dependence on its strategic partners; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Back To Index

Website:	Manila Times	Word count	1958
Published Date	11 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://www.manilatimes.net/2026/08/11/tmt-newswire/globenewswire/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld/2402928

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease

On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights

Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales

Companies will collaborate to refine the Phase 3 design during short option period

LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo or the "Company), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. ("Sentynl), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynls commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design, said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

"This partnership marks a pivotal moment for Sentynls rare disease strategy. Mereos alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people, said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive $40 million in upfront and R&D payments. Under these terms, Mereo would also be eligible to receive up to $435 million in regulatory and

commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in

class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl) is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

Forward-Looking Statements

This press release contains "forward-looking statements that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Companys reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Companys dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Companys dependence on its key executives; the Companys dependence on its strategic partners; and the Companys ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Companys business, including those described in the "Risk Factors section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Companys subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe, "expect, "anticipate, "plan, "intend, "foresee, "should, "would, "could, "may, "estimate, "outlook, "will, "continue and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Companys current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.

[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.

[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.

[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts

[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Investor Contacts

Mereo BioPharma

Denise Scots-Knight, Chief Executive Officer

Christine Fox, Chief Financial Officer

+44 (0)333 023 7300

investors@mereobiopharma.com

Sentynl Therapeutics, Inc.

Media: Maureen Roberts, maureen.roberts@omc.com

Sentynl: Michael Hercz, ir@sentynl.com

Zydus Lifesciences Limited

Media: Sujatha Rajesh; sujatha.rajesh@zyduslife.com; +91-9974051180

Investor Relations: Arvind Bothra, arvind.bothra@zyduslife.com, +91-7045656895

Back To Index

Website:	Market Business Sider	Word count	1958
Published Date	11 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://markets.businessinsider.com/news/stocks/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld-1036440674

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease
On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights
Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales
Companies will collaborate to refine the Phase 3 design during short option period

LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (Zydus), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynls commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design, said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

This partnership marks a pivotal moment for Sentynls rare disease strategy. Mereos alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people, said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive $40 million in upfront and R&D payments. Under these terms, Mereo would also be eligible to receive up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is

driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. (Sentynl) is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Companys reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Companys dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Companys dependence on its key executives; the Companys dependence on its strategic partners; and the Companys ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Companys business, including those described in the Risk Factors section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Companys subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words believe, expect, anticipate, plan, intend, foresee, should, would, could, may, estimate, outlook, will, continue and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Companys current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.
[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.
[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.
[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts
[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Investor Contacts

Mereo BioPharma

Denise Scots-Knight, Chief Executive Officer
Christine Fox, Chief Financial Officer
+44 (0)333 023 7300
investors@mereobiopharma.com

Sentynl Therapeutics, Inc.

Media: Maureen Roberts, maureen.roberts@omc.com
Sentynl: Michael Hercz, ir@sentynl.com

Zydus Lifesciences Limited

Media: Sujatha Rajesh; sujatha.rajesh@zyduslife.com; +91-9974051180
Investor Relations: Arvind Bothra, arvind.bothra@zyduslife.com, +91-7045656895

Back To Index

Website:	Morning Star	Word count	1949
Published Date	11 Aug 2026	Journalist:	Bureau

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://www.morningstar.com/news/pr-newswire/20260811cg23462/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

PR Newswire

SOLANA BEACH, Calif. and AHMEDABAD, India and LONDON, Aug. 11, 2026

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease

On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights

Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, and double-digit tiered royalties on U.S. sales

Companies will collaborate to refine the Phase 3 design during short option period

SOLANA BEACH, Calif. and AHMEDABAD, India and LONDON, Aug. 11, 2026 /PRNewswire/ -- Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus") and Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need," said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life."

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people," said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon

that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development."

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs' airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl") is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; the Company's dependence on its strategic partners; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based

on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.

[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.

[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.

[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts

[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

View original content to download multimedia:https://www.prnewswire.com/news-releases/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld-302847861.html

SOURCE Sentynl Therapeutics

Back To Index

Website:	My Carroll County News	Word count	1958
Published Date	11 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://www.mycarrollcountynews.com/online_features/press_releases/article_3b5111ea-a6d5-5a1b-8469-6e83f9df384c.html

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease
On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights
Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales
Companies will collaborate to refine the Phase 3 design during short option period

LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (Zydus), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynls commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design, said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

This partnership marks a pivotal moment for Sentynls rare disease strategy. Mereos alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people, said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive $40 million in upfront and R&D payments. Under these terms, Mereo would also be eligible to receive up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is

driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. (Sentynl) is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Companys reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Companys dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Companys dependence on its key executives; the Companys dependence on its strategic partners; and the Companys ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Companys business, including those described in the Risk Factors section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Companys subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words believe, expect, anticipate, plan, intend, foresee, should, would, could, may, estimate, outlook, will, continue and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Companys current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.

[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.

[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.

[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts

[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Investor Contacts

Mereo BioPharma

Denise Scots-Knight, Chief Executive Officer

Christine Fox, Chief Financial Officer

+44 (0)333 023 7300

investors@mereobiopharma.com

Sentynl Therapeutics, Inc.

Media: Maureen Roberts, maureen.roberts@omc.com

Sentynl: Michael Hercz, ir@sentynl.com

Zydus Lifesciences Limited

Media: Sujatha Rajesh; sujatha.rajesh@zyduslife.com; +91-9974051180

Investor Relations: Arvind Bothra, arvind.bothra@zyduslife.com, +91-7045656895

Back To Index

Website:	NDTV Profit	Word count	2168
Published Date	11 Aug 2026	Journalist:	Bureau

Stocks To Watch Today: HAL, Apollo Hospitals, Petronet LNG, Tata Motors And IRCTC

https://www.ndtvprofit.com/markets/stocks-to-watch-today-hal-apollo-hospitals-petronet-lng-tata-motors-and-irctc-11896913

Here's a look at stocks that are likely to be in focus during the trading session on Wednesday.

Here are the notable corporate announcements that came after Tuesday's market hours.

Shares of Tata Motors Ltd., Petronet LNG Ltd., Hindustan Aeronautics Ltd., Apollo Hospitals Ltd., and Indian Railway Catering And Tourism Corp. Ltd. will be in focus on Wednesday.

Here are the notable corporate announcements that came after Tuesday's market hours:

Earnings Today

63 Moons Technologies, Abbott India, AIA Engineering, Apollo Hospitals, Arvind, Astral, Bliss GVS Pharma, Caplin Point Laboratories, DCX Systems, Dev Accelerator, EID Parry India, EMS, Eureka Forbes, Fiem Industries, Gujarat Fluorochemicals, General Insurance Corporation of India, Globe Civil Projects, GMR Airports, Gujarat Pipavav Port, Grasim Industries, Gujarat State Fertilizers & Chemicals, Hindustan Aeronautics, H.G. Infra Engineering, Hindustan Oil Exploration Company, Hindware Home Innovation, Hi-Tech Pipes, Indo Count Industries, India Glycols, Indian Hume Pipe Company, Indiqube Spaces, IRCON International, IRCTC, Jagran Prakashan, Jyothy Labs, Kirloskar Industries, La Opala RG, Man Infraconstruction, Marksans Pharma, MIDHANI, Motisons Jewellers, MTNL, National Fertilizers, Petronet LNG, Religare Enterprises, Sansera Engineering, Scoda Tubes, Shalby, Shringar House of Mangalsutra, Shriram Properties, SKF India, Somany Ceramics, Sudarshan Chemical Industries, Sun TV Network, Tasty Bite Eatables, Titagarh Rail Systems, Tata Motors, Vadilal Industries, Vesuvius India, VIP Industries, VA Tech Wabag, West Coast Paper Mills, Yatra Online.

Earnings Post Market Hours

IFCI (Q1 FY27, Consolidated YoY)

Total income down 19.6% to Rs. 358 crore versus Rs. 445 crore.

Net profit down 16% to Rs. 33.5 crore versus Rs. 39.9 crore.

RHI Magnesita India (Q1 FY27, Consolidated YoY)

Revenue up 5.6% to Rs. 1,014 crore versus Rs. 960 crore.

EBITDA up 34.9% to Rs. 137.5 crore versus Rs. 101.9 crore.

EBITDA margin at 13.6% versus 10.6%.

Net profit up 83% to Rs. 64.6 crore versus Rs. 35.3 crore.

S.P. Apparels (Q1 FY27, Consolidated YoY)

Revenue down 0.6% to Rs. 401.1 crore versus Rs. 403.4 crore.

EBITDA up 16.1% to Rs. 61.4 crore versus Rs. 52.9 crore.

EBITDA margin at 15.3% versus 13.1%.

Net profit up 20.3% to Rs. 24.9 crore versus Rs. 20.7 crore.

Final dividend of Rs. 3 per share approved for FY26.

Approves stock split of 1 share into 5 shares.

Sunflag Iron & Steel (Q1 FY27, Consolidated YoY)

Revenue up 6.5% to Rs. 1,079 crore versus Rs. 1,013 crore.

EBITDA up 8.6% to Rs. 119 crore versus Rs. 110 crore.

EBITDA margin at 11% versus 10.8%.

Net profit up 5.6% to Rs. 66.1 crore versus Rs. 62.6 crore.

EPL (Q1 FY27, Consolidated YoY)

Revenue up 25.3% to Rs. 1,388 crore versus Rs. 1,108 crore.

EBITDA up 15.2% to Rs. 261 crore versus Rs. 227 crore.
EBITDA margin at 18.8% versus 20.5%.
Net profit down 1.4% to Rs. 98.6 crore versus Rs. 100 crore.
Piccadily Agro Industries (Q1 FY27, Consolidated YoY)
Revenue up 18.1% to Rs. 270.5 crore versus Rs. 229 crore.
EBITDA up 16.2% to Rs. 43.8 crore versus Rs. 37.7 crore.
EBITDA margin at 16.2% versus 16.5%.
Net profit up 15.1% to Rs. 21.3 crore versus Rs. 18.5 crore.
JSW Dulux (Q1 FY27, Consolidated YoY)
Revenue down 2.8% to Rs. 965 crore versus Rs. 993 crore.
EBITDA down 14.4% to Rs. 115 crore versus Rs. 134 crore.
EBITDA margin at 11.9% versus 13.5%.
Net profit down 12.4% to Rs. 79.7 crore versus Rs. 91 crore.
Approves stock split of 1 share into 10 shares.
TD Power Systems (Q1 FY27, Consolidated YoY)
Revenue up 72% to Rs. 640 crore versus Rs. 372 crore.
EBITDA up 74.9% to Rs. 121.4 crore versus Rs. 69.4 crore.
EBITDA margin at 19% versus 18.7%.
Net profit up 72% to Rs. 86 crore versus Rs. 50 crore.
Borana Weaves (Q1 FY27, YoY)
Revenue up 24.7% to Rs. 101 crore versus Rs. 81 crore.
EBITDA up 51.4% to Rs. 26 crore versus Rs. 17.2 crore.
EBITDA margin at 25.8% versus 21.2%.
Net profit up 35.2% to Rs. 16.5 crore versus Rs. 12.2 crore.
Manappuram Finance (Q1 FY27, Consolidated YoY)
NII up 28.2% to Rs. 1,725 crore versus Rs. 1,346 crore.
AUM up 57% to Rs. 69,635 crore versus Rs. 44,304 crore.
Net profit at Rs. 585 crore versus Rs. 138 crore.
Gujarat Energy (Q1 FY27, Consolidated QoQ)
Revenue up 64.8% to Rs. 9,545 crore versus Rs. 5,792 crore.
EBITDA at Rs. 1,381 crore versus Rs. 609 crore.
EBITDA margin at 14.5% versus 10.5%.
Net profit at Rs. 999 crore versus Rs. 351 crore.
Precision Camshafts (Q1 FY27, Consolidated YoY)
Revenue down 3.6% to Rs. 188 crore versus Rs. 195 crore.
EBITDA down 49% to Rs. 7.5 crore versus Rs. 14.7 crore.
EBITDA margin at 4% versus 7.5%.
Net profit down 55.3% to Rs. 8.4 crore versus Rs. 18.8 crore.
Harsha Engineers (Q1 FY27, Consolidated YoY)
Revenue up 25.2% to Rs. 457 crore versus Rs. 365 crore.
EBITDA up 22% to Rs. 67.6 crore versus Rs. 55.4 crore.
EBITDA margin at 14.8% versus 15.2%.
Net profit down 1.3% to Rs. 37.4 crore versus Rs. 37.9 crore.
Repco Home Finance (Q1 FY27, Consolidated YoY)
Total income up 6.2% to Rs. 468 crore versus Rs. 441 crore.
Net profit up 5.7% to Rs. 114.2 crore versus Rs. 108 crore.
TARC (Q1 FY27, Consolidated YoY)
Revenue at Rs. 217.1 crore versus Rs. 75.9 crore.

EBITDA at Rs. 40.2 crore versus loss of Rs. 120.3 crore.
Net profit down 58.1% to Rs. 22.7 crore versus Rs. 54.2 crore.
Other income at Rs. 1.6 crore versus Rs. 219 crore.
Flair Writing Industries (Q1 FY27, Consolidated YoY)
Revenue up 10.7% to Rs. 319 crore versus Rs. 289 crore.
EBITDA up 7.9% to Rs. 53.4 crore versus Rs. 49.5 crore.
EBITDA margin at 16.7% versus 17.1%.
Net profit down 0.3% to Rs. 28.6 crore versus Rs. 28.6 crore.
Landmark Cars (Q1 FY27, Consolidated YoY)
Revenue up 22.7% to Rs. 1,302 crore versus Rs. 1,062 crore.
EBITDA up 18.2% to Rs. 72.1 crore versus Rs. 61 crore.
EBITDA margin at 5.5% versus 5.7%.
Net profit at Rs. 14.5 crore versus Rs. 6.9 crore.
Linde India (Q1 FY27, Consolidated YoY)
Revenue up 21.6% to Rs. 694 crore versus Rs. 571 crore.
EBITDA up 1.8% to Rs. 201 crore versus Rs. 197 crore.
EBITDA margin at 28.9% versus 34.5%.
Net profit down 2.4% to Rs. 104.6 crore versus Rs. 107.2 crore.
Appoints Vikash Dokania as CFO from September 15.
Innova Captab (Q1 FY27, Consolidated YoY)
Revenue up 34% to Rs. 471 crore versus Rs. 351.5 crore.
EBITDA up 40.3% to Rs. 73.1 crore versus Rs. 52.1 crore.
EBITDA margin at 15.5% versus 14.8%.
Net profit up 42.3% to Rs. 44.1 crore versus Rs. 31 crore.
Ashiana Housing (Q1 FY27, Consolidated YoY)
Revenue down 63.3% to Rs. 108 crore versus Rs. 293 crore.
EBITDA down 36.3% to Rs. 7.6 crore versus Rs. 11.9 crore.
EBITDA margin at 7% versus 4%.
Net profit up 3.1% to Rs. 13.1 crore versus Rs. 12.7 crore.
Nephrocare Health Services (Q1 FY27, Consolidated YoY)
Revenue up 23.7% to Rs. 282 crore versus Rs. 228 crore.
EBITDA up 34.2% to Rs. 63.9 crore versus Rs. 47.6 crore.
EBITDA margin at 22.7% versus 20.9%.
Net profit up 35% to Rs. 32 crore versus Rs. 23.7 crore.
Som Distilleries & Breweries (Q1 FY27, Consolidated YoY)
Revenue down 49.2% to Rs. 269 crore versus Rs. 528 crore.
EBITDA down 78.8% to Rs. 14.9 crore versus Rs. 70.2 crore.
EBITDA margin at 5.5% versus 13.3%.
Net profit down 96.2% to Rs. 1.6 crore versus Rs. 42.1 crore.
DAM Capital Advisors (Q1 FY27, Consolidated QoQ)
Total income up 2.4% to Rs. 30 crore versus Rs. 29.3 crore.
Net profit down 40% to Rs. 15 lakh versus Rs. 25 lakh.
PI Industries (Q1 FY27, Consolidated YoY)
Revenue down 10.4% to Rs. 1,702 crore versus Rs. 1,901 crore.
EBITDA down 29.2% to Rs. 367.4 crore versus Rs. 519.1 crore.
EBITDA margin at 21.6% versus 27.3%.
Net profit down 39% to Rs. 244 crore versus Rs. 400 crore.
Bata India (Q1 FY27, Consolidated YoY)

Revenue up 3.9% to Rs. 979 crore versus Rs. 942 crore.
EBITDA up 2.6% to Rs. 204 crore versus Rs. 199 crore.
EBITDA margin at 20.8% versus 21.1%.
Net profit up 23.1% to Rs. 64 crore versus Rs. 52 crore.
Declares interim dividend of Rs. 25 per share.
Polyplex Corporation (Q1 FY27, Consolidated YoY)
Revenue up 29.6% to Rs. 2,254 crore versus Rs. 1,739 crore.
EBITDA at Rs. 297 crore versus loss of Rs. 0.6 crore.
Net profit at Rs. 91 crore versus loss of Rs. 19.3 crore.
MMTC (Q1 FY27, Consolidated YoY)
Revenue down 50% to Rs. 0.7 crore versus Rs. 1.4 crore.
EBITDA loss at Rs. 20.2 crore versus loss of Rs. 23.1 crore.
Net profit at Rs. 104 crore versus Rs. 44 crore.
Other income at Rs. 145 crore versus Rs. 70 crore.
Techno Electric & Engineering (Q1 FY27, Consolidated YoY)
Revenue up 19.8% to Rs. 630.3 crore versus Rs. 526 crore.
EBITDA up 7.7% to Rs. 99.5 crore versus Rs. 92.4 crore.
EBITDA margin at 15.8% versus 17.6%.
Net profit down 31.5% to Rs. 93.3 crore versus Rs. 136 crore.
Man Industries (Q1 FY27, Consolidated YoY)
Revenue up 41.9% to Rs. 1,053 crore versus Rs. 742 crore.
EBITDA up 89.2% to Rs. 143 crore versus Rs. 75.8 crore.
EBITDA margin at 13.6% versus 10.2%.
Net profit at Rs. 61.4 crore versus Rs. 27.6 crore.
Senco Gold (Q1 FY27, Consolidated YoY)
Revenue up 67.4% to Rs. 3,056 crore versus Rs. 1,826 crore.
EBITDA up 16.2% to Rs. 213 crore versus Rs. 184 crore.
EBITDA margin at 7% versus 10%.
Net profit down 3.4% to Rs. 101 crore versus Rs. 105 crore.
Delta Corp (Q1 FY27, Consolidated YoY)
Revenue down 8.2% to Rs. 169 crore versus Rs. 184 crore.
EBITDA down 19.5% to Rs. 31.5 crore versus Rs. 39.2 crore.
EBITDA margin at 18.7% versus 21.3%.
Net loss at Rs. 212 crore versus profit of Rs. 29.5 crore.
Saw one-time loss of Rs. 307 crore in Q1.
Caliber Mining & Logistics (Q1 FY27, Consolidated YoY)
Revenue up 67.2% to Rs. 657 crore versus Rs. 393 crore.
EBITDA up 15.8% to Rs. 110.2 crore versus Rs. 95.2 crore.
EBITDA margin at 16.8% versus 24.2%.
Net profit down 21.1% to Rs. 30 crore versus Rs. 38 crore.
JNK India (Q1 FY27, Consolidated YoY)
Revenue up 81.8% to Rs. 180 crore versus Rs. 99 crore.
EBITDA at Rs. 16.3 crore versus Rs. 3.2 crore.
EBITDA margin at 9.1% versus 3.2%.
Net profit at Rs. 11.5 crore versus Rs. 1.1 crore.
SKF India (Q1 FY27, YoY)
Revenue up 18.3% to Rs. 971 crore versus Rs. 821 crore.
EBITDA down 5.5% to Rs. 89 crore versus Rs. 94 crore.

EBITDA margin at 9.2% versus 11.5%.

Net profit down 13.9% to Rs. 62 crore versus Rs. 72 crore.

Ashoka Buildcon (Q1 FY27, Consolidated YoY)

Revenue down 20.5% to Rs. 1,500 crore versus Rs. 1,887 crore.

EBITDA down 56.9% to Rs. 258 crore versus Rs. 599 crore.

EBITDA margin at 17.2% versus 31.7%.

Net profit down 41.0% to Rs. 127.8 crore versus Rs. 217.4 crore.

ESAB India (Q1 FY27, YoY)

Revenue up 19.6% to Rs. 421 crore versus Rs. 352 crore.

EBITDA up 33.8% to Rs. 79.2 crore versus Rs. 59.2 crore.

EBITDA margin at 18.8% versus 16.8%.

Net profit up 37.0% to Rs. 56.1 crore versus Rs. 40.9 crore.

Gokaldas Exports (Q1 FY27, Consolidated YoY)

Revenue up 20.7% to Rs. 1,154 crore versus Rs. 956 crore.

EBITDA up 15.6% to Rs. 112.5 crore versus Rs. 97.3 crore.

EBITDA margin at 9.8% versus 10.2%.

Net profit up 6.8% to Rs. 44.3 crore versus Rs. 41.5 crore.

Stocks In News

Godrej Consumer Products: The company appoints Aasif Malbari as MD & CEO from August 12; Sudhir Sitapati resigns as MD & CEO, while Vishal Kedia takes over as Interim CFO.

L&T: The company signs a business transfer agreement with arm Vyoma.AI to transfer its data centre and cloud services business for Rs. 1,400 crore.

Grasim Industries: The company commences commercial production at its 50,000 MTPA CPVC resin plant in Gujarat.

Firstsource Solutions: The company enters into a partnership with Cresta to deliver AI technology solutions.

GMR Power & Urban Infra: The board will consider raising up to Rs. 3,000 crore via QIP, bonds and other instruments on August 14.

Prestige Estates: CPPIB to invest up to Rs. 3,000 crore in Prestige Hospitality and acquire up to 28% stake.

Zydus Lifesciences: Arm Sentynl enters pact with Mereo BioPharma for commercial and manufacturing rights of Alvelestat; Mereo eligible for up to USD 40 million under the agreement.

Shareholders approve re-appointment of Sharvil Patel as Managing Director for five years.

Canara Bank: The bank hikes 1-month MCLR by 5 bps to 8.05%, 1-year MCLR by 5 bps to 8.80% and 3-year MCLR by 5 bps to 9.10%.

SKF India: The company appoints Sujeeth Pai as MD from September 1; Mukund Vasudevan resigns as MD from August 31. The company also declares an interim dividend of Rs. 20 per share.

Muthoot Microfin: Shareholders approve fundraising through private placement.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel Gold and Silver Prices and Latest Stories On NDTV Profit.

Back To Index

Website:	News 18	Word count	104
Published Date	11 Aug 2026	Journalist:	Bureau

Zydus Arm Secures US Rights Option for Pioneering Oral Drug for Rare Lung Disease

https://one.news18.com/english/article/business/companies/zydus-arm-secures-us-rights-option-for-pioneering-oral-drug-for-rare-lung-disease-cne-6619967018

Sentynl Therapeutics, a Zydus Lifesciences subsidiary, secured an exclusive option for US commercial rights to alvelestat from Mereo BioPharma.

Alvelestat is an experimental oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD), a rare genetic respiratory condition.

If approved, alvelestat could be the first oral drug for AATD-LD, a disease affecting 50,000-80,000 people in the US.

Sentynl will gain global manufacturing rights, while Mereo retains commercial rights outside the US and will lead the global Phase 3 study.

Mereo could receive up to $40 million in payments and double-digit royalties if Sentynl exercises the option; Phase 3 development may begin in early 2027.

Back To Index

Website:	PR Newswire	Word count	1740
Published Date	11 Aug 2026	Journalist:	Bureau

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://www.prnewswire.com/news-releases/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld-302847861.html

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease
On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights
Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, and double-digit tiered royalties on U.S. sales
Companies will collaborate to refine the Phase 3 design during short option period
SOLANA BEACH, Calif. and AHMEDABAD, India and LONDON, Aug. 11, 2026 /PRNewswire/ -- Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus") and Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need," said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life."

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people," said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development."

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs' airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl") is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; the Company's dependence on its strategic partners; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Back To Index

Website:	Scanx	Word count	541
Published Date	11 Aug 2026	Journalist:	Bureau

Zydus subsidiary Sentynl signs option and license deal for alvelestat

https://scanx.trade/stock-market-news/companies/zydus-subsidiary-sentynl-signs-option-and-license-deal-for-alvelestat/48016683

Sentynl Therapeutics, a Zydus Lifesciences subsidiary, has signed an option and license agreement with Mereo BioPharma for alvelestat, targeting Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. Sentynl gains exclusive U.S. commercialization rights and global manufacturing rights, while Mereo leads global development and retains rest-of-world rights. Mereo is set to receive up to $40 million in payments until NDA filing plus royalties.

Sentynl Therapeutics, Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited , has entered into an option and license agreement with Mereo BioPharma Group plc for alvelestat. The agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) in the United States, expanding its rare disease portfolio with a potential first-in-class oral treatment. Mereo BioPharma will retain commercial rights in the rest of the world and lead the global Phase 3 study and regulatory interactions until completion. This partnership addresses a significant unmet need in a rare genetic respiratory disease affecting an estimated 50,00080,000 individuals in the United States.

The financial terms of the agreement include a non-refundable option fee paid by Sentynl to Mereo. Upon exercise of the option, Mereo is eligible to receive up to $40 million in upfront and R&D payments until New Drug Application (NDA) filing. Additionally, Mereo will receive double-digit tiered royalties on U.S. net sales of alvelestat. Sentynl also acquires global manufacturing rights for alvelestat for AATD-LD under this arrangement. The companies plan to collaborate during the short option period to refine the Phase 3 study design and advance manufacturing, with the Phase 3 program potentially initiating in early 2027.

Key Agreement Terms

Term

Asset

Alvelestat (neutrophil elastase inhibitor)

Indication

Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

U.S. Rights

Exclusive commercialization rights for Sentynl upon option exercise

Global Rights

Rest-of-world commercial rights retained by Mereo; global manufacturing rights granted to Sentynl

Development Lead

Mereo leads global Phase 3 study and regulatory interactions

Financials

Up to $40 million in upfront/R&D payments until NDA filing; double-digit tiered royalties on U.S. sales

Alvelestat is a novel oral small molecule designed to specifically inhibit neutrophil elastase, a key enzyme involved in inflammation and lung tissue destruction. It has received Orphan Drug Designation for AATD-LD from both the European Commission and the FDA, as well as Fast Track designation from the FDA. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with various respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19, and bronchiolitis obliterans syndrome. Positive efficacy data from two Phase 2 studies backs the preparation for the global Phase 3 study.

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, stated that the partnership marks a pivotal moment for Sentynl's rare disease strategy, adding a highly promising candidate that could address significant unmet needs. Matt Heck, Chief Executive Officer of Sentynl Therapeutics, noted that alvelestat offers an opportunity to improve upon the current standard of care, which often relies on demanding intravenous treatments. Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma,

expressed pleasure in partnering with Sentynl, citing its commitment to rare diseases and established commercial infrastructure as ideal for advancing alvelestat.

Historical Stock Returns for Zydus Life Science

fuzz it fuzz it fuzz it Read Next Article

Back To Index

Website:	WBOC	Word count	1958
Published Date	11 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://www.wboc.com/online_features/press_releases/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1/article_6db2be7e-794f-5743-a0d5-5b736ab05519.html

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease
On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights
Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales
Companies will collaborate to refine the Phase 3 design during short option period

LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (Zydus), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynls commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design, said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

This partnership marks a pivotal moment for Sentynls rare disease strategy. Mereos alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need, said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life.

We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people, said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive $40 million in upfront and R&D payments. Under these terms, Mereo would also be eligible to receive up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is

driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. (Sentynl) is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Companys reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Companys dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Companys dependence on its key executives; the Companys dependence on its strategic partners; and the Companys ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Companys business, including those described in the Risk Factors section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Companys subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words believe, expect, anticipate, plan, intend, foresee, should, would, could, may, estimate, outlook, will, continue and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Companys current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.

[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.

[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.

[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts

[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Investor Contacts

Mereo BioPharma

Denise Scots-Knight, Chief Executive Officer

Christine Fox, Chief Financial Officer

+44 (0)333 023 7300

investors@mereobiopharma.com

Sentynl Therapeutics, Inc.

Media: Maureen Roberts, maureen.roberts@omc.com

Sentynl: Michael Hercz, ir@sentynl.com

Zydus Lifesciences Limited

Media: Sujatha Rajesh; sujatha.rajesh@zyduslife.com; +91-9974051180

Investor Relations: Arvind Bothra, arvind.bothra@zyduslife.com, +91-7045656895

Back To Index

Website:	Whalesbook	Word count	439
Published Date	11 Aug 2026	Journalist:	Ananya Iyer

Zydus Lifesciences Shares Rise 6% On US Drug Deal

https://www.whalesbook.com/news/English/healthcarebiotech/Zydus-Lifesciences-Shares-Rise-6percent-On-US-Drug-Deal/6a7b5daf6ffbe1e646133233

Zydus Lifesciences' subsidiary, Sentynl Therapeutics, has secured US rights for the experimental lung disease drug alvelestat. While the market welcomed the news with a 6.43% rise in share price on August 11, 2026, investors are also weighing this against the company's Q1 FY27 results, which showed a profit decline due to rising operational costs.

Zydus Lifesciences stock rose 6.43% on August 11, 2026, closing at Rs 1,191, after its US-based subsidiary, Sentynl Therapeutics, announced a significant strategic agreement. The company has secured an exclusive option for US commercial rights to alvelestat, a drug being developed by the UK-based firm Mereo BioPharma. This treatment targets a rare genetic condition known as Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, or AATD-LD.

The agreement gives Sentynl the right to bring this potential therapy to the US market, provided it clears regulatory hurdles. In addition to commercial rights, the deal includes global manufacturing responsibilities for Sentynl, marking a significant operational expansion. The financial terms are structured around development milestones, with the potential for up to $435 million in payments to Mereo BioPharma if specific targets are met, alongside sales-based royalties. The drug is currently in the investigational stage, with Phase 3 clinical trials expected to begin in early 2027.

While the stock responded positively to the deal, the company's Q1 FY27 financial results were also released on the same day, presenting a mixed picture for investors. The company reported a revenue growth of 22% to Rs 8,017 crore. However, its net profit dropped 35.9% to Rs 940 crore compared to the same quarter last year. This decline in profitability was largely driven by tighter margins, with operating margins falling to 24.1% from 31.8% a year ago, reflecting higher costs related to operations and research and development.

Investors may note that the pharmaceutical sector, particularly for companies with a strong presence in the US, continues to face intense competition which can pressure product pricing. Additionally, as with any pharmaceutical company betting on new drug development, the success of the alvelestat project is subject to clinical and regulatory risks. There is no guarantee that the drug will successfully pass through the Phase 3 trials and receive final regulatory approval, which is a necessary step before it can generate revenue.

The companys ability to manage its cost structure will remain a key monitorable. While the new drug deal signals an attempt to capture high-value opportunities, it also requires sustained investment. Moving forward, shareholders may track the timeline for the 2027 clinical trials and look for signs of margin recovery in upcoming quarterly reports to see if the company can balance its growth spending with healthier profit levels.

Back To Index

Website:	Yahoo Finance	Word count	1903
Published Date	11 Aug 2026	Journalist:	Bureau

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://finance.yahoo.com/healthcare/articles/sentynl-therapeutics-mereo-biopharma-announce-120000288.html

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease

On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights

Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, and double-digit tiered royalties on U.S. sales

Companies will collaborate to refine the Phase 3 design during short option period

SOLANA BEACH, Calif. and AHMEDABAD, India and LONDON, Aug. 11, 2026 /PRNewswire/ -- Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus") and Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

Sentynl Therapeutics, Inc.
Sentynl Therapeutics, Inc.
The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need," said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life."

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people," said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development."

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive up to $40 million in upfront and R&D payments until NDA filing. Under these terms, Mereo would also be eligible to receive double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs' airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl") is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient

outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; the Company's dependence on its strategic partners; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The

Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;

[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.

[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.

[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.

[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts

[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Cision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-lung-disease-aatd-ld-302847861.html

Back To Index

Website:	Yahoo Finance UK	Word count	1947
Published Date	11 Aug 2026	Journalist:	Bureau

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

https://uk.finance.yahoo.com/news/mereo-biopharma-sentynl-therapeutics-announce-120000251.html

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease

On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights

Mereo will receive an upfront option fee and, on option exercise, is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales

Companies will collaborate to refine the Phase 3 design during short option period

LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus"), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Alvelestat is a neutrophil elastase inhibitor being readied for Phase 3 and, if approved, would be the first oral treatment for this rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.1,2,3,4,5,6

The option and license agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States, with Mereo retaining commercial rights in the rest of the world. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD and on option exercise, it provides funding for the alvelestat Phase 3 development program, which could be initiated in early 2027.

"We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase 3 study, backed by positive efficacy data from two Phase 2 studies. We believe Sentynl's commitment to rare diseases and established commercial infrastructure make them the ideal partner for alvelestat and look forward to collaborating with them during the option period, when we plan to refine the global Phase 3 study design," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma.

"This partnership marks a pivotal moment for Sentynl's rare disease strategy. Mereo's alvelestat is a highly promising, differentiated candidate that meaningfully expands our portfolio and has the potential to address an area of significant unmet need," said Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited. "AATD-LD has a profound impact on patients' lives. If approved, alvelestat has the potential to be a meaningful new option that could help their quality of life."

"We take great pride in having built a sustainable approach for developing therapies for ultra-rare conditions, and this partnership allows us to expand that strategic focus to a larger population within the rare disease community, enabling us to help more people," said Matt Heck, Chief Executive Officer of Sentynl Therapeutics. "For patients with AATD-LD, the current standard of care is

demanding, often relying on generalized therapies or frequent intravenous treatments. We see a clear opportunity to improve upon that with alvelestat. Mereo has built a strong foundation for this asset, making them an ideal partner as we collaborate during the option period to prepare for the next phase of development."

Mereo will receive a non-refundable option fee from Sentynl and, on exercise of the option, the Company would also receive $40 million in upfront and R&D payments. Under these terms, Mereo would also be eligible to receive up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and regulatory interactions until the study is completed. However, during the option period, the companies will collaborate to advance manufacturing and streamline the Phase 3 study design.

About Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

AATD is a rare, genetic disease that results in a deficiency of the alpha-1 antitrypsin protein, which protects the lungs against damaging enzymes that the body releases during inflammation. The majority of individuals with severe deficiency develop pulmonary emphysema, a progressive, life-threatening lung disease, which results in severe shortness of breath, chronic cough and sputum production with susceptibility to acute exacerbations. Individuals with AATD may also develop asthma and bronchiectasis, a permanent enlargement of parts of the lungs' airways. The estimated prevalence of AATD-LD (Pi*ZZ variant) in the United States is approximately 50,000-80,000 people.1,2,3,4,5,6

About Alvelestat

Alvelestat is a novel, oral small molecule designed to specifically inhibit neutrophil elastase (NE), a key enzyme involved in inflammation and the destruction of lung tissue. As a small molecule, alvelestat is able to access both cell-bound and soluble elastase and effectively penetrate lung tissue. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19 and bronchiolitis obliterans syndrome following allogeneic stem cell transplant.

Alvelestat has received Orphan Drug Designation for AATD-LD from the European Commission and the FDA. It has also received Fast Track designation from the FDA.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with shibio, Inc., for vantictumab in ADO2. shibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

For more information visit https://www.mereobiopharma.com/

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com.

About Sentynl Therapeutics, Inc.

Sentynl Therapeutics Inc. ("Sentynl") is a commercial stage U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. Recognized for its commitment to the rare disease community, Sentynl leverages its global operations as well as its parent organization, Zydus Lifesciences Limited, to advance the development, manufacturing, and delivery of treatments to patients who need them in numerous countries worldwide. Sentynl is dedicated to improving patient outcomes and access while upholding ethical standards and operating in compliance with applicable laws, regulations, and industry guidelines. For more information, visit www.sentynl.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; the Company's dependence on its strategic partners; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

[1] Blanco I, Diego I, Castan C, Estimated Worldwide Prevalence of the PI*ZZ Alpha-1 Genotype Antitrypsin in Subjects with Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologa. 2023 Jul 10.1016 427-434;
[2] Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569.
[3] de Serres FJ, Blanco I, Fernndez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD. 2006;3(3):133-139.
[4] Stoller JK, Aboussouan LS. AAT deficiency. Lancet. 2005;365(9478):2225-2236.
[5] U.S. Census Bureau. QuickFacts: United States. U.S. Department of Commerce; 2023. Accessed Aug. 4, 2026. https://www.census.gov/quickfacts
[6] U.S. Census Bureau. B02001: Race, 2022 American Community Survey 1-Year Estimates. U.S. Department of Commerce; 2022. Accessed Aug. 4, 2026. https://data.census.gov/

Investor Contacts

Mereo BioPharma

Denise Scots-Knight, Chief Executive Officer
Christine Fox, Chief Financial Officer
+44 (0)333 023 7300
investors@mereobiopharma.com

Sentynl Therapeutics, Inc.

Media: Maureen Roberts, maureen.roberts@omc.com
Sentynl: Michael Hercz, ir@sentynl.com

Zydus Lifesciences Limited

Media: Sujatha Rajesh; sujatha.rajesh@zyduslife.com; +91-9974051180
Investor Relations: Arvind Bothra, arvind.bothra@zyduslife.com, +91-7045656895

Back To Index